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Abstract 
Hypoglycaemia is the commonest and most feared side - effect of insulin therapy for diabetes, 
which is increased during strict glycaemic control. It can have detrimental effects on many 
aspects of cerebral function, but also provokes widespread changes in blood components and 
vascular flow such that theoretical concerns have been raised regarding its potential effects 
on the vasculature of people with diabetes. The aims of this thesis were: (a) to further 
examine the effects of hypoglycaemia on cognitive function, specifically to assess the effects 
on spatial abilities, and (b) to explore the potential effects of hypoglycaemia on several 
parameters that influence vascular function. 
Spatial ability was assessed using the French and Ekstrom Kit of Factor Referenced 
(cognitive) Tests in 16 subjects with type 1 diabetes during euglycaemia and hypoglycaemia, 
which was induced using the hyperinsulinaemic glucose clamp technique. Vascular function 
was evaluated in a preliminary study by assessing the endothelin response to acute 
hypoglycaemia in 20 subjects with type 1 diabetes. Subsequently, 16 adult human subjects 
with type 1 diabetes and 16 subjects without diabetes were studied during hypoglycaemia 
and euglycaemia with measurement of an extensive battery of tests relevant to vascular 
function (soluble markers of platelet function, coagulation, and inflammation). Flow 
cytometry was used to assess the effects of hypoglycaemia and euglycaemia on platelet - 
monocyte aggregation, CD40 expression on monocytes and CD40 ligand expression on 
platelets, as these parameters are known to play a role in the initiation and progression of 
atherogenesis and vascular disease. 
Results have indicated that spatial ability was significantly affected during hypoglycaemia, 
which is relevant to the everyday activities of people with diabetes. In response to 
hypoglycaemia, significant changes were observed in several intra- vascular indices that 
could compromise vascular function and exacerbate vascular disease. These findings are of 
concern given the fact that the main objective of optimal glycaemic control in diabetes is to 
prevent the development and progression of micro- and macrovascular disease. This research 
provides a basis for further studies to investigate this concept in greater detail, and adds to 
the body of evidence demonstrating the importance of avoiding hypoglycaemia while 
maintaining optimal glycaemic control. 
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1.1 Aims of research programme 
The aims of this programme of research were to investigate in detail the potential adverse 
consequences of hypoglycaemia on both spatial abilities and vascular biology. The more 
information that can be gained about the effects of hypoglycaemia, the more appropriately 
we can target glycaemic control in the safest possible fashion. 
1.2 Epidemiology of hypoglycaemia - The size of the problem 
Hypoglycaemia is a fact of life for people with insulin- treated diabetes. Striving to meet 
glycaemic targets means that it is common; it affects most people with type 1 diabetes at 
some stage, as well as many people with type 2 diabetes on insulin or insulin secretagogues. 
It can be unpredictable and there are potentially dangerous sequelae if it is not identified and 
treated in a timely fashion. Due attention must also be paid to the more chronic effects it can 
have a day -to -day life. It can provoke fear and anxiety 
for the person with diabetes and for their family, friends and colleagues. Even people with 
suboptimal glycaemic control who run a higher glycated haemoglobin (HbA1c) can be at 
risk of hypoglycaemia, as they may exhibit more erratic control with greater swings in blood 
glucose. 
1.2.1 Definitions 
There is no current consensus as to the most appropriate way to define hypoglycaemia. It can 
be defined using the traditional 'Whipple's triad'; symptoms consistent with hypoglycaemia, 
a low blood glucose concentration, and reversal of the symptoms on correction of the low 
glucose. However, the alteration of symptom profiles with duration of diabetes or exposure 
to recurrent hypoglycaemia is a well -recognised phenomenon, leading to the development of 
impaired hypoglycaemia awareness. In those people, that traditional triad of features may not 
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be present for every episode (Pramming, 1991). Therefore, using a biochemical cut -off has 
been recommended, particularly as this makes reporting during clinical trials easier, but 
again, no consensus exists as to the most appropriate figure to utilise in this regard. The 
American Diabetes Association definition is of a blood glucose concentration less than 
4.0mmo1/1 (American Diabetes Association, 2005), but as we will go on to discuss when 
describing the physiology of hypoglycaemia and the provocation of symptoms and cognitive 
dysfunction that ensues with a declining blood glucose, symptoms will rarely be produced at 
a level of 4.0mmo1/1. As a result, many experts feel this definition is too high, and that a 
level of 3.5mmo1/1 may be more practically appropriate as symptoms are usually provoked at 
this level (Frier, 2009). Many health care professionals involved in diabetes management 
would believe, however, that advising patients not to treat until their blood glucose is less 
than 3.5mmo1/1 could lead to hazardous consequences. 
Furthermore, a definition of the severity of an episode of hypoglycaemia is required. It is 
generally accepted that a mild episode is one that can be self -treated, and a severe episode 
requires some degree of external assistance for treatment. As a result of the ongoing 
controversy surrounding definitions, reporting of hypoglycaemia can vary substantially 
between studies, which makes interpretation and comparison problematic. In addition, self - 
reporting of hypoglycaemia history is not always reliable. It has been shown that severe 
hypoglycaemia reporting is reliable up to 1 year after the event (Pederson -Bjergaard, 2003), 
but recall of mild episodes may only be accurate for up to 1 week (Pramming, 1991). This 
introduces another problem in analysing hypoglycaemia data. 
1.2.2 Frequency of hypoglycaemia 
There is no doubt that good glycaemic control can limit the development and progression of 
microvascular complications. The Diabetes Control and Complications Trial (DCCT), and 
the long term follow up study, Epidemiology of Diabetes Interventions and Complications 
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(EDIC), showed that the onset, progression and severity of diabetic complications, in people 
with type 1 diabetes, can be limited by strict glycaemic control (DCCT Group, 1993, 
DCCT /EDIC Group, 2005). However, this intensive insulin therapy can increase the risk of 
severe hypoglycaemia (DCCT Group, 1993). 
The annual prevalence of severe hypoglycaemia has been reported as being between 30% 
and 40% in several large studies including the DCCT (DCCT Group, 1993, EURODIAB 
Group, 1994, MacLeod, 1993, ter Braak, 2000) with rates increasing with duration of 
diabetes (UK Hypo Study Group, 2007). The incidence of severe hypoglycaemia ranges 
from around 1.0 to greater than 3.0 episodes /patient /year, depending on the duration of the 
disorder, as reported in a collection of studies in type 1 diabetes (Strachan, 2007). The 
DCCT reported incidences of 0.19 to 0.62 episodes /patient /year in the conventional and 
intensive treatment groups respectively (DCCT Group, 1993), but subjects were recruited on 
the basis that they were at relatively low risk of severe hypoglycaemia. Following a 
feasibility study, patients who had a preceding history of severe hypoglycaemia were 
excluded from the DCCT, which therefore excluded people with impaired hypoglycaemia 
awareness, and most people with long duration of diabetes (DCCT Group, 1987). A more 
recent, inclusive study revealed an incidence of 1.1 episodes /person/year in patients with 
type 1 diabetes of short duration ( <5 years), who are usually well -controlled, and 3.2 
episodes /person /year in those with longer duration ( >15 years). This study included those 
people at higher risk of hypoglycaemia. Overall glycaemic control in the study was good, 
with patients having a mean glycated haemoglobin concentration of 7.8% in the long 
duration group and 7.3% in the short duration group (UK Hypo Group, 2007). 
A summary of the epidemiology of severe hypoglycaemia in type 1 diabetes is shown in 
Table 1.1 (Pramming, 1991, MacLeod, 1993, ter Braak, 2000, Pedersen -Bjergaard, 2004). 
From an economic perspective, around 10% of episodes of severe hypoglycaemia affecting 
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people with type 1 diabetes require some form of emergency medical assistance (Donnelly, 
2005); this is not an insignificant cost to the NHS in the UK. 
Severe hypoglycaemia in type 2 diabetes has attracted much less attention, but remains a risk 
in those treated with insulin or sulfonylureas. This population is much larger and includes 
many elderly people. They may therefore have other co- morbidities such as macrovascular 
disease, osteoporosis, social isolation and general frailty, making occurrence of severe 
hypoglycaemia even more hazardous. In the UK Prospective Diabetes Study (UKPDS) 
(UKPDS Group, 1998), and in several observational studies of people with type 2 diabetes, 
hypoglycaemia was associated either with intensive treatment with insulin or with 
sulfonylureas (Zammitt, 2005), but the frequencies may have been underestimated. 
Hypoglycaemia rates were measured prospectively in the UK Hypoglycaemia Group study, 
which demonstrated a lower overall incidence of severe hypoglycaemia in people with 
insulin -treated type 2 diabetes compared to type 1 diabetes, but it increased with duration of 
insulin therapy (UK Hypo Group Study, 2007, Abraira, 1995, Henderson, 2003, Leese, 2003, 
Donnelly, 2005; see table 1.2). In the UKPDS, severe hypoglycaemia associated with 
sulfonylureas was reported to be low with an annual prevalence of 1% (UKPDS Group, 
1998), but this was likely to be an underestimate because of the way hypoglycaemic events 
were recorded; in people with well -controlled type 2 diabetes in the UK Hypoglycaemia 
Study, the annual prevalence was 7 %. Sulfonylurea- induced hypoglycaemia is probably 
much more common than is appreciated, particularly in an elderly population, although the 
degree of risk varies with different agents (Amiel, 2008). A third of episodes of severe 
hypoglycaemia affecting people with type 2 diabetes require emergency medical assistance 
(Donnelly, 2005). The estimated annual cost to the NHS in the UK of hypoglycaemia in type 
2 diabetes is approximately £7.4 million (Amiel, 2008), indicating that it is not an 
insignificant burden. 
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Table 1.1: Epidemiology of severe hypoglycaemia in type 1 diabetes 
Study Severe hypoglycaemia 





Pramming S et al (1991) 36% 1.4 





MacLeod K M et al 
(1993) 
29.2% 1.6 
Ter Braak E W et al 
(2000) 
40.5% 1.5 
Pedersen -Bjergaard U 
et al (2004) 
36.7% 1.3 
UK Hypoglycaemia 
Group study (2007) 
22% ( <5 yrs duration) 
46% ( >15 yrs duration) 
1.1 ( <5 yrs duration) 
3.2 ( >15 yrs duration) 
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Table 1.2: Epidemiology of severe hypoglycaemia in type 2 diabetes 
Study Severe hypoglycaemia 




Abraira et al (1995) n/a 0.02 
Henderson et al 
(2003) 
15% 0.28 





Donnelly et al (2005) 3% 0.35 
UK Hypoglycaemia 
Group study (2007) 
7% (oral agents) 
7% ( <2 yrs duration) 
25% ( >5 yrs duration) 
0.1 (oral agents) 
0.1 ( <2 yrs duration) 
0.7 ( >5 yrs duration) 
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1.3 Physiology of Hypoglycaemia 
In response to a decreasing blood glucose, a well- described series of events is triggered. This 
includes physiological, hormonal and neuro- cognitive changes. Some of these responses 
create symptoms, which may alert the person with diabetes to the impending danger and 
allow them to take action to restore their blood glucose (figure 1.1). 
Counterregulatory hormonal secretion occurs in response to evolving hypoglycaemia. 
Glucagon and epinephrine are the most prominent in restoring blood glucose to normal, and 
their secretion follows suppression of endogenous insulin secretion. The glucagon response 
to hypoglycaemia is attenuated within five years of developing type 1 diabetes, and the 
epinephrine response may also become attenuated with increasing duration of the disorder 
(Gerich, 1973, Bolli, 1983). These counterregulatory hormonal deficiencies interfere with 
normal recovery of blood glucose and can promote prolonged hypoglycaemia in people with 
diabetes (Thompson, 1993). The same deficiency in glucagon production has been reported 
in people with advanced type 2 diabetes (Bolli, 1984, Segel, 2002), although there has been 
some conflicting evidence in this regard (Heller, 1987', Levy, 1998). The epinephrine 
response appears to be preserved in type 2 diabetes (Heller, 19872, De Galan, 2001). 
Secretion of cortisol and growth hormone in response to hypoglycaemia also helps to restore 
glucose to normal. 
Neuroglycopenia is the direct consequence of hypoglycaemia on the brain (Cryer, 2002). It 
triggers various responses including activation of central autonomic centres. This then 
stimulates the peripheral sympatho- adrenal system and creates a further series of 
physiological events. Many of these autonomic responses are manifested as symptoms such 
as sweating, tremor, palpitation, hunger and feelings of anxiety (McAulay, 2001'). Cognitive 
dysfunction is experienced in a number of ways, including difficulty concentrating, 
drowsiness and inco- ordination (McAulay, 20011). Most cognitive modalities are impaired 
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when arterialised blood glucose concentration falls below 2.8 mmol/1. Simple motor function 
and reaction time tests are preserved, while tests incorporating speed, complexity, or demand 
careful attention are affected most (Deary, 19931). Perception of any of these symptoms at an 
early stage can alert the individual to the development of hypoglycaemia and prompt them 










































































































































































































































































































1.4 Causes and risk factors for hypoglycaemia - Why does it occur? 
Many different factors can contribute to the development of hypoglycaemia, and several may 
underlie a particular episode. However, in many severe hypoglycaemic events, no specific 
cause can be identified (Frier, 1993). There are both causes and risk factors that can 
contribute. Table 1.3 illustrates many of the potential causes and risk factors that may 
influence the development of hypoglycaemia. 
1.4.1 Causes 
In type 1 diabetes and advanced type 2 diabetes, there is little or no endogenous insulin 
secretion so there is a loss of the natural homeostatic mechanisms usually present to control 
blood glucose. It is difficult to achieve appropriate plasma insulin concentrations when 
exogenous insulin is administered, and of course once exogenous insulin is given, the rate of 
delivery cannot be adjusted. Hypoglycaemia occurs when insulin concentration is 
inappropriately high when compared to blood glucose concentration. This can be a particular 
issue overnight. Additionally, hypoglycaemia can result when too much insulin is injected 
relative to carbohydrate intake, or when a meal is missed or delayed after insulin has been 
administered. Hypoglycaemia can occur accidentally when a higher dose of insulin than 
intended is administered in error, and is occasionally a deliberate act of self -harm, by taking 
an overdose of insulin or a sulfonylurea. Physical activity can precipitate hypoglycaemia, 
through accelerated absorption of insulin, and depletion of muscle glycogen stores. Alcohol 
enhances the risk of prolonged hypoglycaemia by inhibiting hepatic gluconeogenesis, and 
the hypoglycaemia may be delayed for several hours. The development of other autoimmune 
disorders such as adrenal insufficiency or coeliac disease predisposes to hypoglycaemia and 
may present with an unexplained increase in its occurrence. There are also occasions when 
insulin sensitivity is increased, making hypoglycaemia more likely, such as weight loss, 
physical training, the postpartum period, and sometimes in relation to hormonal changes 
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during the menstrual cycle. The duration of action of insulin may also be prolonged, as in 
renal failure, by reducing the rate of clearance of insulin from the circulation. 
1.4.2 Risk factors 
1.4.2.1 Intensive glycaemic control 
The risk of hypoglycaemia is increased when insulin therapy is intensified in an attempt to 
meet glycaemic targets for type 1 and insulin- treated type 2 diabetes. Severe hypoglycaemia 
was increased threefold following the institution of intensive insulin regimens in the DCCT 
(DCCT Group, 1993). Exposure to antecedent episodes of hypoglycaemia can diminish the 
counterregulatory hormonal response to subsequent hypoglycaemia, and therefore blunt the 
intensity of symptoms perceived by the patient (Heller, 1991). The glycaemic threshold for 
epinephrine release is usually at around 3.5 mmol/1 (arterialised blood glucose), and 3.0 
mmol /1 for the onset of autonomic symptoms. However, recurrent episodes of 
hypoglycaemia can re -set these thresholds at lower blood glucose levels. This leaves a 
smaller window of opportunity to take corrective action between the onset of symptoms and 
the development of significant cognitive impairment, so increasing the risk of severe 
hypoglycaemia. Counterregulatory hormonal deficiencies and impaired awareness of 
hypoglycaemia often develop when HbAl c declines to near the non -diabetic range (Kinsley, 
1995). 
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Table 1.3: Causes of and risk factors for hypoglycaemia in insulin- treated 
diabetes 
CAUSES RISK FACTORS 
Inadequate dietary carbohydrate 
a. Unexpected physical exertion 
b. Social: sport, training, travel, change of 
occupation 
c. Dieting /eating disorders 
d. Breast feeding 
e. Malabsorption (Coeliac disease) 
f. Gastroparesis (autonomic neuropathy) 
Changes in insulin sensitivity /bioavailability 
a. Acute remission in newly diagnosed 
diabetes following treatment (honeymoon 
period) 
b. Post -delivery in diabetic pregnancy 
c. Menstruation (variable effects) 
d. Renal impairment/failure 
e. Effects of exercise 
Change in insulin pharmacokinetics 
a. Change of insulin formulation 
b. Change of insulin injection site 
c. Effects of temperature (e.g. hot bath, 
sauna) 
Other related conditions 
a. Endocrine failure (Adrenal insufficiency, 
hypopituitarism, hypothyroidism) 
b. Factitious insulin administration 
Duration of diabetes 
Age 
Strict glycaemic control 
Impaired awareness of 
hypoglycaemia 




C- peptide negativity 
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1.4.2.2 Duration of diabetes 
Increasing duration of diabetes is associated with an increasing frequency of severe 
hypoglycaemia (SH) (Pramming, 1991). SH is relatively uncommon in the early stages of 
type 1 and insulin- treated type 2 diabetes because there is usually some residual capacity for 
endogenous insulin secretion, which is suppressed when blood glucose falls (Davis, 1997). 
Additionally, in the early stages of type 1 diabetes, a period of remission often occurs, with 
partial recovery of pancreatic beta cell function, which may necessitate a reduction of insulin 
dose to avoid hypoglycaemia (the honeymoon period). As progressive beta cell failure 
ensues, this is accompanied by an increment in the frequency of SH. This is partly because 
the plasma insulin concentration is then determined by the absorption and dose of exogenous 
insulin, and is partly associated with reduction of the counterregulatory hormonal 
mechanisms, which diminish with time; in particular the glucagon response is attenuated 
within five years of diagnosis in type 1 diabetes (Gerich, 1973, Bolli, 1983). 
1.4.2.3 Extremes of age 
Severe hypoglycaemia is more common at extremes of age - in very young children and in 
the elderly. Young children are unable to either recognise or interpret the warning symptoms 
of hypoglycaemia, and hypoglycaemia may be promoted by irregular eating patterns, erratic 
physical activity and long periods of sleep. In the ageing population, neurological and non- 
specific symptoms are prominent (Jaap, 1998), which may cause confusion with the 
identification of hypoglycaemia. The ageing brain may be more susceptible to the effects of 
hypoglycaemia, while renal impairment becomes more common with age, and increases the 
risk of hypoglycaemia (Rabkin, 1984, Muhlhauser, 19911). 
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1.4.2.4 Impaired awareness of hypoglycaemia 
Any condition that reduces the symptomatic awareness of hypoglycaemia and the ability to 
take early action to treat and reverse hypoglycaemia in response to symptoms will increase 
the risk of severe hypoglycaemia. This includes sleep when the intensity of warning 
symptoms is reduced because the sympatho- adrenal response to hypoglycaemia is attenuated 
and epinephrine secretion is much lower (Jones, 1998). Symptoms are also diminished when 
lying flat (Hirsch, 1991). Antecedent hypoglycaemia reduces the counterregulatory hormonal 
response to a subsequent episode of hypoglycaemia (Heller, 1991), and can induce impaired 
awareness of hypoglycaemia (IAH); recurrent hypoglycaemia during sleep has been 
implicated in the development of this syndrome (Veneman, 1993). IAH becomes more 
common with increasing duration of diabetes (Pramming, 1991), and with more frequent 
exposure to hypoglycaemia, thus creating a vicious circle of recurrent hypoglycaemia. This 
condition affects 20 -25% of people with type 1 diabetes (Hepburn, 1990, Muhlhauser, 
19912), but is less common in insulin -treated type 2 diabetes, where the reported prevalence 
is around 8 -9% (Henderson, 2003, Schopman, 2010). Impaired awareness of hypoglycaemia 
can be very debilitating, with some people being so severely affected that they experience no 
warning symptoms and can progress rapidly to unconsciousness. Others who are less 
severely affected have an increasing reliance on neuroglycopenic symptoms or the assistance 
of relatives and friends to recognise hypoglycaemia. Maintenance of strict glycaemic targets 
in this group of patients may promote recurrent severe hypoglycaemia and targets should 
therefore be modified. 
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1.5 Management of hypoglycaemia 
Mild hypoglycaemia is defined by the ability of the person experiencing the episode to self - 
treat. Successful treatment of hypoglycaemia relies on early detection of a fall in blood 
glucose to allow prompt self -treatment and prevent progression to more severe 
hypoglycaemia. Over -treatment of hypoglycaemia will encourage rebound hyperglycaemia 
and promote weight gain through the consumption of additional carbohydrate. This can also 
result from prophylactic eating which is undertaken to prevent the initial fall in blood 
glucose. An algorithm summarising the treatment of acute hypoglycaemia is shown in table 




















































































































































































































































































































































1.5.1 Treatment of acute hypoglycaemia 
1.5.1.1 Oral carbohydrate 
Many guidelines recommend that 10 -15 grams of carbohydrate should be consumed (3 to 5 
glucose tablets), followed by some form of starchy carbohydrate to prevent a recurrence of 
hypoglycaemia (Brodows, 1984). Fifteen grams of oral fast -acting carbohydrate will raise 
blood glucose by 2.1 mmoUl within 20 minutes (Brodows, 1984). It has been recognised 
that, while sufficient quantities of orange juice and glucose gel will provide at least 15 grams 
of carbohydrate, these agents may not provide a very rapid rise in blood glucose, and 
therefore were not recommended as first -line treatment by the authors of a study assessing 
available methods of treatment (Slama, 1990). In real life, however, it is generally found that 
fresh orange juice is effective in treating mild hypoglycaemia. It has been suggested that a 
supplementary snack to follow the acute treatment should consist of a combination of 
carbohydrate and protein, but in a comparative study, a protein -enriched snack appeared 
merely to add calories rather than providing any longer -term protection against a recurrence 
of hypoglycaemia (Gray, 1996). After consuming the appropriate amount of carbohydrate, 
the blood glucose should be retested after 15 minutes to confirm that it has risen and by how 
much, then a further 15 grams of carbohydrate should be consumed if the blood glucose 
remains below 4 mmol/1 (Brodows, 1984). By contrast, when a patient is receiving 
continuous subcutaneous insulin infusion therapy via a pump, only rapid- acting carbohydrate 
is required to treat the low blood glucose, and a snack containing complex carbohydrate is 
not required, as the insulin infusion can be temporarily discontinued. 
In severe hypoglycaemia, the nature of the treatment that is required will depend on the 
conscious level of the individual. If an individual is fully conscious and can swallow, then 
oral carbohydrate can be administered, but may be refused or resisted if confusion is present. 
The risk of aspiration is also a concern in a drowsy individual. If oral carbohydrate can be 
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administered safely the recommended amount is 20 grams. This should produce a rise in 
blood glucose of approximately 3.6 imnol /1 over 45 minutes (Brodows, 1984). If, at 15 
minutes, the blood glucose remains below 4.0 mmol/1, a further 15 grams of carbohydrate 
should be consumed (Brodows, 1984). 
1.5.1.2 Glucagon and intravenous dextrose 
In any person whose conscious level is reduced, parenteral treatment is necessary. Glucagon, 
administered either intramuscularly or subcutaneously in a dose of lmg (except children <5 
yrs old who should receive 0.5 mg), or intravenous dextrose can be given. Family members, 
friends and colleagues can be taught to administer glucagon. This either restores 
consciousness or at least prevents progression to more profound coma, and may avoid the 
occurrence of a seizure or serious injury while waiting for emergency help to arrive. 
Glucagon can increase the blood glucose from between 3 to 12 mmol/1 over the course of 60 
minutes (Muhlhauser, 1985), and while usually effective, is slower to raise the blood glucose 
than intravenous dextrose (Collier, 19871). It acts by mobilising glucose from the liver and 
by stimulating hepatic glycogenolysis. Treatment with glucagon can induce nausea and 
vomiting. 
Occasionally, administration of glucagon is ineffective in patients who have protracted 
hypoglycaemia and have exhausted stores of hepatic glycogen. This may also occur in 
people with cachexia, anorexia nervosa, advanced malignancy or severe liver disease 
(Dewar, 2004). Intravenous glucose may be required to treat severe hypoglycaemic episodes 
that fail to respond to glucagon, or to treat severe iatrogenic hypoglycaemia, particularly 
when this has been caused by a long- acting sulfonylurea. Initially 25g of dextrose (50m1 of 
50% dextrose) should be administered, but in the case of prolonged hypoglycaemia a 
continuous infusion of glucose and frequent oral feeding will be required (Krentz, 2005). A 
50% solution of dextrose is very irritant to veins and leakage can cause localised thrombosis 
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and extravascular tissue damage. As a consequence, 20% dextrose is now recommended in 
hospital practice. A study comparing intravenous glucagon with intravenous dextrose as the 
treatment of severe hypoglycaemia in a hospital emergency department showed that 
intravenous glucagon is a satisfactory alternative to dextrose, being easier to administer with 
very little risk of thrombosis or extravascular complications, although it takes longer to 
restore normoglycaemia (Collier, 1987'). 
1.5.1.3 Management of severe hypoglycaemia /coma in hospital 
If a person remains in a hypoglycaemic coma that has not responded to intravenous dextrose, 
hospital admission to an intensive care unit is essential. Neuroimaging must be performed to 
look for cerebral oedema, and to exclude other intracranial pathologies. Cerebral oedema is a 
dangerous complication of severe hypoglycaemia and is associated with a high mortality 
rate. Treatment includes intravenous mannitol and high dose corticosteroids, with other 
supportive measures such as high flow oxygen, sedation, and anticonvulsant therapy if 
indicated (MacCuish, 1993). People may not recover from hypoglycaemic coma until several 
days have passed, so it is difficult to gauge for how long treatment should be continued. If 
recovery occurs after prolonged unconsciousness, permanent neurological sequelae may be 
evident. Measurement of markers of acute neuronal damage such as neurone- specific 
endolase (NSE) and protein S100 have been advocated as a prognostic aid, as serum levels 
have been shown to rise acutely in fatal cases within 24 -48 hours of the onset of 
hypoglycaemic coma (Strachan, 1999). 
1.5.1.4 Sulfonylurea- induced hypoglycaemia 
Severe hypoglycaemia secondary to long- acting sulfonylureas may be prolonged and is 
likely to be more dangerous in the elderly, particularly if they are frail. Severe 
hypoglycaemia in these circumstances may not respond to glucagon, and should be treated 
with intravenous dextrose followed by continuous glucose infusion, which may have to be 
41 
maintained for several hours or even days (Krentz, 2005). There is little evidence to support 
the suggestion that glucagon is contraindicated in the treatment of sulfonylurea- induced 
hypoglycaemia on the basis that it might encourage further secretion of endogenous insulin 
(Taylor, 1978). Those affected may require hospital admission to ensure that hypoglycaemia 
does not recur. Octreotide may be a useful adjunct in the treatment of refractory 
sulfonylurea- induced hypoglycaemia (Krentz, 1993). 
1.5.1.5 Conclusion 
Any guidelines proposed for the management of acute hypoglycaemia need to be flexible in 
order that treatment can be tailored to individual situations. With experience, many people 
learn how much carbohydrate they require to ingest to treat an isolated episode of mild 
hypoglycaemia, and this may be less or more than would be dictated if strict guidelines were 
to be followed. However, the suggested amount of carbohydrate can be used as a starting 
point, and as experience is gained, self -management can be modified by the individual to suit 
the severity and circumstances of an event, and their individual treatment regimen, therefore 
avoiding potential under- or over -treatment of the episode. 
1.5.2 Treatment of chronic and recurrent hypoglycaemia 
The treatment of an acute episode of hypoglycaemia must include an analysis of why the 
episode occurred and how it could be avoided in future. Prevention of hypoglycaemia is an 
important aspect of management because chronic fear of hypoglycaemia is a major limiting 
factor in the maintenance of optimal glycaemic control. 
1.5.2.1 Dietary measures 
Modification of diet in the longer term can influence the propensity to develop 
hypoglycaemia. It has been demonstrated that maintaining a high fibre, low glycaemic index 
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diet can both improve glycaemic control and reduce the frequency of hypoglycaemic events 
(Giacco, 2000). 
1.5.2.2 Dealing with risk factors 
The possible contribution of the previously described causes and risk factors should be 
considered for each individual patient to identify those at higher risk, and to assist with 
modification of those factors in order to avoid severe hypoglycaemia. Elderly people with 
diabetes who are receiving treatment with insulin or insulin secretagogues are at high risk of 
developing hypoglycaemia, and in these patients, less strict targets for glycaemic control 
may be appropriate (American Diabetes Association, 2007). This is especially important 
when considering the problems associated with hypoglycaemia in people who have multiple 
co- morbidities, including some which may also be risk factors for hypoglycaemia (such as 
renal impairment). In addition, many elderly people live alone, and they may not have family 
support at home to help treat a hypoglycaemic episode should early warning symptoms be 
missed. Patients should be asked routinely about exposure to hypoglycaemia, the symptoms 
they experience, and how easily these are identified and treated. 
1.5.2.3 Impaired awareness of hypoglycaemia 
A few studies have shown that in people with impaired awareness of hypoglycaemia, 
hypoglycaemic symptoms can be restored following a period of scrupulous avoidance of 
hypoglycaemia (Fanelli, 1993). Alternatively, by reducing insulin doses and relaxing 
glycaemic control, HbAlc can be allowed to rise (Liu, 1996). If hypoglycaemia awareness 
can be restored, it may be possible to re- establish better glycaemic control with a lower risk 
of severe hypoglycaemia subsequently. This restoration of symptoms is not guaranteed with 
these measures, however, particularly in those people who have chronic impaired awareness 
of hypoglycaemia, suggesting that they have suffered permanent dysfunction of blood 
glucose sensing within the brain. In this situation, acceptance of less strict glycaemic targets, 
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as with the elderly, is an appropriate strategy, and intensive insulin therapy should be 
avoided. Asymptomatic biochemical hypoglycaemia is more common in affected patients, so 
frequent home blood glucose monitoring is essential to detect an early fall in blood glucose 
to allow time for effective intervention. Re- education using structured education 
programmes can also be beneficial in this group, and these are discussed later in this chapter. 
1.5.2.4 Sleep 
To avoid the risk of developing nocturnal hypoglycaemia, patients should be advised to 
measure their blood glucose before they go to bed, as there is considerable risk of this 
occurring if the bedtime blood glucose is <6.0 mmol/1. A prophylactic bedtime snack can be 
taken if necessary, but is unlikely to last throughout the night (Raju, 2006, Kalergis, 2003). 
Inappropriate hyperinsulinaemia during the night is the underlying problem, so changes to 
the therapeutic regimen may be required to reduce the risk of developing nocturnal 
hypoglycaemia. Delaying administration of evening isophane insulin until bedtime can 
reduce the risk of nocturnal hypoglycaemia, and the use of a rapid -acting insulin analogue 
with the evening meal instead of using soluble insulin (Mohn, 1999) can lower the risk of 
hyperinsulinaemia in the early part of the night. Using a long- acting insulin analogue, 
injected in the morning, as the basal insulin may confer less risk of inducing nocturnal 
hypoglycaemia (Pieber, 2000), mainly because the duration of action is usually less than 24 
hours. Continuous subcutaneous insulin infusion (CSII) also reduces nocturnal 
hypoglycaemia, as the nocturnal insulin requirement can be tailored using a variable rate of 
insulin infusion (Kane, 1998). Pharmaceutical interventions could potentially reduce the risk 
of nocturnal hypoglycaemia, but remain in the experimental phase. Inhaled ß- agonists such 
as terbutaline have been proposed as a method of increasing blood glucose overnight, and 
studies have shown that blood glucose rises for several hours following administration 
(Wiethrop, 1993). Unfortunately this may cause an elevated fasting blood glucose and its 
potential as a treatment option is unproven. 
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1.5.2.5 Exercise 
Hypoglycaemia is a potential risk of strenuous exercise and is determined by the plasma 
insulin concentrations at the time of exercise. Hypoglycaemia occurs when plasma insulin 
concentrations are elevated; conversely hyperglycaemia may occur when plasma insulin is 
low. In addition, the nature of the exercise influences the propensity to develop 
hypoglycaemia, with an increased risk being more likely with exercise of long duration and 
high intensity. This is not always predictable, and can be influenced by other factors. The 
timing of exercise in relation to food intake and insulin doses has to be considered. Insulin 
doses may need to be reduced, or the timing altered, to avoid experiencing the peak of 
insulin action at the time of exercise. If prolonged exercise over several hours is planned, 
insulin dosage should be reduced and slowly absorbed carbohydrate should be consumed to 
reduce the likelihood of developing hypoglycaemia. Exercise of short duration and high 
intensity requires a different approach, with reduction of the preceding dose of rapid- acting 
insulin, and prophylactic consumption of some form of short- acting carbohydrate. 
Counterregulatory hormonal responses to hypoglycaemia are attenuated following 
antecedent exercise, and conversely antecedent hypoglycaemia reduces the counterregulatory 
response to subsequent exercise (Galassetti, 2001, Galassetti, 2003). This may potentiate the 
problem of exercise -related hypoglycaemia. 
1.5.3 Education 
Educating patients about all aspects of their diabetes care is of vital importance to their self - 
management of hypoglycaemia. This should include information regarding carbohydrate 
intake, both prophylactically to avoid hypoglycaemia, and for its immediate treatment, and 
also in relation to adjustment of insulin and dosage of oral medication, alcohol intake, 
exercise and driving. Review of this information should be routine practice in ongoing care. 
Lack of understanding of their therapeutic regimen and poor knowledge of the symptoms of 
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hypoglycaemia and how it should be treated may contribute to recurrent problems with 
hypoglycaemia (Sumner, 2000, Thomson, 1991, Mutch, 1985). Structured education 
programmes, such as DAFNE (Dose Adjustment for Normal Eating) or DESMOND 
(Diabetes Education and Self -Management for Ongoing and Newly Diagnosed), are now 
being adopted more widely to empower patients to self -adjust their treatment regimens in an 
effort to improve glycaemic control, and to promote flexible attitudes to Diabetes. DAFNE 
incorporates adjustment of insulin dose to match carbohydrate intake, and can help to 
minimise risk of hypoglycaemia although appears to be less effective in lowering HbAl c 
(DAFNE Study Group, 2002, Davies, 2008, Sämann, 2006). It follows a five day format for 
groups of patients, and has a curriculum covering education and training about dietary 
flexibility and insulin dose adjustment. DESMOND focuses on the diagnosis of Type 2 
Diabetes, with initiation of the appropriate self- management skills. Structured education has 
been shown to decrease the risk of hypoglycaemia, but the resources required are significant, 
meaning it is not an option available to all, particularly in developing countries. 
Family members, friends and colleagues also require education about hypoglycaemia and its 
treatment, particularly in an emergency situation. Knowledge of the symptoms of 
hypoglycaemia will help them to identify the onset of hypoglycaemia, and enable them to 
undertake emergency treatment, and they should be instructed how to administer glucagon to 
treat severe hypoglycaemia, which can be stored at home or in the workplace. 
Specific training to improve the detection and avoidance of hypoglycaemia can improve 
overall glycaemic control, and reduce the risk of future hypoglycaemia. Blood Glucose 
Awareness Training (BGAT) is one such programme, developed in the USA to help people 
with impaired awareness of hypoglycaemia. The programme involves educating people 
about the identification and interpretation of physical symptoms, performance and mood 
changes as internal cues to blood glucose awareness. In addition, patients are advised about 
the influence of food, exercise, insulin doses and action profiles, time of day and previous 
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blood glucose values as external cues to help them determine the current level of blood 
glucose. It can be utilised when an intensified insulin regimen increases the frequency of 
hypoglycaemia and induces impaired hypoglycaemia awareness to improve the accuracy of 
estimating blood glucose, and BGAT has been shown to reduce the frequency of undetected 
biochemical hypoglycaemia (Cox, 1985, 1988, 1989, 1991). It also prevents further 
counterregulatory deficiencies and may modify the severity of hypoglycaemia associated 
with improved glycaemic control (Cox, 2001, Kinsley, 1999). However, a trial of a modified 
version of the BGAT programme in a European population suggested that the programme 
may not be so effective outside of the USA (Broers, 2002). 
Another training programme called HyPOS has been developed in Germany to assist people 
who are suffering from recurrent severe hypoglycaemia. When compared with standard 
methods of education and optimisation of insulin regimens, HyPOS has been shown to 
improve hypoglycaemia awareness, promote the effective treatment of hypoglycaemia, and 
reduce the overall risk of hypoglycaemia (Hermanns, 2007). HyPOS focuses on avoiding 
low blood glucose values, on informing patients fully about the causes of impaired 
hypoglycaemia awareness, and attempts to modify health beliefs as these could be 
contributing to frequent hypoglycaemia by perpetuating the vicious cycle of recurrent 
episodes. People are taught how to detect falls in blood glucose more effectively, and how to 
treat them promptly. A further five day intensive in- patient education programme, devised in 
Germany, was shown to reduce the incidence of severe hypoglycaemia over a prolonged 
follow up period, while simultaneously improving HbAlc (Bott, 1997). Unfortunately, the 
extensive clinical resources that are required to operate these educational interventions are 
not available in many countries, as is the case for the general education strategies discussed 
previously. 
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1.5.4 Blood glucose monitoring 
Measuring home blood glucose levels is necessary for effective management of insulin - 
treated diabetes, and is particularly valuable for the detection of asymptomatic biochemical 
hypoglycaemia. It allows both patients and healthcare professionals to review the results, 
recognise fluctuations and glycaemic patterns, and identify hypoglycaemia recurring at 
particular times of day. This assists with appropriate adjustment of therapeutic regimens. For 
people at higher risk of hypoglycaemia, such as those with impaired awareness of 
hypoglycaemia, frequent blood glucose monitoring may be the only way to identify 
asymptomatic biochemical hypoglycaemia and provide adequate warning to enable action to 
be taken. Monitoring blood glucose before, and during, demanding tasks such as driving and 
exercise can help to avoid hypoglycaemia at potentially dangerous times (Cox, 2000). 
However, this very much depends on how often blood glucose is measured, and testing at 
some times of day, such as during the night, may be impractical. Frequent home blood 
glucose monitoring may be considered unacceptable by the patient as it is invasive and can 
be painful, and it only provides single time point information, with no guidance to trends or 
direction and speed of change of glucose concentration (Gomis, 2004). 
Continuous glucose monitoring systems (CGMS) measure glucose in interstitial fluid, and 
may be useful in people at increased risk of hypoglycaemia, as it can be employed to detect 
asymptomatic hypoglycaemia, and to observe fluctuations in glucose that may be missed by 
single point home testing. This is most valuable when the results are available in real time, 
which is possible with some systems. However, CGMS does have limitations. Nocturnal 
measurements may indicate a lower interstitial glucose value than the equivalent capillary 
blood glucose sample, thus giving the impression that hypoglycaemia is more prolonged than 
in reality (Wentholt, 2007, Kubiak, 2004). Continuous glucose monitoring systems have 
been shown to be useful in detecting problems with hypoglycaemia awareness, and in 
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reassessing these people following therapeutic interventions to try to restore their 
hypoglycaemic symptoms (Kubiak, 2004). 
1.5.5 Modifying treatment strategies 
Modification of a patient's insulin regimen may be necessary to reduce the frequency of 
hypoglycaemia. The time -action profile of particular insulins in different regimens has to be 
considered, and in some cases the use of an alternative insulin with a different time -action 
profile may be necessary. With a basal -bolus regimen, fasting hypoglycaemia implicates the 
effect of the long or intermediate- acting insulin preparation, administered the previous day. 
Daytime hypoglycaemia may be caused by either the rapid- acting or long- acting insulins, 
depending on the regimen used. If pre -prandial soluble (regular) human insulin is being used, 
changing to a rapid- acting analogue insulin may reduce daytime hypoglycaemia (Heller, 
1999). The risk of nocturnal hypoglycaemia may be diminished by substituting the evening 
dose of intermediate- acting insulins such as isophane (NPH), or pre -mixed insulin 
formulations (30% rapid- acting/70% intermediate- acting or 50% rapid- acting/50% 
intermediate - acting for example), with a long- acting insulin analogue such as insulin 
glargine or insulin detemir (Home, 2004, Ashwell, 2006). 
In people with type 2 diabetes, several new pharmacological therapies, including the 
incretin- mimetic class of agents, have a lower risk of hypoglycaemia in comparison with the 
sulfonylureas, especially when they are combined with other oral agents or insulin. Analogue 
insulins are also beneficial in lowering hypoglycaemia risk in type 2 diabetes. This can 
consequently reduce both the patient's and the clinician's fear of hypoglycaemia and make 
achievement of glycaemic targets more realistic (Boyle, 2008). 
In cases of intractable recurrent hypoglycaemia, where the problem persists regardless of the 
insulin regimen being used, continuous subcutaneous insulin infusion (CSII) therapy may be 
beneficial, allowing greater flexibility with adjustment of basal insulin rates and prandial 
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bolus doses as necessary (Boland, 1999). A pilot study in people with type 1 diabetes who 
had impaired awareness of hypoglycaemia and recurrent severe hypoglycaemia compared 
the use of education alone in patients on conventional insulin regimens, with education plus 
multiple daily injections using analogue insulins, or education plus CSII using insulin 
pumps. Prevention of severe hypoglycaemia and restoration of hypoglycaemia awareness 
appeared to be possible while maintaining optimal glycaemic control, either with multiple 
injections of insulin analogues or with CSII (Thomas, 2007). A meta -analysis of trials 
assessing the impact of CSff on severe hypoglycaemia rates has shown that CSII 
significantly reduces the risk of severe hypoglycaemia when compared with multiple 
injection therapy (Pickup, 2008). 
1.5.6 Future developments in treatment 
Methods of improving recovery from hypoglycaemia have been explored using agents such 
as the amino acid, alanine, and the beta -2 agonist, terbutaline, and the effects of caffeine on 
enhancing symptom awareness. A suitable form of these pharmacological treatments may be 
useful to treat and prevent mild to moderate hypoglycaemia (Raju, 2006, Wiethrop, 1993, 
Kerr, 1993). Selective serotonin reuptake inhibitors (SSRIs) have also been investigated as a 
possible method of improving counterregulatory responses (Briscoe, 2008). 
The use of continuous subcutaneous insulin delivery systems and real time CGMS are likely 
to increase. Hypoglycaemia detection should improve as a consequence of better glucose 
sensing technology, as users will receive more detailed and more frequent information about 
their blood glucose than can be provided by intermittent single -point testing. This will allow 
greater flexibility in the adjustment of basal rates and bolus doses of insulin, particularly as 
real -time glucose sensors become more readily available for routine clinical use (Klonoff, 
2005). Real -time sensors will not only improve hypoglycaemia detection but will allow 
patients more freedom in their daily lives (Klonoff, 2005) and should help to reduce fear of 
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hypoglycaemia. The coupling of CSII with a real time glucose sensing system will allow the 
development of an effective closed loop system to deliver insulin At present the limiting 
factor is the availability of an inexpensive and reliable glucose sensor. A cheap and effective 
glucose sensor with an alarm system would be of great help in detecting asymptomatic 
nocturnal hypoglycaemia. 
Islet cell transplantation is a promising avenue in the treatment of recurrent severe 
hypoglycaemia unresponsive to analogue multiple injection therapy or CSII. Follow up data 
after five years has shown that even when a person is no longer insulin independent, the 
lower risk of severe hypoglycaemia is maintained (Shapiro, 2006). This, however, is an 
expensive treatment with very limited availability and the need for long term 
immunosuppression, and further investigation is needed prior to consideration of more 
widespread, routine use. 
Despite these promising developments, hypoglycaemia remains a major limiting factor in the 
effective management of insulin- treated diabetes, with significant morbidity, so treatment 
and prevention are fundamental components of any therapeutic regimen. 
1.6 Hypoglycaemia and cognitive function 
1.6.1 General cognitive function 
Hypoglycaemia has a detrimental effect on cognitive function, as the human brain relies 
solely on glucose as its source of energy. This decline in cognitive function may be 
perceived as symptoms by the person with diabetes, and may be their first warning to 
evolving hypoglycaemia if they have impaired hypoglycaemia awareness (Deary, 2007). 
In order to characterise this effect in more detail, there have been many studies of 
experimental hypoglycaemia, assessing many different facets of cognition. Early studies 
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showed that at blood glucose concentrations of less than 3.0 mmoUl, there was a reduction in 
fine motor skill, mental speed, concentration and memory function (Deary, 2007). These 
early studies were performed using the insulin infusion technique to induce hypoglycaemia; 
this method results in variable insulin concentration, with a variable blood glucose nadir, 
making interpretation and comparison of results challenging. Since then, developments in the 
field of hypoglycaemia research, and attention to safety, mean that most experimental 
hypoglycaemia is induced by the hyperinsulinaemic clamp technique (DeFronzo, 1979). This 
doesn't accurately mimic the hypoglycaemia experienced in day -to -day life, in the way that 
the infusion method is more likely to, but it is a safe and effective method of inducing a 
decline in blood glucose which can be stabilised for a reasonable time period, allowing in- 
depth study of cognitive performance. Reproducible blood glucose target levels can also be 
achieved by this method, whereas variable levels will be achieved using alternative strategies 
such as the insulin infusion method. 
Studies performed using the hyperinsulinaemic clamp technique have shown that at blood 
glucose concentrations between 3.1 and 3.4 mmol/1, there is a decrease in reaction times, 
slowing of mental arithmetic, impairment of verbal fluency and impairment of performance 
on parts of the Stroop test. There appears to be sparing of simple motor and sensory skills, 
and the speed of reading out loud (Deary, 2007). Even amongst studies using the saine 
technique to induce hypoglycaemia, there remains heterogeneity between the studies, 
including the glycaemic target, the actual cognitive test battery used, whether there is a 
euglycaemic control arm to the study, and the baseline cognitive abilities of the subjects 
participating in the studies. There is no consensus on which cognitive tests are the best ones 
to identify a cognitive decline during experimental hypoglycaemia. Many of the tests used 
do not assess one pure domain of cognitive function, but encompass many different facets of 
cognition. In addition, the experimental setting of a clamp study is clearly an artificial one, 
which may affect a person's cognitive performance on the tests administered. The subjects 
52 
are stationary in a bed or chair, with infusions being administered through a cannula in one 
arm, and with blood sampling occurring regularly, which may discourage people from free 
movement and may affect their results on some tests. 
A summary of studies assessing cognitive function in adults with type 1 diabetes is shown in 
table 1.5. There have also been many assessments of cognitive function in non -diabetic 
adults, which have shown similar findings in the majority of tests, although some aspects of 
psychomotor function were affected in the non- diabetic cohort but not the subjects with 
diabetes, suggesting a possible element of cerebral adaptation in those who have previous 
experience of hypoglycaemia (Geddes, 2008). Conversely, an early study by insulin infusion 
that had a mean glucose nadir of 2.0mmol/1 revealed bigger decrements in cognitive function 
in those with diabetes than the non -diabetic subjects. It was postulated that this may have 

































































































































































































































































































































































































































































































































































































































































































































































































































































It therefore appears that hypoglycaemia has a pronounced effect on complex cognitive tasks 
both in diabetic and non -diabetic humans, whereas simple mental tasks are less affected 
(Deary, 2007). On review it appears that this generally occurs at blood glucose levels below 
3.0 mmol/1(Hoffman, 1989, Mitrakou, 1991, Widom, 1990, Wirsen, 1992, McAulay, 20012, 
Sommerfield, 2003', Sommerfield, 20032, Warren, 2004). This relative preservation of 
simple motor tasks may be explained by a functional MRI study which examined the effects 
of hypoglycaemia on brain function. There was a decrease in blood oxygen level- dependent 
(BOLD) activation in the motor area of the brain on MRI scanning when motor tasks were 
being performed (Rosenthal, 2001). Simple motor tasks such as finger tapping resulted in 
smaller areas of BOLD activation as compared with more complex tasks, such as the four 
choice reaction test (4CRT). This may reflect the increased cognitive load required with 
more complex tasks such as the four choice reaction test. 
The recovery of different aspects of cognitive function varies from between 40 and 90 
minutes following restoration of blood glucose to normal (Deary, 2007, Zammitt, 2008). 
This has particular relevance to the task of driving in daily life for people with diabetes. The 
Driver and Vehicle Licensing Authority (DVLA) in the UK now have comprehensive 
guidelines based on this evidence which suggest a delay of at least 45 minutes prior to 
continuation of driving following treatment of hypoglycaemia. 
Of course, cognitive decline will not occur at a set blood glucose concentration for every 
individual. Other factors will influence this, and it is a dynamic process. The factors 
contributing to an increased likelihood of cognitive decline during hypoglycaemia include 
male sex, impaired hypoglycaemia awareness, type 1 diabetes and a high baseline IQ (Deary, 
2007). Those patients with intensively controlled diabetes are more likely to experience 
hypoglycaemia, and are more at risk of developing impaired hypoglycaemia awareness; this 
can result in a reduction in the blood glucose threshold at which autonomic activation occurs, 
with the cognitive dysfunction beginning at higher blood glucose concentrations than the 
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sensation of autonomic warning symptoms. This can be a dangerous consequence of 
intensive glycaemic control, narrowing the window of opportunity to take appropriate action 
to avoid development of more severe hypoglycaemia. 
In real life, most activities will actually involve a combination of multiple aspects of 
cognition, a good example of which is driving. This is a complex cognitive task requiring 
attention, memory, auditory and visual information processing, psychomotor function, 
reaction time and spatial perception, amongst others. Studies have been performed using a 
sophisticated driving simulator (Cox, 2000), which have demonstrated the decline in driving 
ability as blood glucose decreases. There is a slowing of reaction times, and an increase in 
accidents. These simulator studies make this cognitive dysfunction more relevant to real life 
activities. 
1.6.2 Hypoglycaemia and spatial ability 
Spatial ability can be defined as the ability to interpret the surrounding enviromnent using 
visual cues. These visual cues must be generated, then structured and manipulated by the 
brain, in order to orientate and interpret the images appropriately. This translates into how a 
human being can deal with two - and three- dimensional objects, navigation and path -finding 
(Linn, 1985). Understandably, spatial ability is therefore a component of many cognitive 
function tests used experimentally, particularly the more complex or demanding tasks. It is a 
part of many daily tasks, with particular practical relevance to driving and map -reading, for 
example. No studies to date have specifically focused on the effects of hypoglycaemia on 
spatial abilities, although many tests that are impaired during experimental hypoglycaemia 
may include an element of spatial ability and spatial processing (Geddes, 2008). 
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1.6.3 Long -term effects of hypoglycaemia on the brain 
1.6.3.1 Cognitive function 
It is, as yet, unclear as to whether repeated episodes of hypoglycaemia may have progressive 
long term effects on mental abilities. The concept of diabetic encephalopathy has been 
described in the literature, and it is possible that exposure to repeated hypoglycaemia is one 
of the contributing factors to this phenomenon, along with the additional contribution by 
vascular disease and conventional cardiovascular risk factors (Dejgaard, 1991, Biessels, 
1994, Makimattila, 2004). In essence, the brain can be considered to be an end -organ 
susceptible to the effects of diabetes in the same way that the retina, kidneys and nerves are, 
although the contribution of hypoglycaemia to this process remains uncertain. 
Several studies in children with Type 1 diabetes have shown that repeated, severe 
hypoglycaemia, particularly before the age of 5, can reduce mental capabilities in adult life. 
This effect appeared more profound in those diagnosed at a younger age and with longer 
duration of diabetes (Ryan, 1984, Rovet, 1987, Golden, 1989, Hershey, 2005, Ryan, 2005). 
However, there have been some conflicting studies more recently suggesting this premise not 
to be true (Wysocki, 2003, Strudwick, 2005). 
Adults with type 1 diabetes have been shown to have reduced mental abilities when 
compared with non -diabetic individuals (Ryan, 2006, Brands, 2005). The reasons for this 
have not been fully explained. It is believed that recurrent exposure to severe hypoglycaemia 
may result in a modest reduction in IQ, but the full explanation is likely to be multifactorial, 
and include vascular and blood flow related effects of diabetes (Brands, 2005). The DCCT 
and its follow up study, EDIC, showed that over the 10 years of follow up performed, there 
was no reduction in IQ or cognitive abilities associated with exposure to severe 
hypoglycaemia (DCCT Group, 1993, DCCT Group, 1996, DCCT /EDIC Group, 2007). It 
should again be noted that the DCCT was designed with very strict inclusion/exclusion 
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criteria, and that those included had low risk of hypoglycaemia, with resulting lower rates of 
severe hypoglycaemia than have been described in less selective studies. As a result, the 
subjects were not typical of routine clinical practice. 
Retrospective cross -sectional studies have been undertaken to look at the impact of previous 
severe hypoglycaemia exposure on intellectual capacity in adults with type 1 diabetes. These 
studies have suggested that those with increased severe hypoglycaemia exposure in the past 
have lower intellectual functioning (Wredling, 1990, Langan, 1991, Lincoln, 1996, Deary, 
19932). Retrospective analysis of hypoglycaemia occurrence can be flawed, as previously 
discussed, however, and there are possible additional confounding variables in all of these 
analyses, including the contribution of the diagnosis of diabetes itself, and the premorbid IQ; 
participants experiencing more hypoglycaemia may have had lower IQ scores to begin with. 
These results therefore suggest an association between SH exposure and reduction in IQ, but 
do not confirm causality, and disagree with the findings of the prospective long term trials to 
date. 
The evidence in type 2 diabetes of an association between cognitive decline and diabetes 
seems fairly robust (Cukierman, 2005). It has been reported, however, that because 
hypoglycaemia rates are relatively low in people with type 2 diabetes, that it is unlikely to 
play a part in the pathogenesis of this decline. There appears to be an accelerated rate of 
cognitive decline and an increased risk of dementia in type 2 diabetes, but the interplay of 
vascular risk factors and other risk factors is acknowledged (Stewart, 1999, Allen, 2004). 
The role of hypoglycaemia in this process remains to be established. 
1.6.3.2 Structural and neurological changes 
It is known that a severe, prolonged episode of hypoglycaemia can result in serious and 
permanent brain damage (Malouf, 1985, Yoneda, 2005). It should be noted that these 
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instances have often involved the consumption of alcohol which has compounded the effects 
of the episode of hypoglycaemia. 
Hypoglycaemia can induce seizure activity. Neurophysiological changes are apparent during 
hypoglycaemia, including a decrease in alpha wave activity, increase in theta waves, and 
increased bursts of delta waves, particularly evident in the anterior brain. There is also 
increased latency and reduced amplitude of sensory - evoked potentials. These changes are 
more marked in those patients with impaired hypoglycaemia awareness, and can become 
permanent in those with recurrent severe hypoglycaemia (Pramming, 1988, Tallroth, 1990, 
Bjorgaas, 1998, Hyllienmark, 2005). 
Regional blood flow changes occur, which are usually temporary and return to normal on 
recovery, but these may also become permanent in people with impaired hypoglycaemia 
awareness; an increase in blood flow to the frontal lobes is seen, which may be an adaptive 
phenomenon to protect a vulnerable region of the brain (MacLeod, 1996). These alterations 
will be discussed further in the section on cerebrovascular disease and hypoglycaemia later 
in this chapter. Hypoglycaemia can mimic the symptoms of acute stroke, causing, for 
example, hemiparesis. It has been shown that these clinical signs can correspond to transient 
abnormalities in cerebral imaging, suggesting that there has been focal reduction in blood 
flow to result in an area of ischaemia (Shirayama, 2004, Koppel, 1993, Gold, 1996, 
Cordonnier, 2005). 
Furthermore, imaging studies have been undertaken in an attempt to clarify whether 
exposure to recurrent hypoglycaemia may impact on brain structure and function in the 
longer term. A study in 1997 demonstrated that people with type 1 diabetes exposed to 
recurrent severe hypoglycaemia had increased cerebral atrophy on MRI scanning as 
compared with a matched control group (Perros, 1997; figure 1.2). 
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Figure 1.2: Brain abnormalities seen in people with type 1 diabetes exposed to 
recurrent severe hypoglycaemia. Reproduced from Perros, 1997. 
A. Small white lesions (leukoariosis); see arrow B. Cortical atrophy 




These findings have not been replicated to date. It is evident that structural cerebral changes 
do occur in people with diabetes, as compared with non -diabetic control subjects, but there 
does not appear to be an association with exposure to recurrent severe hypoglycaemia. 
Instead, the main association is with the presence of microangiopathy, particularly 
retinopathy (Ferguson, 2003, Brands, 2005, Ryan, 2006). The implication that this removes 
the possible contribution of hypoglycaemia from the equation may, however, not be correct, 
particularly as the usual issues in hypoglycaemia studies with heterogeneity in definitions 
used and reporting methods are present in all of these studies. 
It is apparent that there are potential long term sequelae of hypoglycaemia on brain function, 
although much of the longitudinal data thus far appears to be relatively reassuring with little 
evidence of a causal role in any abnormalities detected in those people with diabetes. There 
remains the issue of selection of subjects with low hypoglycaemia risk for the larger trials, 
differences in reporting hypoglycaemia and definitions used, and differences in the 
neurological and psychological assessments used. More information is required to fully 
examine the possible long -term effects of recurrent hypoglycaemia on brain structure and 
function. 
1.7 Diabetes and Cardiovascular disease 
Atherosclerosis is a major cause of cardiovascular morbidity and mortality in people with 
diabetes and is very common. It can develop prematurely, can be more diffuse and 
widespread and can be more aggressive than in people who do not have diabetes (Banga, 
1994, Deckert, 1978, Kirpichnicov, 2001). 
Several studies have now been undertaken to investigate the underlying pathogenesis of 
atherosclerosis and vascular complications in people with diabetes. These studies support the 
hypothesis that inflammation contributes to the pathogenesis of atherosclerosis and 
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cardiovascular disease, and it is likely that external influences on endothelial function and 
the blood components can have an effect on blood vessels and contribute to this. In the past, 
athero -thrombotic disease was believed to originate from collections of lipid in vessel walls, 
which form plaques, in combination with the effects of conventional cardiovascular risk 
factors such as hypertension, smoking and diabetes. Animal and human studies have now 
suggested that atherogenesis contains a significant inflammatory component, from the early 
stages of development, which contributes to its progression and the subsequent emergence of 
thrombotic complications (Libby, 2002). Research has therefore advanced from an 
examination of traditional cardiovascular risk factors to investigation of the processes that 
involve the vasculature at a cellular level, particularly examining the cells that are implicated 
in atherogenesis, including endothelial cells, macrophages, monocytes, platelets and smooth 
muscle cells. 
1.7.1 Diabetes and vascular biology 
There is a chronic systemic pro -inflammatory and pro -coagulant state in both type 1 and type 
2 diabetes. The EURODIAB prospective complications study showed that inflammatory 
markers (C- reactive protein [CRP], interleukin -6 [IL -6] and tumour necrosis factor -a [TNF- 
a]) were found to be strongly, and independently, associated with vascular disease in people 
with type 1 diabetes (Schram, 2005). This has been supported by other studies that have 
shown an association between chronic inflammation, endothelial dysfunction and platelet 
hyperactivity, and the microvascular complications of retinopathy and nephropathy (Yngen, 
2004, Vestra, 2005, van Hecke, 2005). Even in the absence of vascular complications, 
markers of endothelial dysfunction including CRP, von Willebrand factor (vWF) and 
vascular cell adhesion molecule (VCAM) -1 are elevated (Schalkwijk, 1999, Targher, 2005), 
while plasma concentrations of the anti -inflammatory cytokine interleukin (IL) -10 are lower 
in people with type 2 diabetes (van Exel, 2002). 
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Endothelin -1, a potent vasoconstrictor, has been demonstrated to be elevated in people with 
both type 1 and type 2 diabetes (Takahashi, 1990). Levels increase in the presence of 
microvascular disease, and it has therefore been postulated that endothelins may play a role 
in the development of these complications (Dhaun, 2006). 
The evaluation of markers that may be associated with the presence of vascular disease, or 
signify increased future risk, has now gained momentum. C- reactive protein (CRP) has 
received much attention in this regard. CRP has been shown to be elevated in people with 
established vascular disease, and has been associated with a poorer prognosis in patients who 
present with unstable coronary heart disease (Mendall, 1996, Morrow, 1998). 
Platelet -monocyte aggregation has been shown to be a sensitive indicator of platelet 
activation. Activated platelets bind to leucocytes, predominantly monocytes, to form 
aggregates. This induces secretion of interleukin-1 ß, interleukin -8, monocyte chemotactic 
protein, Mac -1 and tissue factor (Neumann, 1997, Celi, 1994). In apolipoprotein E- deficient 
mice, monocyte adhesion to the activated endothelium and atherogenesis per se are promoted 
by platelet -monocyte aggregation (Huo, 2003). 
There is also increasing evidence to suggest that the CD40 -CD40 ligand (CD4OL) signalling 
pathway plays an important role in the pathogenesis of atherosclerosis and of plaque rupture 
(Schonbeck, 2000', Mach, 1998'). CD40 is a type I transmembrane protein and is a member 
of the tumour necrosis factor (TNF) receptor family. CD4OL is a type II transmembrane 
protein (Schonbeck, 20002). Their interaction regulates cell proliferation, differentiation and 
apoptosis, and is thought to induce a pro -inflammatory, prothrombotic response by causing a 
cascade of cytokine and chemokine release, and expression of adhesion molecules, matrix 
metalloproteinases and tissue factor (Schonbeck, 20002, Mach, 1997, Heim, 1998). A 
soluble, biologically active form also exists as soluble CD40 ligand (sCD4OL). CD40 ligand 
and its receptor CD40 are present on the surface of platelets, monocytes, endothelial cells 
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and smooth muscle cells, all of which are associated with the formation of atheroma. 
Ligation of CD4O-CD4OL activates these atheroma- associated cells (Mach, 1997, Henn, 
1998). Studies in hypercholesterolaemic mice show that interruption of the CD40 /CD4OL 
dyad slows the initiation and progression of atherosclerotic lesions (Mach 19982, Schonbeck, 
20003). In humans, clinical studies in patients with acute coronary syndromes have revealed 
the presence of an elevated level of sCD4OL (Aukrust, 1999, Garlichs, 2001). Apparently 
healthy women who have increased plasma concentrations of sCD4OL, have been shown to 
be at increased risk of acute vascular events (Schonbeck, 20012). It has been postulated that 
this test could potentially be used for risk. stratification. 
Recently it has been shown that diabetes is associated with increased CD4OL expression and 
platelet -monocyte aggregation (Harding, 2004). Plasma levels of sCD4OL are elevated, and 
correlate with HbAlc, suggesting that hyperglycaemia is responsible. An improvement in 
glycaemic control was associated with a reduction in plasma sCD4OL by 37.5 %, in 40% of 
patients with type 1 diabetes (Cipollone, 2005). Other studies, however, have suggested that 
improving metabolic control has no effect on endothelial dysfunction (Yudkin, 2000). 
It remains controversial as to whether these vascular biomarkers are elevated in response to 
vascular disease rather than as promoters of vasculopathy. The fact that CRP and sCD4OL 
are markers that predict the future risk of vascular disease is supportive of a causative role. 
In addition, it is known that systemic inflammation can precipitate vascular events. Such an 
example is viral infection with influenza, which provokes inflammatory and thrombotic 
effects on atherosclerotic plaques, and can increase the mortality from cardiovascular causes 
(Madjid, 2003). 
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1.8 Hypoglycaemia and vascular disease 
It has been suggested that hypoglycaemia may aggravate the microvascular complications of 
diabetes (Frier, 1985). The profuse secretion of counterregulatory hormones, such as the 
catecholamines, and acute stimulation of the autonomic nervous system in response to 
hypoglycaemia, may contribute to these effects on haematological constituents, but to date 
investigation of this has been limited, partly due to a lack of sophisticated tests to assess this 
risk further. Figure 1.3 depicts a theoretical model of the increasing prevalence of diabetic 
complications associated with progressive duration of the disorder, and suggests the premise 
that recurrent exposure to hypoglycaemia may exert an increasingly adverse effect when the 
vasculature has already become compromised. Clinical evidence that hypoglycaemia may 
impact on the cardiovascular system has been accumulating for many years. Although much 
of the evidence is circumstantial, it does raise serious concerns, and indicates the need for 
more information on the potential hazards of hypoglycaemia. 
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Figure 1.3: Risks of hypoglycaemia on the vasculature: theoretical model of 
the increasing impact of hypoglycaemia once vascular complications have 
developed. Reproduced from Wright, 2008. 
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1.8.1 Myocardial ischaemia 
It seems logical that the stress of acute hypoglycaemia, inflicted upon a diseased coronary 
arterial circulation may provoke myocardial ischaemia. But the evidence is limited and 
conflicting. A few anecdotal reports have been published indicating that angina or 
myocardial infarction had been precipitated by hypoglycaemia. It would now be considered 
dangerous and unethical to induce hypoglycaemia in patients who are known to have 
ischaemic heart disease, but such patients were studied in the past, particularly when 
hypoglycaemic coma was induced to treat psychiatric disorders. In 1932, hypoglycaemia was 
induced in seven subjects with type 1 diabetes with known cardiovascular disease, two of 
whom developed chest pain consistent with myocardial ischaemia (Strouse, 1932). In 1956 
when a similar study was undertaken in 11 non -diabetic subjects who had known coronary 
heart disease, none experienced symptoms of angina (Judson, 1956). Another study in 1960, 
which examined the effects of hypoglycaemia on 38 non -diabetic patients with ischaemic 
heart disease, also failed to provoke angina (Egeli, 1960). 
However, continuous ECG monitoring was not performed during these studies, and it is now 
recognised that people with type 1 diabetes, many of whom have autonomic dysfunction, 
often have `silent' myocardial ischaemia and do not experience angina even when overt 
ischaemia is revealed by ECG changes. Ambulatory ECG studies of people with diabetes 
with known coronary heart disease have demonstrated ischaemia with ST segment 
depression in the absence of angina (Nesto, 1988). A case report of a patient who developed 
significant ST depression in the absence of angina during an episode of nocturnal 
hypoglycaemia has been described (Pladziewicz, 1989). So, although there are limited 
reports of hypoglycaemia- induced angina, this may reflect the relatively "silent" nature of 
ischaemic heart disease in people with diabetes. 
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Myocardial infarction or cardiovascular death have been associated with hypoglycaemia 
(Kinsey, 1941, Gilbert, 1946, Partaiman, 1965), and a direct association between 
hypoglycaemia and myocardial ischaemia has been described in a study of 21 patients who 
had co- existent insulin- treated type 2 diabetes and coronary heart disease, and were receiving 
treatment with basal -bolus insulin regimens (Desouza, 2003). Continuous blood glucose 
monitoring was combined with Holter monitoring to identify myocardial ischaemia. A 
significant association (p <0.01) was observed between hypoglycaemia and either symptoms 
or electrocardiographic changes of ischaemia, which was not observed with either 
hyperglycaemic or normoglycaemic states (Desouza, 2003). In addition, the Veterans 
Affairs Co- operative Study on Glycaemic Control and Complications (VACSDM) revealed 
that more cardiac events were recorded after the institution of strict glycaemic control (32% 
vs. 20 %), when the intensively treated patients experienced 16.5 episodes /patient/year of 
mild hypoglycaemia vs. 1.5 in the conventional treatment group (Abraira, 1997). Studies of 
diabetic patients with coronary heart disease, which examined the influence of glycaemic 
control at the time of an acute coronary event on subsequent mortality have shown a positive 
association between both hypo- and hyperglycaemia and all -cause mortality risk over the 
course of two years (Svensson, 2005). In a large study from Israel that followed patients with 
coronary heart disease over an eight year period, hypoglycaemia at initial presentation 
emerged as a marker for increased all -cause mortality (Fisman, 2004). 
1.8.2 Cardiac arrhythmia 
Acute hypoglycaemia can precipitate T wave abnormalities and QT prolongation on the 
electrocardiogram. The evidence for any true pro -arrhythmic effect remains limited. 
Anecdotal reports have observed an increase in ectopic beats of atrial and ventricular origin, 
and of atrial fibrillation, during insulin- induced hypoglycaemia, although this occurred in 
patients who had established heart disease (Strouse, 1932). In diabetic subjects without any 
known cardiac disease, sporadic hypoglycaemia has provoked atrial fibrillation, which 
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reverted to sinus rhythm after correction of the low blood glucose (Collier, 19872). These 
disturbances of cardiac rhythm are probably a consequence of the adrenergic response to 
hypoglycaemia, possibly mediated via a fall in serum potassium concentration, which may 
precipitate the cardiac arrhythmias (Burke, 1999, Thordarson, 1995, Marques, 1997, Harris, 
1999). Alternatively, in those patients with pre- existing ischaemic heart disease, an 
arrhythmia may develop secondary to an ischaemic insult. 
1.8.3 Cerebrovascular disease 
Hypoglycaemia can induce localised neuroglycopenia and transient focal neurological signs, 
which resolve on correction of blood glucose. However, neuroimaging techniques have not 
demonstrated direct evidence that hypoglycaemia can cause cerebral ischaemia. It is not 
known whether the haemodynamic and haematological effects of hypoglycaemia on the 
vasculature can also contribute to the neurological deficit. In individual cases, when 
neuroimaging was performed after the development of a neurological deficit associated with 
severe hypoglycaemia, areas of reduced density that were consistent with ischaemia have 
been observed in the appropriate cerebral area; these changes have usually resolved 
following correction of hypoglycaemia (Shirayama, 2004, Koppel, 1993, Gold, 1996, 
Cordonnier, 2005). Permanent disability does occasionally result from severe 
hypoglycaemia, which may be mediated by cerebral damage secondary to glucose 
deprivation or by cerebral infarction. Transient ischaemic attacks and hemiplegia are 
recognised sequelae of hypoglycaemia, and the acute haemodynamic and haematological 
effects may provoke a stroke, presumably in the areas of the brain where the regional blood 
flow is compromised, but information is not available to determine the prevalence or 
mechanisms behind this (Malouf, 1985, Ben -Ami, 1999). 
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1.8.4 Microvascular disease 
The DCCT confirmed that intensive glycaemic control limited the development and delayed 
the progression of long -term complications of diabetes over a mean follow up period of 6.5 
years, but an initial deterioration in retinopathy was noted shortly after the intensive 
treatment regimen was instituted (DCCT Study Group, 1993, Agardh, 1992). In studies in 
the 1980s (Lauritzen, 1983, Dahl- Jorgensen, 1985), a similar phenomenon had been 
observed during the two to four months after rapid improvement of glycaemic control, 
although this gradually improved despite persistence of intensive therapy. Although the 
long -teen progression of retinopathy is prevented by intensive control, established 
retinopathy is not reversed, and the temporary worsening of retinopathy can be clinically 
significant. A reduction in retinal blood flow is described as the most likely mechanism, but 
it is also noteworthy that hypoglycaemia frequency increases when tight control is instituted, 
as one might expect (Lauritzen, 1983, Dahl- Jorgensen, 1985). The haemodynamic and 
haematological effects of hypoglycaemia seem to be transient in an undamaged circulation, 
so are unlikely to contribute to the initial development of long term complications, but these 
effects may aggravate complications in an already compromised circulation (Frier, 1985). 
Acute vitreous haemorrhage has been reported following nocturnal hypoglycaemia (Taman, 
1979), which may be related to the rapid fall in intra- ocular pressure which occurs during 
hypoglycaemia (Frier, 1987), causing rupture of the fragile new capillary vessels that have 
developed as a consequence of retinal ischaemia, 
At present the evidence for the possible effects of hypoglycaemia on microangiopathy 
remains circumstantial and the potential effects are hypothetical. It is possible, however, that 
hypoglycaemia may have adverse consequences on small blood vessels and thereby 
aggravate pre- existing microvascular disease. 
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1.8.5 Possible mechanisms of vascular damage 
Hypoglycaemia may exacerbate vascular damage in a number of ways. These include direct 
effects on blood vessels through changes in vascular physiology, blood cell alterations and 
activation, vasoconstriction, and inflammation. Each of these will be examined in turn. 
1.8.5.1 Physiological changes 
In response to hypoglycaemia (see earlier section on the physiology of hypoglycaemia), 
epinephrine is released in large quantities through sympathetic neural activation and this 
hormone is known to have direct cardiovascular effects. Heart rate and systolic blood 
pressure rise, while a small decrement in diastolic blood pressure occurs (MacDonald, 2007). 
By studying patients with autonomic deficits, the increment in heart rate has been found to 
be mediated via sympathetic activity. This response is absent in tetraplegic patients with 
presynaptic sympathectomy caused by traumatic transection of the cervical cord (Corrall, 
1979); it appears to be mediated via ßl adrenoceptors (Kerr, 1990). The blood pressure 
changes are thought to be caused by epinephrine via a and ßZ adrenoceptors, and can be 
reproduced by infusing epinephrine intravenously (Kerr, 1990). Myocardial contractility and 
cardiac output both increase and peripheral vascular resistance declines (Hilsted, 1984). The 
left ventricular ejection fraction (LVEF) rises, as has been demonstrated using radionuclide 
ventriculography, and represents a surrogate measure for myocardial contractility. The 
change in LVEF can be abolished by f3 adrenoceptor blockade (Fisher, 1987). 
Insulin- induced hypoglycaemia provokes cardiac electrophysiological changes including 
flattening or inversion of T waves in the ECG (Middleton, 1931), while QT prolongation 
(Parrish, 1952, Egeli, 1960) and ST depression (Parrish, 1952, Lloyd -Mosten, 1975) have 
been observed but are not readily reproducible. The T wave changes were shown to resolve 
during concomitant intravenous infusion of potassium during hypoglycaemia (Parrish, 1952, 
Egeli, 1960), and could be abolished by f3 blockade (Lloyd -Mosten, 1975). Administration of 
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selective f3' blockade before the induction of acute hypoglycaemia prevented QT 
prolongation (Lee, 2005). This implicates a ß adrenoceptor- mediated mechanism, probably 
acting via a fall in serum potassium and so precipitating the electrophysiological changes 
(Fisher, 1991'). 
1.8.5.2 Regional blood flow 
The sympathetic nervous system response to hypoglycaemia seems to play a major role in 
the regional changes in blood flow seen throughout the body. Total cerebral blood flow 
increases at blood glucose concentrations below 2.0 mmol/1 and the regional distribution of 
blood flow within the brain alters to provide glucose to the areas that are most vulnerable to 
neuroglycopenia, such as the cerebral cortex and the basal ganglia (Bryan, 1990, MacLeod, 
1994, Tallroth, 1992). Although this has been disputed by the results of one study (Segel, 
2001), the hypoglycaemic nadir in that study was 3.0 mmol/1, which may not have been 
sufficient to stimulate a rise in cerebral blood flow. 
Total splanchnic blood flow increases (Beam, 1952, Braatvedt, 1993) and splenic blood flow 
decreases (Fisher, 19901), while there is a relative increase in hepatic blood flow which 
should enhance hepatic glucose production. Blood flow to skeletal muscle increases 
(Allwood, 1959), while blood flow to the kidneys declines (Patrick, 1989). Blood flow to the 
skin is initially increased, causing vasodilatation and flushing, but it subsequently declines, 
causing pallor (Maggs, 1994). This redistribution of blood flow has two main hypothetical 
roles: (i) to protect vital organs such as the brain, and (ii) to maintain a supply of glucose by 
increasing the delivery of gluconeogenic precursors to the liver. It is possible that diversion 
of blood flow to more vital parts of the brain during hypoglycaemia may result in greater 
cerebral ischaemia in other areas. 
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1.8.5.3 Haemorrheological changes 
1.8.5.3.1 Blood cells 
Erythrocytes 
Experimental studies of acute hypoglycaemia have demonstrated an increase in the number 
of circulating erythrocytes in relation to the peak of plasma epinephrine concentration in 
response to the hypoglycaemic stimulus (Frier, 1983, Hilsted, 1985). This apparent 
erythrocytosis is probably caused by haemoconcentration and a rise in packed cell volume, 
rather than the entry of new red blood cells into the circulation, as this response is preserved 
in patients post- splenectomy (Hilsted, 1990). When hypoglycaemia was induced in 
sympathectomized subjects, who do not generate an epinephrine response to hypoglycaemia, 
an increment in erythrocyte number was not observed, suggesting that this phenomenon is 
mediated by an adrenergic mechanism (Frier, 1983). The response can also be reproduced by 
the intravenous infusion of epinephrine (Hilsted, 1990), and while the increment can be 
abolished by a blockade with phentolamine (Fisher, 19912), it is unaffected by selective or 
non -selective ß blockade (Frier, 1983), implicating that the change is mediated by a 
adrenoceptors. 
Leucocytes 
The absolute number of leucocytes increases in response to acute insulin- induced 
hypoglycaemia (Collier, 1990). This leucocytosis consists of an initial increment in 
lymphocytes coinciding with the acute autonomic reaction, and this is followed within one 
hour by a rise in granulocytes (Frier, 1983, Fisher, 1989), and a fall in circulating T- 
lymphocytes (Fisher, 1989). The lymphocytosis that coincides with the autonomic reaction 
appears to be mediated predominantly through a adrenoceptors, as this response is absent in 
sympathectomized individuals and is abolished by a blockade with phentolamine, while 
being only mildly attenuated following unselective ß blockade (Fisher, 19902). That this 
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response is adrenergically- mediated has also been demonstrated by the administration of 
exogenous epinephrine, which provoked a lymphocytosis (Steel, 1971). In addition, acute 
experimental hypoglycaemia has been shown to induce a proliferation of (32 adrenoceptors on 
the surface of mononuclear leucocytes (van Tits, 1990). By contrast, the later proliferation of 
granulocytes is mediated by cortisol, which was demonstrated by comparing the cortisol and 
granulocyte responses to hypoglycaemia in normal subjects with patients who had 
deficiencies of the hypothalamo -pituitary- adrenal axis (Fisher, 1989). Neutrophils are 
activated during hypoglycaemia, as demonstrated by the release of neutrophil elastase 
(Collier, 1990), a protease that has been implicated in the development of microangiopathic 
complications in diabetes. 
Platelets 
Platelet aggregation is promoted by hypoglycaemia (Hutton, 1979). Platelet factor 4 
(Trovati, 1986) and plasma 13 thromboglobulin both increase, and are thought to represent the 
activation of platelets in vivo (Trovati, 1986, Monnier, 1984, Kishikawa, 1988, Takeda, 
1988). In addition, the aggregation of platelets in response to ADP is promoted, and this 
probably develops secondary to the adrenergic stimulation that is associated with 
hypoglycaemia (Trovati, 1986). The mechanisms underlying platelet aggregation and 
activation have been investigated; both processes are inhibited by a2 adrenoceptor blockade 
with either mianserin ( Kishikawa, 1988) or midaglizole (Takeda, 1988). 
1.8.5.3.2 Coagulation and fibrinolysis 
In addition to the changes that involve blood cells, hypoglycaemia has substantial 
haemorrheological effects. Acute hypoglycaemia causes an increment in coagulation factor 
VIII activity of 96% (Corrall, 1980). This response was reproduced by the intravenous 
infusion of epinephrine, and was absent in sympathectomized subjects, while in non -diabetic 
subjects it was blocked by the administration of propranolol, but not metoprolol, indicating a 
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132 adrenoceptor- mediated process, a conclusion that has been supported by other studies 
(Ibbotson, 1995, Mikhailidis, 1985). 
Von Willebrand factor rises in response to hypoglycaemia (Fisher, 19912), and accelerated 
rates of thrombin generation have been documented (Ibbotson, 1995). Activation of the 
fibrinolytic system occurs, demonstrated by a rise in tissue plasminogen activator (tPA) and 
a fall in plasminogen activator inhibitor (PAI), suggesting the formation of complexes with 
tPA (Fisher, 19912). Euglobulin lysis time (a test of plasminogen activator activity) is 
shortened and fibrin plate lysis increases, also indicating increased fibrinolysis (Fisher, 
19912). Fibrinolysis is altered by insulin infusion alone, while euglycaemia is maintained 
using a hyperinsulinaemic glucose clamp technique, with a simultaneous rise in tPA levels 
and fall in PAI levels (Landin, 1991). Changes in fibrinogen or fibrinogen degradation 
products (FDPs) have not been observed during hypoglycaemia (Fisher, 19912, Ibbotson, 
1995). 
1.8.5.3.3 Inflammation 
The study of the inflammatory mechanisms underlying many disease states is currently 
receiving a lot of attention. It is known that acute hyperglycaemia, for example following an 
oral glucose load, provokes oxidative and inflammatory stress. This effect is also observed 
following induction of hyperglycaemia by intravenous glucose infusion (Dandona, 2007). 
Chronic hyperglycaemia has been shown to promote inflammatory changes and increase the 
generation of free radicals, which may be one of the mechanisms underlying the 
development of angiopathy in diabetes. It has also been reported that post -prandial glucose 
excursions can increase oxidative stress, thereby potentially increasing the risk of developing 
or aggravating vascular complications of diabetes ( Monnier, 2006), suggesting that post- 
prandial hyperglycaemia should be targeted during treatment to achieve optimal glycaemic 
control. However, a recent study has disputed the importance of glucose fluctuations, being 
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unable to demonstrate a relationship with markers of oxidative stress (Wentholt, 2008). 
Conversely, insulin therapy has been shown to have potent anti -inflammatory properties 
when used to treat obese insulin- resistant individuals, and also demonstrates these effects 
when administered during a normoglycaemic clamp study (Dandona, 2007). 
Investigation of the potential effect of hypoglycaemia on inflammatory factors has so far 
been limited, in part because it is only in recent years that access to sophisticated measures 
of inflammation and endothelial function has been widely available. Galloway et al 
(Galloway, 2000) have reported a significant increase in C- reactive protein at 24 hours after 
acute insulin- induced hypoglycaemia, both in subjects with type 1 diabetes (0.77mg/1 to 
2.31mg /1) and in healthy volunteers (0.32mg/1 to 0.96mg/1). While it is unclear as to the role 
of CRP in the causation of atherogenesis, as discussed earlier, increasing evidence has 
implicated its involvement in acute vascular events, with data in vitro and in vivo 
demonstrating its possible pathogenetic qualities, and additionally CRP levels are predictive 
of outcome following cardiovascular events (Pepys, 2005, Jialal, 2004). 
1.8.6 Conclusion 
It is therefore imperative that further information is sought on the potential effects of 
hypoglycaemia on the vasculature. There is now a plethora of soluble marker assays and 
methods of assessing blood constituents available to examine the hypothesis that 
hypoglycaemia may aggravate micro- and macrovascular disease in people with diabetes. 
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Subjects recruited for this programme of research had to meet the following criteria for 
participation in any of the studies: 
2.1.1 Non -diabetic subjects 
Healthy adult volunteers recruited for the studies were only included if they met all of the 
following criteria: 
1. Age range 18 -45 years (either gender). 
2. Normal body weight (Body Mass Index: 20- 26kg /m2). 
3. On no medications (with the exception of the oral contraceptive pill). 
2.1.2 Subjects with Type 1 Diabetes 
Healthy adult patients with type 1 diabetes were recruited from the diabetes outpatient clinic 
at the Royal Infirmary of Edinburgh. They could be included in the studies if they met all of 
the following criteria: 
1. Type 1 diabetes of at least 2 years duration. 
2. HbAlc values between 7% and 9% for the preceding 6 -12 months (non -diabetic 
range: 5.0- 6.05 %). 
3. No microvascular or macrovascular complications. 
4. On no medications other than insulin (with the exception of the oral contraceptive 
pill). 
5. Age range 18 -45 years (either gender). 
Subjects were excluded from participation if they met any of the following criteria: 
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1 Impaired awareness of hypoglycaemia. 
2. Co- existent systemic disease. 
3. Past history of severe morbidity during or in response to hypoglycaemia (e.g. 
convulsions). 
4. Past history of cerebral injury, seizure, alcoholism or psychiatric disorder. 
5. Pregnancy. 
6. Any evidence of microvascular complications. 
7. Evidence of autonomic neuropathy using standard tests of cardiovascular reflexes 
(Ewing, 1985). 
8. Documented clinical evidence of peripheral neuropathy. 
All subjects gave written informed consent before participating in the studies, which had 
been approved by the Lothian Research Ethics Committee, in accordance with the 
Declaration of Helsinki. 
2.2 Hyperinsulinaemic clamp technique (DeFronzo, 1979) 
After an overnight fast, and confirmation of avoidance of biochemical hypoglycaemia in the 
preceding 48 hours in subjects with diabetes, a retrograde intravenous cannula is inserted 
into the non -dominant hand vein for regular sampling of blood glucose. This hand is placed 
in a heated blanket in order to arterialise the venous blood (Abumrad, 1981). A cannula is 
also inserted into a vein in the antecubital fossa of the same arm for intravenous infusion of 
20% dextrose and soluble human insulin (Human Actrapid, Novonordisk Pharmaceuticals, 
Crawley, UK). Insulin is infused at a constant rate of 1.5mU/kg /min using a Gemini PCI 
pump (Alaris Medical Systems, San Diego, CA). Dextrose (20 %) is infused at a rate that 
varies according to the arterialised blood glucose concentration, which is measured at 5 
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minute intervals using the glucose oxidase method (2300 Stat; Yellow Springs Instrument, 
Yellow Springs, OH). During a run -in period, arterialised blood glucose is maintained at 4.5 
mmol/1 for 30 minutes. Blood glucose is then stabilised and maintained at 4.5 mmol/1 
throughout (euglycaemia), or lowered over 20 minutes to 2.5 mmol/1 (hypoglycaemia), and 
is maintained at this level for 1 hour, during which either cognitive testing or blood sampling 
can be undertaken. At the end of this experimental hour, euglycaemia (4.5 mmol/1) is 
restored and maintained (see figure 2.1). The glucose clamp is then discontinued and the 
subjects are given a standardised meal. Subjects with diabetes are then advised regarding 
doses and timing of insulin to be taken for the rest of the day. 
The subjects are not informed as to which condition of the study is being performed. 
Hypoglycaemia and euglycaemia order is randomised and counterbalanced. Glucose for 
intravenous injection is available to reverse hypoglycaemia. 
2.3 Insulin infusion method of hypoglycaemia induction 
After an overnight fast, and confirmation of avoidance of hypoglycaemia in the preceding 48 
hours, hypoglycaemia is induced by administering a continuous intravenous infusion of 
soluble insulin at a rate of 2.0mU/kg /min in 0.9% sodium chloride solution, through an 
indwelling venous cannula in the antecubital fossa. The insulin infusion is continued until 
the onset of symptoms of hypoglycaemia, which is usually coincidental with objective 
evidence of an acute autonomic reaction (R). This can be identified by a rapid increase in 
heart rate, a rise in systolic blood pressure, and the onset of sweating and finger tremor, as 
described previously (Hepburn, 1991). Euglycaemia is then restored by infusion of Dextrose 
(20 %), and subjects are given a standardised meal. Subjects with diabetes are then given 
advice on insulin doses for the rest of the day. Glucose for intravenous injection is available 
throughout. 
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Figure 2.1: Protocol for hyperinsulinaemic clamp studies 
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2.4 Assessment of hypoglycaemia awareness 
All subjects with and without diabetes underwent assessment of hypoglycaemia awareness 
and symptoms during their experimental procedures. The Edinburgh Hypoglycaemia Score 
was used for this purpose (Gold, 1994). This method utilises a Likert scale of 1 (not present) 
to 7 (intensely present) to assess a combination of autonomic, neuroglycopenic and non- 
specific (malaise) symptoms, and asks participants to rate how aware of hypoglycaemia they 
are on the same scale; 1 (always aware) to 7 (never aware). This is a validated self - 
assessment questionnaire. 
2.5 Cognitive function assessment 
The Digit Symbol Substitution test and Trail Making B test are administered in order to 
confirm the recognised effect of hypoglycaemia on cognitive function as described 
previously (McAulay, 20012, Sommerfield, 2003', Sommerfield, 20032, Warren, 2004). 
Tests of spatial ability were drawn from the French and Ekstrom Kit of Factor -Referenced 
(cognitive) Tests (Ekstrom, 1976, Ekstrom, 1979). As per the traditional design of studies 
assessing the effects of hypoglycaemia on cognition, the studies are randomised and 
counterbalanced, and different versions of each test, where available, are administered on 
each study day in order that no practice effects are seen. 
2.5.1 Digit Symbol Substitution test 
This test is from the Wechsler Adult Intelligence Scale -III (WAIS -III) and assesses the 
ability of the subject to perform coding as quickly as possible. It is particularly sensitive to 
cerebral insults, but is not sensitive to the location of the insult. The subject is given a key of 
numbers 1 -9 which each have a corresponding symbol. They must then fill in as many 
symbols as possible for a list of numbers in 120 seconds. 
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2.5.2 Trail Making B 
The Trail Making B test is a computerised version of the test, and similar in principle to the 
classic test, from the Halstead Reitan battery. It is used to assess complex visual processing, 
and also assesses motor function with regards to visual motor tracking. It is performed on a 
handheld computer. The subject is presented with a grid containing letters and numbers in a 
random order, and must connect the numbers and letters in numerical and alphabetical order, 
alternating number with the letter in the fashion `1- A- 2- B- 3 -C...' etcetera. 
2.5.3 Spatial Ability Tests (French and Ekstrom Kit of Factor Referenced 
(cognitive) Tests) 
2.5.3.1 Hidden patterns test 
The Hidden Patterns Test requires subjects to identify a figure that is hidden among other 
lines. The figure is the same throughout, with the same orientation, and subjects have 3 
minutes to correctly identify as many of the patterns in which the figure is concealed as 
possible. 
2.5.3.2 Card rotations test 
The Card Rotations test requires the subject to look closely at a shape on the left hand side of 
a page, and then assess whether the 8 shapes on the right hand side are the same shape, 
rotated through a variable number of degrees, or whether the shapes are different, and have 
in fact been reversed or are a mirror image of the initial shape. Three minutes are allowed to 
complete as many items as possible. 
2.5.3.3 Cube comparisons test 
This test involves pairs of cubes, such as the wooden building blocks played with by 
children, with a letter or shape of each side of the cube. Subjects have 3 minutes to analyse 
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as many pairs of cubes as possible, and must determine whether the 2 cubes could be the 
same cube viewed from different sides, or whether they must be different cubes if the letters 
on the sides do not correspond with each other if the cube is turned over. 
2.5.3.4 Paper folding test 
The Paper Folding test involves showing participants a sequence of folds in a piece of paper, 
through which a set of holes is then punched. The participants must choose which one of a 
set of punched and unfolded papers corresponds to the one they have just seen. 
2.5.3.5 Building memory test 
This is a test of the subject's ability to remember the position of buildings on a street map. 
Four minutes are permitted to memorise the map, and then a further 4 minutes to place the 
buildings correctly on a blank version of the map. 
2.5.3.6 Maze tracing test 
This is a test of the subject's ability to find a path through a maze quickly. A pencil line must 
be drawn through the maze without crossing any of the `walls'. The maze is broken down 
into blocks, and the score is the number of blocks that are successfully navigated in 3 
minutes. 
2.6 Flow cytometry 
2.6.1 Background 
Flow cytometry allows the measurement of properties of individual particles. A sample 
solution can be injected into a flow cytometer, where the sample is ordered into a stream of 
individual particles which can be interrogated by the cytometer's detection system. Figure 
2.2 illustrates the basic structure of a flow cytometer. 
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Figure 2.2: Flow cytometer structure - hydrodynamic focusing produces a 




The system comprises a central channel through which the sample is injected. This is 
enclosed by an outer sheath that contains fluid which flows at a faster rate (sheath fluid). The 
drag effect of this fast -flowing outer fluid slows the central channel fluid down, so that a 
single file of particles is generated. The particles then pass through one or more beams of 
light, and light scattering can be used to determine the size and properties of the particle. 
Forward scatter of light roughly equates to the particle size, and the side scatter provides 
information about the granular content of the particle. Both aspects are unique for every 
particle, and can therefore be used to differentiate between cell types (figure 2.3). 
Fluorochromes can be attached to the particles as well, and fluorescence emission will 
provide additional information about the particle. These can be used to identify cell surface 
receptors or intracellular molecules such as DNA and cytokines. The light emitted is 
detected and a small current is generated; this current is then amplified and can be plotted 
graphically as a histogram (figure 2.4). Typical fluorochromes include phycoerythrin (PE) 
and fluorescein isothiocyanate (FITC). The use of an isotype control allows the truly positive 
datasets to be identified as shown in figure 2.4. 
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Figure 2.3 a and b: Plot of forward scatter and side scatter demonstrating cell 
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Figure 2.4 (Reproduced from Rahman, 2006): 
a. Histogram depicting 2 positive datasets identified using conjugated 
fluorochromes 
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By incubating blood cells with antibodies to cell surface markers with conjugated 
fluorochromes, it is possible to further clarify, by both size and wavelength of light emitted, 
which cell is being examined. And by incubating with more than one antibody of interest, 
information can be derived about aggregates of cells or suspected ligand -dyad pairings. 
Figure 2.5 shows the dot plot generated when a sample of whole blood is incubated with two 
antibodies of interest. The x -axis represents one antibody /fluorochrome, and the y -axis the 
other. Quadrants are then put in place on the dot plot (using the information gained from the 
histogram data) which allows the population of interest to be gated, and therefore identifies 
the molecules appearing in the right upper quadrant as being positive for both sets of 
antibodies /fluorochromes. 
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Figure 2.5: Dot plot of FITC -labelled molecules vs. PE- labelled molecules 
(Reproduced from Rahman, 2006). 
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2.6.2 Current method 
Whole blood samples were collected using D- Phenylalanyl -L- prolyl -L- arginine 
chloromethyl ketone (PPACK), a selective thrombin inhibitor, as an anticoagulant, at pre- 
determined time points during the conduct of study 3 (baseline, test phase, during recovery, 6 
hours and 24 hours). Samples (100 µL) of whole blood were immediately incubated with 10 
µL of each monoclonal antibody for 30 minutes at room temperature (AbD Serotec, 
Kidlington, UK), with subsequent red cell lysis by the addition of 1 mL of FACS Lyse 
solution (Becton Dickinson, Oxford, UK). Flow cytometry using the FACS Calibur system 
(Becton Dickinson, Oxford, UK) was performed within 24 hours of obtaining the sample, 
preparation with antibody and red cell lysis. Isotype controls were performed in addition to 
both mono- and dual -stain for each parameter assessed: platelet -monocyte aggregation 
(CD14- CD42a), CD40 expression on monocytes (CD14- CD40), and CD40 ligand expression 
on platelets (CD 154- CD42a). 
2.6.2.1 CD14 
Mouse anti -human CD14 monoclonal antibody conjugated to FITC was obtained from AbD 
Serotec, Kidlington, UK. CD14 is a cell surface receptor predominantly expressed by 
monocytes and macrophages, and in this programme of research has been use to select out 
the monocyte population. 
2.6.2.2 CD42a 
Mouse anti -human CD42a monoclonal antibody conjugated to RPE was obtained from AbD 
Serotec, Kidlington, UK. CD42a is a cell surface receptor expressed by platelets, and is the 




Mouse anti -human CD40 monoclonal antibody conjugated to RPE was obtained from AbD 
Serotec, Kidlington, UK. CD40 is a tumour necrosis factor receptor family member. 
2.6.2.4 CD154 (CD40 ligand) 
Mouse anti -human CD154 monoclonal antibody conjugated to FITC was obtained from AbD 
Serotec, Kidlington, UK. CD154 (CD4OL) is a member of the TNF family of molecules. It 
binds to CD40 on antigen presenting cells, and can be present on a wide variety of cells 
including T lymphocytes, platelets, mast cells, macrophages, B lymphocytes, NK cells in 
addition to endothelial cells. 
2.6.2.5 Isotype controls 
IgG 1 and IgG2a isotype control antibodies were obtained from AbD serotec, Kidlington, 
UK. 
2.6.3 Validity Experiments 
During the design of the study protocol it became apparent that flow cytometry could not be 
done on the same day as the clamp study, particularly as it was planned to obtain a 24 hour 
sample from each study participant the day after the clamp itself. Therefore, we had concerns 
that the samples, having been incubated with the appropriate antibody combinations and red 
cells lysed, may not be robust enough to wait for later analysis. In order to ensure stability of 
the samples over time after preparation, validity experiments were performed. 
2.6.3.1 Method 
100 µL of whole blood collected in a PPACK tube was incubated with 10 µL of each 
monoclonal antibody combination for the required 30 minutes at room temperature. Red cell 
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lysis was subsequently performed using 1 ml of FACS lyse solution. The samples were then 
analysed using the flow cytometer at the following times: 
0 hours (immediate testing) 
24 hours 
48 hours 
The samples were refrigerated until the 24 hour and 48 hour time points as per manufacturer 
advice. 
2.6.3.2 Results 
Platelet -monocyte aggregation samples remained stable over the 48 hour period. CD40 
expression on monocytes increased at 24 hours, and very dramatically again at 48 hours. 
CD40 ligand expression on platelets appeared to be stable over the 48 hours. Results are 
shown in table 2.1. 
2.6.3.3 Conclusions 
This validity study has shown that both platelet -monocyte aggregation and CD40 ligand 
expression on platelets remain stable over a 48 hour period. CD40 expression on monocytes 
dramatically increased at 48 hours, so any analysis beyond the 24 hour period of storage 
would be likely to endanger the accuracy of the results obtained. It was therefore ensured 
that all samples were analysed within the 24 hour window to prevent degradation of sample 
quality. 
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Table 2.1: Flow cytometry validity results 
0 hours 24 hours 48 hours 
Platelet -monocyte 
aggregation 
0.52% 0.47% 0.50% 
CD40 expression 6.71 % 11.52% 27.23% 
CD40ligand 
expression 
2.72% 2.79% 2.20% 
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2.7 Endothelin-1 (ET-1) 
Immunoreactive ET was measured by radioimmunoassay (ITS Production BV) after samples 
were collected at the pre -specified time points, cold -centrifuged and flash frozen at -70 °C 
until analysis. The sensitivity of this assay is 2 pg /ml immunoreactive ET. Cross -reactivity of 
the assay with ET -1, ET -2, ET -3 and big ET -1 is 100 %, 52 %, 96% and 7% respectively. 
Plasma ET concentrations were measured at baseline, at the onset of the hypoglycaemic 
reaction (R), and at 15 and 60 minutes following R in study 2. 
2.8 Soluble Blood Marker Analysis 
Citrated plasma and serum samples were collected at the predetermined time points during 
hyperinsulinaemic clamp studies in study 3: baseline, test phase, during recovery, 6 hours 
and 24 hours. These samples were separated immediately and frozen at -80 °C until analysis 
for the soluble markers, described below. 
2.8.1 Von Willebrand Factor (In -house assay [Royal Infirmary of Edinburgh Haematology 
Laboratory]; ELISA; CV 7.3 %). 
2.8.2 Tissue Plasminogen Activator antigen (Hyphen Biomed Zyinutest; intra -assay CV 
3.5 %, inter -assay CV 4.4 %). 
2.8.3 Soluble CD40 ligand (high sensitivity ELISA, Bender Medsystems; intra -assay CV 
5.5 %, inter -assay CV 7.2 %). 
2.8.4 Soluble P- selectin (ELISA, R &D Systems; intra -assay CV 5.1 %, inter -assay CV 
8.8 %). 
2.8.5 Interleukin -6 (High sensitivity ELISA, R &D Systems; intra -assay CV 5.9 %, inter- 
assay CV 9.9 %). 
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2.8.6 High sensitivity CRP (DRG Diagnostics, DRG Instruments GmbH Germany; intra- 
assay CV 4.2 %, inter -assay CV 4.1 %). 
2.9 Counterregulatory hormone assays 
Samples for counterregulatory hormone assessment were collected in EDTA tubes and 
immediately separated and frozen at -80 °C until analysis. Epinephrine and norepinephrine 
were analysed by high performance liquid chromatography and electrochemical detection 
(Epinephrine: Intra -assay CV 8.5 %, Inter -assay CV 9.9%; Norepinephrine: intra -assay CV 
1.2 %, inter -assay CV 3.9 %). Samples were also assessed by radioimmunoassay for glucagon 
(interassay CV 12 %) and pancreatic polypeptide ( interassay CV 10 %). 
2.10 Statistical analysis 
Results were analysed using SPSS version 15.0 for Windows (SPSS, Chicago, IL, USA), and 
Graphpad Prism 2.0 (GraphPad Software, San Diego, CA, USA). Specific details pertaining 
to each study are described in the appropriate chapter. In general, hyperinsulinaemic clamp 
studies require general linear modelling to compare hypoglycaemia with euglycaemia 
(repeated measures ANOVA), with order of session (euglycaemia -hypoglycaemia or 
hypoglycaemia -euglycaemia) as a between- subjects factor, and condition (euglycaemia or 
hypoglycaemia) as a within -subjects factor. A p -value <0.05 was considered to be 
significant. Where applicable, paired t -tests were utilised. 
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Chapter 3: 
The effects of acute insulin- induced 
hypoglycaemia on spatial abilities in adults 
with type 1 diabetes 
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3 Study 1: The effects of acute insulin- induced hypoglycaemia on spatial 
abilities in adults with type 1 diabetes 
3.1 Introduction 
It is well documented that hypoglycaemia impairs many domains of cognitive function, but 
the effect of hypoglycaemia on spatial abilities has not previously been investigated in detail. 
However, spatial ability is undoubtedly a component of some of the tests used to assess other 
aspects of cognition in previous studies (Geddes, 2008). Spatial ability may be defined as the 
ability to generate, retain, retrieve, and transform or manipulate structured visual images in 
order to orientate and interpret the surrounding environment. Translating this into real life 
terms, spatial ability is concerned with how human beings deal with interpreting two - and 
three- dimensional shapes and objects, space, navigation, and pathfinding. On a day to day 
basis, this involves interpreting how shapes and objects will appear and function when they 
are rotated or viewed differently. This process is very important, with particular relevance 
for complex tasks such as driving and map reading. A large variety of mental tests are 
available for the assessment of spatial abilities. Largely, these tests can be separated into 
tests of spatial perception, which is the ability to determine spatial relations despite 
distracting information, spatial visualisation, which is the ability to manipulate complex, 
multi -step spatial information, and mental rotation, which is the ability to rotate two- or 
three- dimensional figures in the mind (Linn, 1985). 
The aim of this study was to investigate the effects of acute insulin- induced hypoglycaemia 
on spatial abilities in adults with type 1 diabetes, utilising a well- characterised battery of 





Sixteen adults with type 1 diabetes (7 male, 9 female) participated in the study. Subjects 
were recruited from the diabetes clinic at the Royal Infirmary of Edinburgh. Baseline 
demographic characteristics are shown in table 3.1. HbAlc was measured by high 
performance liquid chromatography (non- diabetic reference range 5.0- 6.05 %; Bio -Rad 
Laboratories, Munich, Germany), and was DCCT -aligned. The subjects had no history of 
hypertension or macrovascular disease, and microvascular disease was excluded prior to 
recruitment. The presence of retinopathy was sought using digital retinal photography, 
neuropathy was assessed by clinical examination, and nephropathy was identified by the 
presence of microalbuminuria. 
Subjects were excluded if they had a history of impaired awareness of hypoglycaemia, or a 
history of previous severe reaction to hypoglycaemia. None of the participants had a history 
of head injury, seizure, blackouts, alcohol or drug abuse or psychiatric illness. Subjects were 
not on any medications other than insulin or the contraceptive pill. All subjects gave written 
informed consent before participating in the study, which had been approved by the Lothian 
Research Ethics Committee. 
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Table 3.1: Baseline demographic characteristics of study participants 
Age (median [interquartile range]) (years) 28 (25 -37.5) 
Diabetes duration (median [IQR]) (years) 10 (4.2 -19) 
BMI (mean [SD]) (kg /m2) 26.4 (4.01) 
HbA1c (mean [SD]) ( %) 7.91 (0.92) 
National Adult Reading 
(mean [SD]) 
Test (NART) 34.2 (5.1) 
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12.2 Study Design 
The study was conducted at the Clinical Research Facility at the Royal Infirmary of 
Edinburgh. Each subject underwent two laboratory sessions, separated by at least two weeks. 
Subjects attended after an overnight fast, and subjects with diabetes had to confirm absence 
of biochemical hypoglycaemia in the preceding 48 hours prior to proceeding with the 
session. Intravenous cannulae were inserted into the non -dominant antecubital fossa for 
variable infusion of dextrose (20 %) and soluble human insulin, and retrogradely into the 
non -dominant hand vein for regular blood glucose sampling at the bedside. The hand was 
heated to arterialise the venous blood (Ábumrad, 1981). Insulin was infused at a constant 
rate of 1.5inU/kg /min. A modified hyperinsulinaemic glucose clamp (DeFronzo, 1979) was 
used to maintain blood glucose at a predetermined level; euglycaemia at 4.5 mmol/1 and 
hypoglycaemia at 2.5 mmol /l, as previously described in the methods section. Following the 
experimental period, blood glucose was returned to the euglycaemic target level, or 
maintained at that level if already euglycaemic. The clamp was then discontinued and 
subjects consumed a standardised meal. Subjects with diabetes were given advice on doses 
and timing of insulin for the rest of the day. Each subject underwent a euglycaemic study and 
a hypoglycaemic study in a randomised, counterbalanced fashion. The subjects were blinded 
to the experimental condition. 
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Figure 3.1: Study outline 
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3.2.3 Cognitive function testing 
The previously described cognitive effects of hypoglycaemia were confirmed using the 
Trailmaking B and Digit Symbol Substitution tasks. These were performed during the run -in 
period and repeated during the experimental session once blood glucose targets were stable. 
The spatial ability test battery from the French and Ekstrom Kit of Factor -Referenced 
(cognitive) Tests was undertaken during the experimental period, with a different version 
being utilised during each session to avoid practice effects. These 2 different versions of the 
spatial ability battery were again randomised and counterbalanced. Details of the specific 
tasks undertaken are included in the Methods section. Subjects also completed a symptom 
questionnaire and assessment of hypoglycaemia awareness during the experimental period. 
3.2.4 Statistical analysis 
Results were analysed using SPSS version 15.0 for Windows (SPSS, Chicago, IL). A general 
linear model (repeated measures ANOVA) was used, with order of session (euglycaemia- 
hypoglycaemia or hypoglycaemia -euglycaemia) as a between -subjects factor, and condition 
(euglycaemia or hypoglycaemia) as a within -subjects factor. A p -value <0.05 was considered 
to be significant. 
3.3 Results 
3.3.1 Blood glucose 
The target blood glucose levels were achieved for each experimental condition, as shown in 
figure 3.2. The mean (SD) blood glucose concentration achieved during the hypoglycaemia 
condition was 2.46 (0.22) mmol/1, and during the euglycaemia condition was 4.53 (0.24) 
mmol/1. 
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Figure 3.2 Blood glucose concentrations during hyperinsulinaemic 


















3.3.2 Symptom scores 
Total autonomic (p <0.001), total neuroglycopenic (p <0.001), and non -specific (malaise) 
symptom scores (p <0.001) all increased significantly during hypoglycaemia. Results are 
shown in table 3.2. 
3.3.3 General cognitive function 
This study has demonstrated a decrement in the mean (SD) scores achieved in the Digit 
Symbol Substitution task during the hypoglycaemia study period (72.4 (20.2)) as compared 
with euglycaemia (84.6 (20.7)) (p <0.001). This confirms that a standard measure of speed of 
information processing was significantly impaired at a blood glucose concentration of 2.5 
mmol/1. The Trail Making B test was affected by hypoglycaemia, but statistically this result 
did not achieve significance, though indicated a trend towards a decrease in score during 
hypoglycaemia (p= 0.07). It took 50.45 (24.9) seconds to complete task during 
hypoglycaemia compared with 38.90 (11.6) seconds during euglycaemia (results are mean 
(SD)). 
3.3.4 Spatial ability 
The present study demonstrated that acute insulin- induced hypoglycaemia resulted in a 
significantly lower mean (SD) score on all but one of the spatial ability test battery. The 
score achieved during euglycaemia on the Hidden Patterns test was 94.5 (21.8) compared 
with 73.7 (21.0) during hypoglycaemia (p <0.001; figure 3.3). On the Card rotations test the 
euglycaemia score was 51.9 (15.5), compared with 40.4 (18.7) during hypoglycaemia 
(p= 0.001). The Paper Folding test was again significantly affected with scores of 6.0 (1.9) 
vs. 4.7 (2.0) (p= 0.001) as was the Maze. Tracing test with scores of 11.1 (3.0) vs. 9.4 (2.5) 
(p <0.001). These tests require analysis of shapes and lines in addition to mental manipulation 
of shapes and figures. The Cube Comparisons test was also significantly affected with scores 
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of 11.7 (4.1) vs. 9.4 (5.7) (p= 0.03). The only spatial ability test that was unaffected by 
hypoglycaemia as compared with euglycaemia was the Building Memory test (1)=0.3). 
Table 3.3 summarises the differences in performance on the tests of spatial ability during 
euglycaemia and hypoglycaemia (as mean (SD)). No significant effects were observed of 
order of exposure to glycaemic condition or test battery. 
It is important to consider estimates of effect size in addition to conventional measures of 
statistical significance in order to establish how important an observation is. Table 3.3 
shows, using Cohen's d values, that the impact of hypoglycaemia on these spatial abilities 
was of medium to large effect. In addition, the partial eta squared values in table 3.3 show 
that the hypoglycaemia condition accounted for a large proportion of the variance in the 
results. 
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Table 3.2: Symptom scores during experimental conditions (mean [SD]; 
*= p <0.05) 
Euglycaemia Hypoglycaemia 
Autonomic 1.36 (0.48) 2.76 (1.36)* 
Neuroglycopenic 1.41 (0.80) 3.25(1.23)* 
Non -specific 1.15 (0.28) 1.71 (0.80)* 
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Figure 3.3: Hidden patterns test scores in hypoglycaemia and euglycaemia 









Table 3.3: Spatial ability test scores (results shown as mean [SD]; significance 
level p <0.05; effect sizes computed as Cohen's d and partial eta -squared). 
Spatial test Euglycaemia score Hypoglycaemia score P -value Cohen's 
d 
2 TIP 
Hidden patterns 94.5 (21.8) 73.7 (21.0) <0.001 0.97 0.627 
Card rotations 51.9 (15.5) 40.4 (18.7) 0.001 0.67 0.580 
Cube comparison 11.7 (4.1) 9.4 (5.7) 0.03 0.46 0.298 
Paper folding 6.0 (1.9) 4.7 (2.0) 0.001 0.67 0.604 
Building memory 8.6 (3.1) 7.8 (2.1) 0.3 0.30 0.081 
Maze tracing 11.1 (3.0) 9.4 (2.5) <0.001 0.62 0.621 
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3.4 Discussion 
Acute insulin- induced hypoglycaemia causes significant decrements in most spatial 
cognitive abilities examined here in a group of 16 adults with uncomplicated type 1 diabetes. 
The impairment of this specific cognitive domain was accompanied, as anticipated, by a 
deterioration in the speed of mental processing as demonstrated by the decrease in score for 
the Digit Symbol Substitution task. The effect sizes obtained indicate the development of 
medium to large decrements in spatial abilities during hypoglycaemia in adults with type 1 
diabetes. 
One limitation of the present study was the lack of a control group of non -diabetic subjects. 
This would have allowed the opportunity to assess whether the diagnosis of diabetes per se 
has any impact on spatial ability at baseline, and also to examine whether the decrease in 
performance was as marked in the group of non -diabetic subjects, or if people with diabetes 
actually perform better having been exposed to hypoglycaemia previously. This observation 
was seen in a recent study of the effects of hypoglycaemia on psychomotor function, where 
some form of cerebral adaptation appeared to exist in the subjects with diabetes, who 
performed much better whilst hypoglycaemic (Geddes, 2008). Regardless of these issues, it 
is the everyday effect of hypoglycaemia on the people with diabetes that remains of clinical 
importance. 
Other studies assessing the effects of hypoglycaemia on aspects of cognitive function have 
utilised tests that require a spatial ability component (Geddes, 2008), but no previous study 
has utilised a test battery specifically examining spatial abilities. Spatial cognition has a clear 
role in the safe conduct of tasks such as driving, which rely heavily upon the interpretation of 
the surrounding environment, and it was therefore felt that an examination of specific effects 
was necessary. 
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The Building Memory test exhibited little response to glycaemic condition, and did not 
achieve statistical significance. This test requires the subject to scrutinise a map which 
contains pictures of various buildings for a period of 4 minutes. The subjects are then given a 
blank map without the pictures of buildings, and they must mark on the map the positions 
where they remember the buildings were placed. This test therefore assesses both spatial 
ability and visual memory. This finding is consistent with previous studies that have 
examined memory function using visual memory tests from the Wechsler Adult Intelligence 
Scale, which have also shown that visual memory is preserved during acute hypoglycaemia 
(Warren, 2007). It is also notable that the Building Memory test, unlike the other tests used 
here, only requires participants to complete one task, rather than having the opportunity to 
try several tasks in the one test, and so its scores might be more idiosyncratic. 
The right cerebral hemisphere, particularly the parietal lobe, is the area of the brain that 
dominates the conduct of spatial ability function. The frontal cortex, thalamus and to some 
extent, the cerebellum, are also involved in the co- ordination of spatial cognition (Harris, 
2000, Vogel, 2003). Rosenthal et al showed, using neuroimaging during hypoglycaemia, that 
there was an attenuation of functional response (BOLD activation) in the pre -motor and 
supplementary motor cortex (Rosenthal, 2001). This is consistent with the recognised areas 
of importance in spatial functioning. In addition, it has been shown previously that general 
fluid intelligence is impaired during hypoglycaemia, and it is fluid intelligence, rather than 
crystallised intelligence, that is responsible for spatial cognition (Warren, 2004). 
In conclusion, this study has shown that acute insulin- induced hypoglycaemia has an adverse 
effect on spatial abilities. This information improves our understanding of the domains of 
cognitive function that are affected during hypoglycaemia. Spatial abilities had not 
previously been examined, and now it is clear that they are significantly impacted upon by 
hypoglycaemia. Moreover, spatial abilities are highly relevant to the everyday activities of 
people with type 1 diabetes, and there are now data to show that part of the inability to 
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4 Study 2: The effects of acute insulin -induced hypoglycaemia on 
Endothelin -1 concentrations in adults with type 1 diabetes 
4.1 Introduction 
Acute hypoglycaemia has been shown to cause a collection of haemodynamic, 
haemorrheological and haemostatic responses which are thought to be secondary to 
sympatho -adrenal activation and counterregulatory hormonal secretion, as demonstrated in 
previous experimental studies of acute insulin- induced hypoglycaemia (Fisher, 1993). The 
cardiovascular effects of these changes appear to be transient in healthy young adults with no 
pathophysiological consequences, but people with diabetes who have underlying vascular 
disease may be at risk of tissue ischaemia (Fisher, 1993). Myocardial and cerebral ischaemia, 
and ultimately acute vascular events, can be precipitated by hypoglycaemia (Desouza, 2003, 
Fisher, 2007). This has been reported anecdotally, as well as in a few small observational 
studies. Worsening of diabetic retinopathy may occur when strict glycaemic control is 
implemented (Frier, 1985, Hanssen, 1986), suggesting a further potential adverse effect on 
the microvasculature. The possible mechanisms by which hypoglycaemia might exacerbate 
vascular disease include haemorrheological changes, platelet and neutrophil activation, 
vasoconstriction (Fisher, 1993, Frier, 1985), and release of inflammatory mediators and 
cytokines (Galloway, 2000, Fisher, 19912, Collier, 1990, Corrall, 1980, Frier, 1983). 
The endothelins are potent vasoconstrictors that have a central role in cardiovascular 
regulation. The endothelium- derived peptide, endothelin -1 (ET -1), is the principal isoform in 
humans and causes prolonged vasoconstriction, and promotes smooth muscle proliferation 
(Gossl, 2006). It is released predominantly from the vascular endothelium, with its main role 
being as a regulator of vascular tone, with resultant effects on systemic blood pressure. Once 
released from the vascular endothelium, ET -1 binds to endothelial receptors and initially 
mediates release of nitric oxide and consequent relaxation of vessel walls (Clozel, 1992); 
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there is then subsequent stimulation of two further subtypes of ET receptor, which induces 
slow and sustained vasoconstriction (Bobik, 1990). Endothelins have been implicated in the 
pathogenesis of several disorders including atherosclerosis, diabetes and hypertension 
(Hopfner, 1999, Luscher, 2000, Dhaun, 2006). Plasma endothelin production is stimulated 
by hypoxia, ischaemia, and epinephrine release amongst other factors (Gossl, 2006). Plasma 
levels are elevated in people with uncomplicated type 1 and type 2 diabetes (Takahashi, 
1990), increase with presence of microalbuminuria and retinopathy (Collier, 1992), and may 
have a pathogenetic role in microangiopathy (Dhaun, 2006). 
The aim of this study was therefore to examine changes in plasma endothelin -1 during acute 
insulin- induced hypoglycaemia in adults with type 1 diabetes, with the hypothesis that an 
increment in endothelin -1 concentration would be observed. 
4.2 Methods 
Twenty subjects with type 1 diabetes were studied. Subject characteristics are presented in 
table 4.1. All participants were receiving a combination of short and intermediate- acting 
insulins, either twice daily or as a basal bolus regimen. They were taking no medications 
other than insulin, and had no other medical disorders. Subjects were screened for diabetes 
complications prior to inclusion; retinopathy was assessed using ophthalmoscopy, peripheral 
neuropathy by clinical examination, and autonomic neuropathy using a standard battery of 
cardiovascular reflexes (Ewing, 1985). No participants had any clinical evidence of 
microangiopathy. The Lothian Medical Research Ethics Committee granted approval, and 
written informed consent was obtained from all subjects. 
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Table 4.1: Characteristics of participants with type 1 diabetes. Results are 
expressed as mean (SEM) unless stated otherwise. Non -diabetic range for 
HbA1c is 5.0- 6.05% (measured by ion exchange high performance liquid 
chromatography). 
Age (median {range }) (years) 25.5 {19 -42} 
Sex (male:female) 19:1 
Duration of diabetes (median {range }) 
(years) 
2 {1 -26} 
Body mass index (kg /m2) 24.6 (2.8) 
Insulin dose (units /kg) 0.6 (0.3) 
Systolic blood pressure (mmHg) 124 (8) 
Diastolic blood pressure (mmHg) 74 (18) 
HbA1 c ( %) 7.8 (2.4) 
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After an overnight fast, and confirmation of the absence of hypoglycaemia in the preceding 
48 hours, hypoglycaemia was induced with a continuous intravenous infusion of soluble 
insulin at a rate of 2.0mU/kg/min in 0.9% sodium chloride solution, through an indwelling 
venous cannula in the antecubital fossa. The insulin infusion was continued until the onset of 
symptoms of hypoglycaemia, which was usually coincidental with objective evidence of an 
acute autonomic reaction (R). This was identified by a rapid increase in heart rate, a rise in 
systolic blood pressure, and the onset of sweating and finger tremor, as described previously 
(Hepburn, 1991). This insulin infusion method produces a gradual, predictable and 
controlled decline in blood glucose to induce hypoglycaemia and simulates the development 
of hypoglycaemia in everyday life. It enables the glycaemic threshold for the acute 
autonomic activation to be identified objectively (Hepburn, 1993). Blood sampling was 
timed subsequently in relation to R, the onset of which differs between individuals (Hepburn, 
1991). 
Arterialised venous blood was collected at 5 minute intervals for measurement of whole 
blood glucose concentration using a Yellow Springs Analyser (Yellow Springs, Ohio, USA). 
Blood samples were cold -centrifuged, the plasma separated and flash- frozen, and stored at 
-70 °C for measurement of immunoreactive ET by radioimmunoassay (ITS Production BV). 
The sensitivity of this assay is 2 pg/ml immunoreactive ET. Cross -reactivity of the assay 
with ET -1, ET -2, ET -3 and big ET -1 is 100 %, 52 %, 96% and 7% respectively. Plasma ET 
concentrations were measured at baseline, at the onset of the hypoglycaemic reaction, and at 
15 and 60 minutes following R. 




Plasma glucose concentration declined steadily from a mean (SEM) basal concentration of 
5.2 (0.2) mmol /1, until the symptomatic hypoglycaemic reaction (R) occurred at the nadir of 
1.9 (0.6) mmol/1. The mean (SEM) ET concentration rose from 3.80 (0.31) pg /ml at baseline 
to a peak of 6.72 (1.47) pg /ml at R + 60 minutes (p <0.05). These results are displayed 
graphically in figure 4.1. The different values at R and R + 15 minutes did not achieve 
statistical significance. The observed increase in ET concentration was wide, ranging from 
0.11 pg /ml to 20.18 pg/ml. 
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Figure 4.1: Plasma endothelin concentrations in response to acute insulin - 
induced hypoglycaemia in people with type 1 diabetes. Results are shown as 
mean (SEM). R= autonomic reaction. Grey dotted lines = Normal range (1.5 -4.5 










This study has shown that a significant rise in plasma endothelin -1 occurs in response to 
insulin- induced hypoglycaemia in adults with type 1 diabetes. 
Although there is now a strong evidence base to support a role for ET in the pathogenesis of 
diseases affecting the cardiovascular system, its influence in diabetes remains undefined, and 
its reliability as a marker of endothelial function in people with diabetes is debatable. The 
significance of the current findings is therefore uncertain. In vitro studies have shown that 
insulin (Hu, 1993), vasopressin and epinephrine (Collier, 1992) stimulate ET production 
from endothelial cells. In animal studies, the urinary excretion of ET rises following the 
development of diabetes and may represent endothelial damage induced by the diabetic state 
(Morabito, 1994). A regulatory role of insulin on ET -1 concentration has been suggested in 
patients with type 2 diabetes in whom a rise in plasma ET concentrations occurs during a 
hyperinsulinaemic glucose clamp (Ferri, 19951), and plasma ET and insulin concentrations 
are correlated closely in obese non -diabetic men (Ferri, 19952). The diabetic state in general 
(Takahashi, 1990), and diabetic complications in particular (Morise, 1995), are associated 
with an elevated concentration of plasma endothelin. It is possible that the observed rise in 
plasma endothelin during hypoglycaemia could exacerbate ischaemia through its 
vasoconstrictive effects in a vasculature that is already compromised by micro- or 
macrovascular disease, and thereby enhance the risk of promoting an acute macrovascular 
event and possibly aggravate existing microvascular disease (Fisher, 1993, Frier, 1985). It is 
also plausible that endothelin- induced vasoconstriction may serve as a defense mechanism to 
protect vital organs such as the brain, and also to increase delivery of gluconeogenic 
precursors to the liver, through the regional blood flow alterations seen throughout the body 
in response to hypoglycaemia. 
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These results permit speculation as to the possible role of endothelin in the pathogenesis of 
hypoglycaemia- induced vascular injury, or in regional blood flow alterations, but do not 
provide definitive conclusions. One limitation of the current study was the absence of a 
control group of non -diabetic volunteers to allow the endothelin responses to be compared; 
the response in healthy controls may be similar to subjects with diabetes. The mechanism 
inducing the rise in plasma endothelin is not known. It may have been provoked by insulin 
per se, or it may have been secondary to the hormonal response to acute hypoglycaemia 
(Fisher, 1993) in the form of elevated epinephrine or vasopressin concentrations (Attinà, 
2005). The increased sympathetic nervous system activity may have, through haemodynamic 
effects, increased shear stress on blood vessels and consequently triggered release of 
endothelin. Alternatively there may be a direct effect of neuroglycopenia causing ET release. 
Another potential limitation of the present study design is the method of induction of 
hypoglycaemia, using an insulin infusion to reach the point of symptoms of hypoglycaemia. 
The insulin infusion method does not allow for controlled reduction in blood glucose, and 
cannot be precisely replicated from subject to subject, leading to more inter -individual 
variability, which may be why the degree of endothelin rise varied so much between 
participants. In addition, this method does not allow for a control arm of the study, and in 
current research practice it is rarely utilised so other studies in this field will not be directly 
comparable. However, this method could be seen as a strength in that it simulates the 
development of hypoglycaemia in real life more accurately than the hyperinsulinaemic 
clamp method does. Therefore the degree of rise in endothelin may be more true to that we 
would see in real life. 
Despite these limitations, this preliminary study has demonstrated a significant rise in a 
peptide with potent vasoconstrictive properties, in a group of patients who are at high risk of 
developing vascular complications, caused by an incredibly common side -effect of their 
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5 Study 3: The effects of acute insulin- induced hypoglycaemia on indices of 
inflammation 
5.1 Introduction 
Diabetes is associated with an increased risk of microvascular and macrovascular disease. 
Atherosclerosis develops prematurely and can be more aggressive and widespread in the 
diabetic population (Deckert, 1978, Banga, 1994, Kirpichnikov, 2001). In people with type 1 
diabetes the rapid institution of strict glycemic control has been shown to aggravate 
microvascular complications, particularly retinopathy (Hanssen, 1986). Although this has 
been attributed to reduced capillary blood flow causing localised ischaemia (Hanssen, 1986), 
greater exposure to hypoglycaemia may have worsened microangiopathy through its 
potential effects on local vasculature (Frier, 1985). In addition, cardiovascular stress 
associated with hypoglycaemia may precipitate acute macrovascular events in a diseased 
circulation (Desouza, 2003, Fisher, 2007). 
Experimental studies of hypoglycaemia in humans with and without diabetes have suggested 
several possible mechanisms by which hypoglycaemia may damage blood vessels. These 
include changes in regional blood flow, mobilisation and activation of leucocytes, 
particularly neutrophils, platelet activation, and enhanced coagulation and viscosity of the 
blood (Frier, 1983, Fisher, 19912, Trovati, 1986). In addition, more recently, plasma 
concentrations of C- reactive protein have been shown to increase during hypoglycaemia 
(Galloway, 2000), suggesting promotion of a proinflammatory state, which may aggravate 
vascular disease (Libby, 2002). 
There has been increasing interest in the investigation of processes operating at a cellular 
level to cause atherosclerosis in recent years given the growing economic burden that the 
management of vascular disease occupies. Recent research has predominantly focused on the 
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potential influences of vascular inflammation, endothelial dysfunction, coagulation and 
platelet activation, with the intention that elucidating the underlying pathogenetic processes 
may help in the search for novel, early, therapeutic strategies to treat or even prevent the 
development of vascular disease. 
The aims of the present study were to determine the effects of acute insulin- induced 
hypoglycaemia on inflammation, coagulation, and platelet and monocyte function in adults 
with and without type 1 diabetes. The battery of tests used was specifically selected to 
investigate cellular processes identified as important in the pathogenesis of acute and chronic 
vascular complications in type 1 diabetes. 
5.2 Methods 
5.2.1 Subjects 
Sixteen non -diabetic adult volunteers and 16 healthy adults with type 1 diabetes participated 
in the study (Table 5.1). Subjects had no medical problems other than type 1 diabetes in the 
cohort with diabetes. 
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Table 5.1: Baseline demographic characteristics (shown as mean [SD] unless 
otherwise indicated) 
Non -diabetic subjects 
(n =16) 
Subjects with diabetes 
(n =16) 
Age (years) (median[IQR]) 28 (26.7 -35) 28 (25 -37.5) 
BMI (kg /m2) 22.86 (2.4) 26.40 (4.0) 
Male:Female 6:10 7:9 
Duration of diabetes 
(years) (median[IQR]) 
N/A 10 (4.2 -19) 
HbA1c ( %) N/A 7.91 (0.9) 
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Subjects had no history of hypertension or macrovascular disease, and microvascular disease 
was excluded in the cohort with diabetes who underwent screening prior to inclusion in the 
study. Digital retinal photography was performed to exclude diabetic retinopathy, absence of 
neuropathy was confirmed by clinical examination, and nephropathy was excluded by the 
absence of microalbuminuria. Subjects with a history of impaired awareness of 
hypoglycaemia or a previous serious reaction to hypoglycaemia were excluded from the 
study. Participants had no history of head injury, seizure, blackouts, alcohol or drug abuse 
and psychiatric illness. They were on no medication other than insulin and the oral 
contraceptive pill. DCCT -aligned HbAlc was measured using high performance liquid 
chromatography (non- diabetic reference range 5.0- 6.05 %; Bio -Rad Laboratories, Munich, 
Germany); the mean (SD) of the participants with diabetes was 7.91 (0.92) %. All subjects 
gave written informed consent before participation and the study was approved by the 
Lothian Medical Research Ethics Committee. 
5.2.2 Study Design 
A modified hyperinsulinaemic glucose clamp (DeFronzo, 1979) was used to maintain blood 
glucose at a predetermined level; euglycaemia at 4.5 mmol/1 and hypoglycaemia at 2.5 
mmol/1. Each subject underwent two laboratory sessions, one hypoglycaemic study and one 
euglycaemic study, separated by at least two weeks (mean 7.2 weeks). Studies were assigned 
in a randomised, counterbalanced fashion. 
5.2.3 Study Procedure 
The participants with type 1 diabetes monitored blood glucose intensively during the 48 
hours preceding each study, which was postponed if any blood glucose value was <3.5 
mmol /1 or if symptoms suggestive of hypoglycaemia were experienced. After fasting 
overnight, morning insulin was withheld. A retrograde intravenous cannula for blood glucose 
sampling was inserted into the non -dominant hand, which was heated to arterialise the 
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venous blood (Abumrad, 1981). A cannula in the non -dominant antecubital fossa was used to 
infuse 20% dextrose and soluble insulin (Human Actrapid, NovoNordisk, Crawley, UK) at a 
constant rate of 1.5mU /kg /min using a Gemini PCI pump (Alaris Medical Systems, San 
Diego, CA). Dextrose (20 %) was infused at a variable rate depending on arterialised blood 
glucose concentrations, which were measured at 5 minute intervals using the glucose oxidase 
method (2300 Stat; Yellow Springs Instrument, Yellow Springs, OH). A third cannula in the 
other antecubital fossa was dedicated to blood sampling for inflammatory markers. 
On each study day, the arterialised blood glucose was stabilised initially at 4.5 mmol/1 for 30 
minutes and either maintained at that level (euglycaemia) or lowered over 20 minutes to 2.5 
inmo1/1 for 60 minutes (hypoglycaemia), after which blood glucose was restored to 4.5 
mmol/1. Subjects consumed a standardised meal after each study. Blood sample time points 
were: baseline, during the experimental session ( +45mins), during recovery ( +105mins), at 
+6hours and at +24hours. 
5.2.4 Flow cytometry 
Whole blood samples were collected at the predetermined time points using D- Phenylalanyl- 
L- prolyl -L- arginine chloromethyl ketone (PPACK), a selective thrombin inhibitor, as an 
anticoagulant. 100 µl samples of whole blood were immediately incubated with 10 gl of 
each monoclonal antibody /antibody combination for 30 minutes at room temperature (AbD 
Serotec, Kidlington, UK). Subsequently red cell lysis was performed by the addition of 1 ml 
of FACS Lyse solution (Becton Dickinson, Oxford, UK). Flow cytometry using the FACS 
Calibur system (Becton Dickinson, Oxford, UK) was performed immediately following the 
experimental session to assess platelet -monocyte aggregation (CD14 /CD42a), CD40 
expression on monocytes (CD14 /CD40), and CD40 ligand expression on platelets 
(CD154 /CD42a). Isotype controls were performed in addition to both mono- and dual -stain 
for each parameter assessed at each time point. 
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5.2.5 Soluble marker assays 
Citrated plasma and serum samples were collected at the predetermined time points. These 
were separated immediately and frozen at -80 °C until analysis for the soluble markers: 
Von Willebrand Factor (ELISA; CV 7.3 %), tissue Plasminogen Activator antigen (Hyphen 
Biomed Zymutest; intra -assay CV 3.5 %, inter -assay CV 4.4 %), soluble CD40 ligand (high 
sensitivity ELISA, Bender Medsystems; intra -assay CV 5.5 %, inter -assay CV 7.2 %), soluble 
P- selectin (ELISA, R &D Systems; intra -assay CV 5.1 %, inter -assay CV 8.8 %), interleukin -6 
(High sensitivity ELISA, R &D Systems; intra -assay CV 5.9 %, inter -assay CV 9.9 %), and 
high sensitivity CRP (DRG Diagnostics, DRG Instruments GmbH Germany; intra -assay CV 
4.2 %, inter -assay CV 4.1 %). 
5.2.6 Counterregulatory hormone assays 
Samples for counterregulatory hormone quantification were collected in EDTA tubes and 
immediately separated and frozen at -80 °C until analysis. Epinephrine and norepinephrine 
were assessed by high performance liquid chromatography and electrochemical detection. 
Glucagon and pancreatic polypeptide were determined by radioimmunoassay. 
5.2.7 Hypoglycaemia symptom score 
The Edinburgh Hypoglycaemia Scale (Gold, 1994) was used to assess the symptoms 
experienced during each experimental session. 
5.2.8 Statistical analyses 
Results were analysed using SPSS version 15.0 for Windows (SPSS, Chicago, IL). A general 
linear model (repeated measures ANOVA) was used, with order of session (euglycaemia- 
hypoglycaemia or hypoglycaemia -euglycaemia) as a between -subjects factor, and condition 
(euglycaemia or hypoglycaemia) as a within- subjects factor, to compare hypoglycaemia with 
128 
euglycaemia. Additional analysis using paired t -tests was performed to assess the change in 
any given parameter from baseline. A p -value <0.05 was considered to be significant. 
Results are reported as mean (SD) unless otherwise stated. 
5.3 Results 
5.3.1 Blood Glucose 
Target blood glucose concentrations were achieved as shown in Figure 5.1. In non- diabetic 
subjects, the mean (SD) blood glucose concentrations were 2.58 (0.2) and 4.42 (0.5) mmol/1 
during hypoglycaemia and euglycaemia respectively. In those with type 1 diabetes, blood 
glucose concentrations were 2.46 (0.22) and 4.53 (0.24) mmol/1 respectively. The blood 
glucose nadir was similar in both groups. 
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Figure 5.1: Blood glucose concentrations during hyperinsulinaemic 
hypoglycaemic and euglycaemic clamp studies i. Non -diabetic subjects; ii. 
Subjects with type 1 diabetes. 
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Hypoglycaemia provoked a symptomatic response in all subjects with increased scores of 
autonomic (p <0.002), neuroglycopenic (p<0.001), and non -specific (malaise) (p50.008) 
symptoms compared to baseline. Thesé scores are shown in table 5.2. 
5.3.3 Counterregulatory response 
Plasma epinephrine increased during hypoglycaemia in participants with and without type 1 
diabetes (p <0.001; figure 5.2), with a higher peak in the subjects without diabetes (p =ns). 
The epinephrine response occurred only during hypoglycaemia and returned rapidly to 
baseline as anticipated (Thompson, 1993). Plasma norepinephrine did not show such a 
dramatic response, but was seen to increase more during hypoglycaemia studies in both non- 
diabetic subjects and in subjects with type 1 diabetes (figure 5.3). Again, a higher peak was 
demonstrated in the non -diabetic subjects. Glucagon levels rose slightly, or were at least 
preserved during hypoglycaemia in non -diabetic subjects (figure 5.4). Levels were 
suppressed in the euglycaemia studies, and were attenuated during all studies in subjects 
with type 1 diabetes. This is consistent with the well -established loss of glucagon response in 
people with type 1 diabetes of over 5 years duration; in this study the median duration of 
diabetes was 10 years. Pancreatic polypeptide increased during hypoglycaemia in all 
participants, but to a higher level in non -diabetic subjects (figure 5.5). 
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type 1 diabetes 
- 
Hypoglycaemia 
Autonomic 1.37 (0.37) 2.47 (1.11)* 1.36 (0.48) 2.76 (1.36)* 
Neuroglycopenic 1.35 (0.64) 2.53 (0.83)* 1.41 (0.80) 3.25(1.23)* 
Non -specific 1.18 (0.37) 1.82 (0.69)* 1.15 (0.28) 1.71 (0.80)* 
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Figure 5.2: Epinephrine responses to experimental procedures. i. Non -diabetic 























Figure 5.3: Norepinephrine responses. i. Non -diabetic subjects; ii. Subjects 

























Figure 5.4: Glucagon response to hypoglycaemia. i. Non -diabetic subjects; ii. 



























Figure 5.5: Pancreatic polypeptide responses. i. Non -diabetic subjects; ii. 
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5.3.4 Baseline levels of inflammation 
Comparison of baseline levels of inflammatory, endothelial and platelet markers in non - 
diabetic subjects and subjects with type 1 diabetes showed that levels of all parameters 
except platelet -monocyte aggregation and CD40 ligand on platelets were elevated at baseline 
in subjects with diabetes, with a significantly higher concentration of soluble p- selectin 
(p =0.01) and of CD40 expression on monocytes (p= 0.006) in those with diabetes. This is 
consistent with the chronic inflammatory response associated with diabetes. Surprisingly, 
there was a significantly higher level of CD40 ligand expression on platelets at baseline in 
non -diabetic subjects (p= 0.01). These results are shown in table 5.3. 
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Table 5.3: Baseline levels of inflammation in non -diabetic subjects and 
subjects with type 1 diabetes. Data shown as mean (SD). P -value <0.05 
denotes significance ( *). 
Non -diabetic 
subjects 




tPA 9.28 (10.2) 16.63 (29.7) 0.204 
vWF 0.82 (0.3) 0.92 (0.2) 0.163 
IL -6 0.79 (0.5) 0.99 (1.3) 0.427 
sCD4OL 2.78 (3.2) 3.15 (2.8) 0.629 
P- selectin 32.50 (9.6) 39.48 (13.2) *0.018 
CD40 on 
monocytes 
1.82 (1.9) 3.49 (2.7) *0.006 
PMA 0.65 (0.8) 0.43 (0.4) 0.200 
CD4OL on platelets 7.14 (4.9) 4.66 (2.8) *0.017 
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5.3.5 Platelet activation 
5.3.5.1 Platelet- monocyte aggregation 
In non -diabetic subjects, mean (SD) platelet -monocyte aggregation appeared to rise, from a 
baseline level of 0.72 (0.8)% to 3.09 (8.1)% during hypoglycaemia, and this elevated level 
persisted for 24 hours, with a peak of 3.49 (10.4)% at 24h (figure 5.6). Platelet -monocyte 
aggregation remained unchanged throughout euglycaemia, with a small decline from a 
baseline of 0.70 (0.9) %, to 0.59 (0.4)% during the experimental period. The differences 
between conditions, and from baseline, did not achieve statistical significance. 
In participants with diabetes, there was a late rise in platelet -monocyte aggregation following 
hypoglycaemia at 24h compared with baseline (p= 0.03). 
5.3.5.2 Soluble P- selectin 
P- selectin increased significantly after hypoglycaemia in the non -diabetic group, exhibiting a 
late response at 6 hours (p =0.01) and 24 hours (1)= 0.02). There was a paradoxical decrease in 
P- selectin in those same subjects during euglycaemia (p= 0.006). 
P- selectin also decreased during euglycaemia in the subjects with diabetes (1)= 0.04), but no 
significant increment was identified during hypoglycaemia (figure 5.7). 
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Figure 5.6: Platelet- monocyte aggregation. i. Non -diabetic subjects; ii. 
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5.3.6 Endothelial markers 
5.3.6.1 Tissue Plasminogen Activator (tPA) 
In non -diabetic subjects, mean (SD) plasma tPA concentrations increased during 
hypoglycaemia, with a higher peak tPA concentration (12.55 (16.7) compared with 6.80 
(7.9) ng /ml) (p=ns between conditions). Plasma tPA decreased significantly between 
baseline and test phase (p= 0.004) and recovery phase (1)= 0.006), with a paradoxical rise 
between baseline and 24h (p =0.06) after euglycaemia (table 5.4). However, a diurnal 
variation in tPA concentration is recognised to occur, which may account for the decline 
observed during euglycaemia (Rydzewski, 1997). No significant differences occurred in the 
diabetic group (table 5.5). 
5.3.6.2 Von Willebrand Factor (vWF) 
A trend towards a difference in plasma vWF concentrations was observed between 
hypoglycaemia and euglycaemia at 6h in the non -diabetic subjects (p =0.07) (table 5.4). 
Plasma vWF concentrations decreased between baseline and test phase (p =0.02) and 
recovery phase (p =0.03) after euglycaemia in the participants with diabetes. No such 
decrement was observed during hypoglycaemia (table 5.5). 
5.3.7 Inflammation 
5.3.7.1 CD40 expression 
CD40 expression on monocytes increased following hypoglycaemia in non -diabetic subjects, 
from a baseline of 1.92 (2.2)% to a maximum of 3.13 (2.3)% at 24h (p= 0.009) (results are 
mean (SD)). A significant difference between hypoglycaemia and euglycaemia conditions 
was present at 6h (p =0.05) and at 24h (p =0.04) (table 5.4). 
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In participants with type 1 diabetes, mean (SD) monocyte CD40 expression increased from 
3.69 (3.4)% to 5.54 (4.4)% during hypoglycaemia (p= 0.006), compared with no change 
during euglycaemia (3.64 (2.0)% to 3.65 (1.8)% respectively; p=ns). The increment during 
hypoglycaemia had dissipated by the time of the recovery phase and remained unchanged 
thereafter (table 5.5). 
5.3.7.2 CD40 ligand expression 
CD40 ligand (CD154) expression on platelets was found to have a very small rise during and 
after hypoglycaemia in non -diabetic volunteers (p =ns; table 5.4) but did not change in 
subjects with type 1 diabetes when compared with a euglycaemic control period (table 5.5). 
5.3.7.3 Soluble CD40 ligand (sCD4OL) 
In non -diabetic subjects, plasma sCD4OL concentrations were higher during hypoglycaemia 
than during euglycaemia (mean (SD) 2.80 (3.2) ng/ml vs. 2.41 (2.8) ng /ml), with a trend 
towards significance (p= 0.09). A significant reduction in sCD4OL concentration occurred 
during euglycaemia between baseline and recovery phase (p =0.03) (table 5.4). 
In those with diabetes, a significant difference was observed between the mean (SD) baseline 
levels on each study day: 3.36 (2.9) ng /ml on the hypoglycaemia day compared with 2.86 
(2.8) ng /ml on euglycaemia day 4)= 0.03), rendering subsequent measurements difficult to 
compare. A significant difference was again observed between the experimental condition 
levels, with a level of 3.41 (3.2) ng /ml during hypoglycaemia and 2.85 (2.8) ng /ml during 
euglycaemia (p =0.03) (table 5.5). Changes from baseline did not achieve significance. 
5.3.7.4 Interleukin-6 (IL-6) 
IL -6 levels rose in all experiments, maximally at 6h, irrespective of condition, with no clear 
differences identifiable in either group between the study conditions (table 5.4 and 5.5). 
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5.3.7.5 High Sensitivity C- reactive protein (hsCRP) 
Test phase hsCRP was higher in all subjects during hypoglycaemia (1.81 (1.9) vs. 1.22 (1.9) 
ng /ml in non -diabetic participants (p= 0.02); 2.72 (3.1) vs. 2.20 (2.9) ng /ml in subjects with 
diabetes (p =ns); results are mean (SD)) (table 5.4 and 5.5). A significant difference was 
observed in the baseline concentrations in the non -diabetic participants (p= 0.01), frustrating 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Previous studies have demonstrated that hypercoagulability, platelet and neutrophil 
activation and C- reactive protein are upregulated following acute hypoglycaemia (Frier, 
1983, Fisher, 19912, Trovati, 1986, Galloway, 2000), while a euglycaemic insulin infusion 
(for at least 2 hours) has been shown to reduce inflammatory markers, consistent with an 
anti -inflammatory effect of insulin (Dandona, 2009). The present study sought to replicate 
these effects, while investigating other novel underlying mechanisms of vascular disease. 
This study has shown that hypoglycaemia promoted a response in a number of the vascular 
biomarkers examined, suggesting the premise that hypoglycaemia- induced metabolic stress 
may have adverse pathophysiological consequences. At the same time, the euglycaemic 
insulin infusion caused a potentially beneficial decrement in some parameters. However, the 
actual magnitude of most observed changes was small, and not all markers changed to a 
statistically significant degree. 
This study has confirmed that platelet activation is promoted by hypoglycaemia, with 
increments both in platelet -monocyte aggregation and soluble p- selectin. Conversely, p- 
selectin decreased during euglycaemia. Endothelial function, using vWF and tPA Ag as 
surrogate markers, may have been disrupted, as shown by the increase in vWF after 
hypoglycaemia in non -diabetic volunteers, but this change was not replicated in those with 
diabetes. However, a reduction in vWF occurred after euglycaemia in diabetic participants, 
which should confer vascular benefit. tPA Ag also appeared to increase in non -diabetic 
subjects during hypoglycaemia, while declining during euglycaemia, whereas no significant 
changes occurred in the diabetic group. Soluble markers of inflammation, sCD4OL and 
hsCRP, were higher during hypoglycaemia, with an elevation of hsCRP being observed in all 
subjects. Unfortunately, baseline differences in hsCRP in non- diabetic subjects, and in 
sCD4OL in the diabetic subjects, made subsequent interpretation of responses more difficult. 
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sCD4OL was apparently reduced during euglycaemia in non -diabetic participants. 
Surprisingly, IL -6 increased in all experiments regardless of glycaemic status, with a 
maximal response at 6h. Monocyte CD40 expression also increased, suggesting promotion of 
the interaction of the CD40 -CD40 ligand dyad (from the tumour necrosis factor receptor 
family), thus affecting another process in the pathway leading to atherosclerotic plaque 
rupture (Schonbeck, 20011, Mach, 19981). This change occurred much earlier in the diabetic 
than the non -diabetic subjects, in whom the response was delayed, prolonged, and still 
present at 24 hours. The persistence of these vascular changes for 24 hours after the 
hypoglycaemic stimulus, or their later appearance, suggests that the period of risk following 
hypoglycaemia may be present long after blood glucose has recovered to normal levels. This 
is a very concerning observation, as previously it had been believed that any stress induced 
by hypoglycaemia would be transient, and only likely to cause any adverse effects in those 
with significant underlying vascular abnormalities. It appears from these study results that 
many markers exhibit a delayed or prolonged response, which may pose longer term risks to 
the vasculature. 
For some markers, a positive trend following hypoglycaemia was evident, without achieving 
statistical significance, or the only measurable difference between conditions was a 
beneficial decrement associated with euglycaemia. The sample size may have been 
insufficient to achieve significance, particularly as the magnitude of responses was small. It 
was not feasible in this study to examine a larger number of subjects due to the labour - 
intensive nature of running a hyperinsulinaemic clamp study alongside flow cytometric 
analysis of samples within 24 hours of each experimental session. The depth of 
hypoglycaemia or speed of onset may not have been sufficient to generate a significant 
response, and an insulin infusion may have been more likely to simulate real life induction of 
hypoglycaemia and precipitate the degree of change of markers that is most relevant to 
people with diabetes. 
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A further limitation of the present study was the need to examine the experimental 
conditions on two separate days in a counterbalanced fashion. Because the baseline levels of 
many inflammatory markers can differ on separate days, as was observed with sCD4OL and 
hsCRP, this biological variability hinders the interpretation and comparison of subsequent 
results. However, the present study design was necessary to allow comparison of the 
euglycaemia and hypoglycaemia conditions in individual subjects, as both time and insulin 
infusion per se may exert effects on biomarker levels. This study design cannot control for 
other day -to -day factors that could influence baseline levels of inflammatory markers. 
However, the effects of hypoglycaemia could be evaluated, as each participant acted as their 
own control. This produces less variability than a comparison of results between individuals, 
as inter -individual variation in inflammatory marker levels creates more problems during 
analysis than intra- individual variation, which must be accepted. In addition, it was possible 
to analyse each study separately, by examining changes in parameters from baseline on that 
particular day, enabling the detection of significant effects exerted by hypoglycaemia 
compared to euglycaemia. Baseline levels of most markers (except CD40 ligand expression 
on platelets and platelet -monocyte aggregation) were higher in the diabetic group (significant 
for p- selectin and CD40 expression). This could affect the magnitude of response induced by 
the experimental procedures. However, an analysis of the percentage change from baseline 

























































































































































































































































































































































































































































































































































































































































































































As anticipated, epinephrine secretion was stimulated by hypoglycaemia in all subjects. It is 
likely that hormonal changes underlie the activation and upregulation of the vascular 
biomarkers, although other factors must be involved to generate the prolonged and delayed 
effects seen in some parameters, as epinephrine levels returned to baseline by the recovery 
phase. Catecholamines are known to promote platelet activation (Steel, 1971), while 
adrenoceptor blockade attenuates these effects (Fisher, 19902, Takeda, 1988). The 
participants with type 1 diabetes exhibited attenuated plasma epinephrine responses to 
hypoglycaemia compared with the non -diabetic subjects, who were naïve to such a 
hypoglycaemic stimulus. This is consistent with the recognised decline in the magnitude of 
counterregulatory hormonal responses with increasing duration of type 1 diabetes (Kerr, 
2007). This attenuated epinephrine response may to some extent explain the lower responses 
of vascular biomarkers to hypoglycaemia. 
In summary, the effects of hypoglycaemia on several vascular biomarkers that are implicated 
in the pathogenesis of vascular disease would support the premise that acute hypoglycaemia 
may be detrimental to an already diseased vasculature (Frier, 1985). Euglycaemia, or insulin 
itself, may have a protective, anti- inflammatory effect, consistent with previous reports 
(Dandona, 2009). In the present study the participants had no overt vascular disease and 
were unlikely to develop any demonstrable effects from a short period of exposure to 
hypoglycaemia. However, in people with diabetes of long duration, who are likely to have 
underlying vascular disease, these responses may not be benign. The release of potent 
vasoactive substances could potentially aggravate chronic vasculopathy, and contribute to 
the precipitation of acute macrovascular events. The prolonged increment in some indices 
suggests a longer period of risk following the hypoglycaemic insult than was previously 
believed. These changes may aggravate established diabetic micro- and macrovascular 
disease in those who are exposed to recurrent hypoglycaemia. 
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Chapter 6: 
Discussion, Conclusions and Future 
Research 
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6 Discussion, Conclusions and Future Research 
6.1 Spatial ability 
6.1.1 Summary 
Many facets of cognition have been shown to deteriorate during acute insulin- induced 
hypoglycaemia, but to date no study has focused purely on the effects on spatial abilities. 
The study described in chapter 3 has demonstrated that acute insulin- induced hypoglycaemia 
had an adverse impact on spatial abilities in 16 adults with uncomplicated type 1 diabetes. A 
large battery of tests specifically pertaining to spatial ability was utilised in order to 
investigate this. The decrements seen in all but one assessment were statistically significant, 
with large effect sizes. 
A potential limitation of the present study was the absence of a control group of non -diabetic 
subjects with which to compare responses. It was felt, however, that the effects would be 
most relevant in the subjects with type 1 diabetes, who are actually exposed to 
hypoglycaemia on a regular basis, as opposed to non -diabetic subjects who are 
hypoglycaemia- naive, and who will not experience hypoglycaemia in real life. It would, 
however, be of interest to examine the responses in a group of non -diabetic individuals, as 
any differences between the groups can inform us further with regards to the phenomenon of 
cerebral adaptation to hypoglycaemia in those people who experience it regularly, as 
compared with the non -diabetic volunteers who would never have experienced it previously. 
Many previous studies of hypoglycaemia and cognitive function have been limited by a 
small sample size, a limited selection of cognitive tests and inadequate assessment of both 
physical and psychosocial variables that may affect the results (Amiel, 1998). In this study 
avoidance of these pitfalls was ensured. In addition, there have been many methodological 
issues in hypoglycaemia studies in the past; these have included heterogeneity in the method 
of induction of hypoglycaemia, inadequate depth of hypoglycaemia to detect changes in 
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cognition, issues with blood sampling for glucose estimation and issues with opportunity for 
practice effects to arise during conduct of the cognitive test batteries. This study protocol 
attempted to address all of these potential issues with a robust study design, using a 
controlled induction of hypoglycaemia by hyperinsulinaemic clamp, comparing 
hypoglycaemia with euglycaemia in a randomised, counterbalanced manner. A depth of 
hypoglycaemia of 2.5mmo1 /1 was achieved, and standard cognitive assessment with the Digit 
Symbol Substitution Test and Trail- Making B test was used to confirm that hypoglycaemia 
sufficient to impair cognitive function was reached. Two versions of the spatial ability test 
battery were available to avoid practice effects, again using a randomised, counterbalanced 
approach. Practice effects can mean that performance improves with repeated exposure to 
the tests, but can also mean that performance deteriorates through boredom or irritation with 
repeatedly performing the same task. The drawback of only having 2 versions of each 
cognitive test, though, is that there was not the opportunity for the subject to familiarise 
themselves with the test beforehand, which can mean that the effects of hypoglycaemia are 
underestimated. As a large effect size was demonstrated in the present study, it can be 
assumed that any familiarisation with the tests would have potentially increased the effect 
size demonstrated. Arterialised venous blood collection was performed (Abumrad, 1981) in 
order to provide accurate estimation of blood glucose concentration at the bedside 
throughout the experimental procedures. 
Previous studies of the effects of hypoglycaemia on cognition have used batteries of tests 
that are likely to include a spatial ability component, but the aims of this study were to 
concentrate on spatial ability alone, as it is a task that is so relevant to daily life. Driving, in 
particular, relies heavily on spatial ability, so it is therefore of considerable importance to 
know how hypoglycaemia will impact on it. The French and Ekstrom Kit of Factor 
Referenced (cognitive) tests was used (Ekstrom, 1976). This kit consists of 72 different 
psychological tests representing 23 cognitive factors, and a selection of those pertaining to 
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spatial ability factors was used for our spatial test battery. The selected tests needed to 
examine each factor associated with spatial ability but be manageable within the 
experimental study timeframe. It would have been unacceptable to subject each participant to 
a more prolonged episode of hypoglycaemia in order to administer a larger test battery; this 
would also introduce fatigue as a potential confounding variable as this may impair cognitive 
performance. It was felt that the chosen battery adequately assessed each facet of spatial 
functioning to give an overall assessment of spatial ability during the experimental period, 
and the battery was administered comfortably during the 1 hour experimental window, 
including the need for explanation of each test. The sub -divisions assessed were: Flexibility 
of Closure (Hidden Patterns), Spatial Orientation (Card Rotations and Cube Comparisons), 
Visualisation (Paper Folding), Visual Memory (Building Memory), and Spatial Scanning 
(Maze Tracing) (Ekstrom 1979). Each of these will now be discussed in turn (Ekstrom, 1976, 
Ekstrom, 1979). 
Flexibility of Closure: this is defined as 
`the ability to hold a given visual percept or configuration in mind so as to disembed it from 
other well -defined perceptual material'. 
Tests of this factor require the subject to search a distracting visual field in order to find a 
given model/pattern. 
Visual Memory: 
`the ability to remember the configuration, location and orientation of figural material'. 
It is felt that visual memory encompasses processes beyond other memory functions, with 
the existence of iconic memory used to store visual impressions. 
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Spatial Orientation: 
`the ability to perceive spatial patterns or to maintain orientation with respect to objects in 
space'. 
This is a complex sub -division of spatial ability in that it is difficult to completely extract 
this factor from others associated with spatial ability. It is intricately linked to Visualisation. 
It is thought that the figure is perceived as a whole in Spatial Orientation, but that it requires 
mental restructuring and manipulation in Visualisation (Carroll, 1974). Spatial Orientation 
may be a more difficult or less practiced aspect of perceptual speed, which is assessed by a 
different selection of tests not utilised in our present test battery. Both aspects require visual 
memory, but serial operations are required in Visualisation. 
Spatial Scanning: 
`speed in exploring visually a wide or complicated spatial field'. 
The tests of this factor require the ability to scan the field quickly, follow paths with the eye 
and reject false leads. There is an element of planning involved, but it is felt to be limited in 
these maze -type tasks which simply require the desire to scan for the right path before 
wasting time drawing a line on the paper. These tasks are certainly at risk of practice effects, 
but we eliminated this possibility by only performing the task during experimental periods, 
and we had 2 versions of the test available for each experimental session. 
Visualisation: 
`the ability to manipulate or transform the image of spatial patterns into other 
arrangements'. 
This requires restructuring and mental manipulation of the images seen. Many researchers 
feel that this is not a primary factor in itself, but comprises multiple factors including figural 
adaptive flexibility, speed of closure and flexibility of closure. Some subjects may utilise an 
analytical strategy to perform these tests, looking for symmetry and planes of reflection as 
clues to the solution (Cattell, 1971). Alternative suggestions are that there are primary and 
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higher order levels of visualisation (Royce, 1973). This is not a major issue in the present 
study as a collection of tests was used to represent spatial ability together. 
Only one aspect of the spatial test battery was not significantly affected by hypoglycaemia, 
and that was the Building Memory test. This test requires the subject to memorise the 
position of various buildings on a map, and then try to re -site those buildings on a blank map 
thereafter. It therefore encompasses both a spatial ability function and visual memory 
function, and in the Kit of Factor -Referenced Cognitive Tests comes under the `Visual 
Memory' factor. It is noteworthy that visual memory has been investigated previously, and 
that it was shown not to be affected by hypoglycaemia (Warren, 2007). In that study, the 
visual reproduction (immediate and delayed) test was utilised from the Wechsler Memory 
Scales (revised) battery. A `ceiling' effect was demonstrated, where almost all candidates 
achieved a near perfect score, suggesting that this was not a very discriminatory test for the 
study of the effects of hypoglycaemia. This ceiling effect did not seem to be present in 
analysis of the scores for the Building Memory test, but there were fewer items in this test 
than in others used, and this seems more likely to have contributed to the lower 
discriminatory value of the test. 
6.1.2 Mechanisms of cognitive dysfunction 
6.1.2.1 Regional blood flow changes 
It has been shown that hypoglycaemia causes an overall increase in total cerebral blood flow 
at blood glucose concentrations below 2.0 minol/1. The regional distribution of blood flow 
within the brain is altered from baseline, with an increase to the frontal cortex and the 
thalamus, perhaps to provide glucose to the areas that are most vulnerable to 
neuroglycopenia (Bryan, 1990, MacLeod, 1994, Tallroth, 1992). Consequently there are also 
areas that experience a reduction in flow, for example the right posterior cingulate gyms and 
putamen (MacLeod, 1996). These areas will experience a reduction in fuel delivery, and 
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these areas may have a role in co- ordinating the affected components of cognitive function. 
The putamen is certainly recognised to be of importance in regulating movement and 
learning. Neuroimaging methods have become very sophisticated in recent years, and are 
able to assist in our understanding of these regional blood flow alterations, to help translate 
them into the functional changes that we see in real life. 
6.1.2.2 Data from functional imaging studies 
In vivo neuroimaging studies are helping to shed light on the effects of hypoglycaemia on 
cognitive function. Changes in regional blood flow can be assessed directly using PET 
(Positron Emission Tomography), or indirectly using functional MRI (magnetic resonance 
imaging). Imaging studies are good at assessing how structure and function are affected by 
hypoglycaemia, but cannot tell us the mechanisms by which these changes are induced. 
Since the brain is dependent on glucose for metabolism and function, acute neurological 
consequences of hypoglycaemia are expected when a hypoglycaemic state is created. This 
has led to the use of imaging techniques to attempt to clarify which regions of the brain are 
most affected during hypoglycaemia. Areas controlling appetite show increased neuronal 
activity, whereas the lateral orbitofrontal cortex sees a downregulation of activity. Global 
blood flow decreases by 6 -8% overall at a blood glucose concentration of 3.0 mmol/1, 
particularly evident at the hippocampi. Conversely, there is a relative increase in activity 
seen in the medial and orbital prefrontal cortex, thalamus, globus pallidus and periaqueductal 
grey (Teves, 2004). 
Spatial ability processes predominantly involve the right cerebral hemisphere, particularly 
the parietal lobe, and spatial cognition is co- ordinated through the frontal cortex, thalamus 
and to some extent the cerebellum (Harris, 2007, Vogel, 2003). It has been demonstrated that 
BOLD activation (blood oxygenation level -dependent activation) is attenuated during 
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hypoglycaemia in the pre -motor and supplementary motor cortex, consistent with some of 
the areas known to be involved in spatial ability processes (Rosenthal, 2001). 
Of considerable interest is the role of the brain in detecting and responding to evolving 
hypoglycaemia. Functional neuroiinaging provides a method to assess which areas of the 
brain switch on or off during hypoglycaemia, and as well as being relevant to cognitive 
function, this is also helping to determine how the brain senses hypoglycaemia. Following on 
from this, the pathogenesis of impaired hypoglycaemia awareness or cerebral adaptation to 
hypoglycaemia in those who are prone to recurrent episodes is an area of intense research at 
the present time. 
6.1.3 Clinical Relevance 
The study described in chapter 3 has provided further evidence of the adverse impact that 
hypoglycaemia has on cognition. Spatial ability is one of the most important components 
involved in the task of driving, along with information processing, psychomotor function and 
attention. Across Europe, people with type 1 diabetes are offered a period- restricted driving 
licence which allows the opportunity for reassessment of clinical status on a regular basis to 
ensure no issues pertaining to vision, proprioception or hypoglycaemia have developed, that 
may hamper a person's ability to drive safely. The Driver and Vehicle Licencing Authority 
(DVLA) in the UK issues 3 year period -restricted licences for driving cars and motorcycles, 
and has recently, in 2011, introduced new guidance to allow annual licences to be issued to 
drivers of buses and lorries, where this was previously banned. Drivers of these larger 
vehicles have to comply with very strict criteria including an annual assessment to ensure 
that they: have had no SH in the preceding 12 months, have full hypoglycaemic awareness, 
prove adequate control through regular blood glucose measurement using a meter with a 
memory function, demonstrate an understanding of the risks of hypoglycaemia and have no 
other debarring complications of diabetes. An additional change to the UK guidelines has 
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been to impose a ban on driving if more than one episode of SH has occurred in the 
preceding year, or if impaired hypoglycaemia awareness is present (defined in this case as 
the total loss of warning symptoms). Previously a one year restricted licence was issued in 
the case of impaired awareness, so the new guidelines are stricter, showing that attention to 
safety is becoming ever more important. 
Studies examining the effects of hypoglycaemia on driving using a driving simulator have 
been conducted in the USA. Using the hyperinsulinaemic clamp technique, as in our spatial 
ability study, the direct consequences of hypoglycaemia on driving have been assessed. At a 
blood glucose concentration of 3.8mmo1/1 or less, driving errors become commonplace. 
These errors include speeding, inappropriate braking, crossing the midline of the road, or 
even driving off the road, and also an increased frequency of crashes. All of these tasks 
involve malfunction of spatial and orientational ability. Only 30% of participants in these 
simulator studies requested treatment to correct their hypoglycaemia, and this only occurred 
at a blood glucose concentration below 2.8mmol/1. Less than 25% of subjects felt they had to 
stop driving once their blood glucose was low (Cox, 1993, Cox, 2000). Although a driving 
simulator is still not equivalent to driving a real vehicle, it is fairly close, and these studies 
demonstrate the relevance to real life that impairments in cognitive function have. 
A further aspect of real life that may be affected by this cognitive impairment during 
hypoglycaemia is employment. Certain vocations are not compatible with insulin therapy 
and risk of hypoglycaemia due to the effect this will have on cognitive function, or even on 
conscious level if left untreated. These include vocations such as working as an airline pilot 
or train driver, and jobs involving working alone in isolated or dangerous areas, or at height. 
Serving in the armed forces is also banned, and work with emergency teams and in the 
offshore oil industry is not usually permitted due to the isolation that occurs, and the 
unpredictable nature of the jobs involved. Therefore people who experience regular 
hypoglycaemia, or have impaired hypoglycaemia awareness, can be limited in the 
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professions that they can follow, and may have restrictions imposed on them at work. It may 
also be necessary for an individual to take time off work following hypoglycaemic events in 
order to recover and restabilise blood glucose, which may again lead to conflict with an 
employer. 
The present study findings are of considerable concern given the importance of spatial ability 
in normal day -to -day functioning. The effects of hypoglycaemia on the brain must not be 
underestimated. 
6.2 Vascular biology 
6.2.1 Summary 
6.2.1.1 Endothelin -1 
Chapter 4 describes a preliminary study performed to evaluate the effects of acute 
hypoglycaemia on levels of plasma endothelin -1, a potent vasoconstrictor. This study 
demonstrated, in 20 subjects with type 1 diabetes, that endothelin -1 concentrations increased 
following hypoglycaemia, with a maximum increase seen at 60 minutes following the 
autonomic reaction. 
The practical aspects of this study were performed prior to the general acceptance that the 
hyperinsulinaemic glucose clamp technique was a safer and more controlled method of 
inducing experimental hypoglycaemia. In this study, hypoglycaemia was induced by the 
insulin infusion method, with the rate of infusion calculated according to body weight. The 
steady infusion is continued until the autonomic reaction is generated, which can occur after 
a variable amount of time in different individuals, and can also occur at different blood 
glucose concentrations. This will be particularly true in this group of patients with type 1 
diabetes, who will have differing levels of prevailing glucose control, and different history of 
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exposure to previous hypoglycaemia. As a result, the exposure to insulin during the 
experiment will also have differed between individuals. There were, therefore, several 
confounding variables that may have influenced the results seen. Another drawback to using 
this method is that it does not allow for a control arm to the study, and therefore there is no 
euglycaemic control experiment to show that insulin infusion, per se, does not affect 
endothelin -1 levels. Additionally, these results will not be directly comparable with other 
studies in the field which have utilised the more commonly used clamp method. Despite this, 
there is no doubt that the levels did rise, but a large inter -individual variation in response was 
seen, which may have been contributed to by the confounders described above. However, in 
favour of this method of inducing hypoglycaemia is the fact that it is a better way of 
mimicking the day to day occurrence of hypoglycaemia in people with type 1 diabetes, and 
therefore perhaps these results are a more true to life representation of how individuals 
would respond. 
The next questions to address are: i) the role of endothelin -1 in diabetes, and ii) the potential 
role and effects it may produce following hypoglycaemia. Patients with diabetes, and many 
other conditions associated with cardiovascular risk including hypertension and renal 
disease, have elevated baseline levels of endothelin -1 (Schneider, 2002, Dhaun, 2006) when 
compared with healthy controls. It is thought possible that elevation in ET -1 concentration 
may precede the development of vascular complications in disease states associated with 
cardiovascular risk (Schneider, 2002). There is evidence to suggest that the presence of 
microvascular complications may lead to increases in ET -1, and that ET -1 levels are 
correlated with presence of microangiopathy, hypertension, increased disease duration and 
family history of diabetes in people with type 2 diabetes (Collier, 1992, Ak, 2001, Dhaun, 
2006). There has been no association found to date with metabolic control, treatment 
modality, age, sex, lipid control, obesity or smoking (Ak, 2001). It is believed that the role of 
ET -1 in health is to maintain vascular tone, so that in disease states increasing the risk of 
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vascular disease, there may be an insensitivity to ET -1, resulting in a compensatory increase 
in concentrations. This may reflect abnormal vascular reactivity in the at risk groups (Ang, 
2001). 
It is also postulated that ET -1 rises in a dose -response relationship with insulin, either 
endogenous or exogenous (Wollesen, 1999). It is therefore plausible that any increment in 
ET -1 concentration seen in these patients may have been induced by insulin infusion rather 
than hypoglycaemia itself. Without a euglycaemic control arm to the experiment this fact 
will be difficult to dispute or confirm. The fact remains that there was an identifiable and 
statistically significant rise in ET -1 concentration following induction of hypoglycaemia, and 
since it is known that ET -1 exerts a vasoconstrictive effect on the vasculature, it must be 
assumed that the potential for reduction in blood flow and ischaemia is a possible adverse 
consequence. The effects of the endothelin rise may also serve to alter the regional blood 
flow around the body, preserving nutrient delivery to important areas, and diverting it from 
those areas deemed less vital. 
6.2.1.2 Platelet function, endothelial markers and inflammation 
Chapter 5 describes a large study undertaken in 16 non -diabetic subjects and 16 subjects 
with type 1 diabetes. This study was designed to further investigate the hypothesis that 
hypoglycaemia may have adverse effects on vascular function, on a larger scale. All subjects 
underwent a euglycaemic and hypoglycaemic study period on two separate occasions, and 
had an extensive battery of soluble markers of platelet function, coagulation and 
inflammation examined, in addition to having platelet and inflammation studies conducted 
by flow cytometry. The battery of tests was selected to address three of the main 
pathophysiological mechanisms recognised to influence the development and progression of 
vascular disease, namely platelet activation, endothelial function and inflammation. 
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This study has demonstrated that moderate hypoglycaemia resulted in platelet activation, as 
shown by an increment in platelet -monocyte aggregation and soluble p- selectin, with 
suppression of p- selectin during the euglycaemic clamps. Endothelial markers, in this study 
using tPA and vWF, were variably affected; in non -diabetic subjects there was an increase in 
tPA during hypoglycaemia, and a suppression during euglycaemia, but these findings were 
not replicated in the group with diabetes. Again, vWF appeared to increase at a later stage 
post -hypoglycaemia in the non -diabetic subjects, with little change in the subjects with 
diabetes, although the euglycaemic clamp did result in suppression of vWF, which may 
confer a beneficial effect of insulin on endothelial function in people with diabetes. Lastly, 
inflammation was assessed using CD40 expression, soluble CD40 ligand, IL -6 and hsCRP as 
markers. CD40 expression increased during hypoglycaemia in subjects with diabetes, and 
also in non -diabetic subjects though this occurred after a delay at 6 and 24 hours following 
hypoglycaemia. Soluble CD40 ligand increased significantly during hypoglycaemia and 
decreased significantly during euglycaemia in non -diabetic subjects. There was also a 
significant difference between the peak response during the experimental phase in subjects 
with diabetes, although baseline levels differed on each study day and this may have 
influenced the outcomes. IL -6 rose regardless of experimental condition in all subjects, so 
this was not indicative of a response to experimental condition, and hsCRP was significantly 
higher in all subjects during hypoglycaemia. Although, again, there was a baseline difference 
in non -diabetic subjects between study days which may have influenced the results. 
Interestingly, some of the increments seen occurred after a delay, and some were even 
present 24 hours after the hypoglycaemic insult. This is a concerning finding, particularly if 
hypoglycaemia is a regular occurrence, as potentially damaging vascular substances may be 
elevated for some time following hypoglycaemia, and with repeated episodes these levels 
may increase further, posing additional risk. This contradicts the previous belief that only 
transient alterations in vascular biology occur following a hypoglycaemic insult, and 
certainly merits careful consideration. 
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Overall these results are suggestive of a pro -inflammatory, pro -atherogenic response to 
hypoglycaemia, although some issues in interpretation of the results are present. The 
baseline differences in sCD40L and hsCRP between study days have frustrated interpretation 
of these parameters. Unfortunately there is day to day intra- individual variation in 
inflammatory parameters, as so many external and internal influences can affect levels. This 
would, of course, be true in real -life too. It is hoped that by assessing a large battery of tests, 
however, that the overall picture becomes clearer. In addition, in some parameters there was 
only a trend towards significance indicated on statistical analysis, or a non -significant result 
was obtained despite a difference being evident on the absolute results. In order to assess the 
trends identified further, percentage change from baseline was also assessed, and this 
confirmed the trends seen in the absolute numbers. The only way to overcome this hurdle 
and improve the statistical power would have been to use a larger sample size, particularly as 
the magnitude of the changes seen was very small. Unfortunately due to time constraints and 
the complicated nature of running a clamp study alongside flow cytometric analysis of study 
samples with only one investigator, this was not practically possible during this programme 
of research. It is anticipated, however, that many other studies in this field will be conducted 
with a similar study design, and that cumulatively these studies together will add strength to 
these results, and lend support to the hypothesis. 
6.2.2 Recent studies 
Since the design and conduct of this study, several further studies in this field have been 
reported. Razavi Nematollahi et al investigated the effects of acute hypoglycaemia induced 
by the insulin tolerance test method, injecting an insulin bolus of 0.lunits/kg into 13 male 
volunteers without diabetes. This resulted in a nadir blood glucose of 2.2mmo1 /1, as 
compared with 2.5mmo1/1 in the clamp study described in chapter 5, and the rate of fall of 
blood glucose was obviously much more rapid. They demonstrated a significant rise in TNF- 
a, IL -113, IL -6 and IL -8, and confirmed a rise in counterregulatory hormones, which they 
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hypothesised were the cause of the increments in inflammatory markers. This study did not 
include a control arm, and was conducted in a small group of non -diabetic individuals, with 
the expected limitations that this would entail (Razavi Nematollahi, 2009). 
Dotson et al showed that IL -6 increases during a hypoglycaemic hyperinsulinaemic glucose 
clamp, with no change seen in the euglycaemic control study. This contradicts the fmdings 
of our study that both experimental conditions resulted in a rise in IL -6, maximal at 6 hours. 
This study only reported results during the clamp period, however, up until 135 minutes, and 
did not comment on recovery levels or on delayed responses (Dotson, 2008). The duration of 
the experimental phase in this study was 120minutes approximately, which is double the 
length of time our subjects were exposed to hypoglycaemia. 
More recently a study in the USA has been conducted with a very similar design to the one 
described in chapter 5. This group used hyperinsulinaemic clamps to compare euglycaemia 
and hypoglycaemia in both diabetic and non -diabetic subjects, and demonstrated a 
significant pro -inflammatory, antifibrinolytic response following hypoglycaemia. The depth 
of hypoglycaemia achieved in this study was a mean of 2.9mmo1/1, but the experimental 
period again lasted for 120minutes compared with 60minutes in our study. Not surprisingly, 
they therefore saw a more impressive response to hypoglycaemia, with increments in 
intercellular adhesion molecule (ICAM), vascular cell adhesion molecule (VCAM), p- 
selectin, e- selectin, plasminogen activator inhibitor -1 (PAI -1), tumour necrosis factor -a 
(TNF -a), interleukin -6 (IL -6) and vascular endothelial growth factor (VEGF). They also 
demonstrated an anti -inflammatory effect of the euglycaemic -hyperinsulinaemic clamp, 
although their results were again more dramatic due to the increased duration of exposure to 
insulin (Gogitidze Joy, 2010). This group have also presented findings looking at similar 
parameters in people with type 2 diabetes following hypoglycaemia, and have compared 
hyperglycaemia with hypoglycaemia in non -diabetic volunteers. Their results indicate that 
there is, again, an increment in inflammatory markers, platelet activation and anti- 
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fibrinolytic mechanisms, and additionally that flow mediated dilation is impaired in subjects 
with type 2 diabetes after hypoglycaemia. Despite some methodological flaws in the study 
design, these findings are highly clinically relevant (Gogitidze Joy, 2011'). They also 
demonstrated that acute hypoglycaemia resulted in greater disruption of these parameters 
than acute hyperglycaemia in non -diabetic volunteers (Gogitidze Joy, 20112). These studies 
add further evidence to our rapidly evolving knowledge of the detrimental effects of 
hypoglycaemia. 
It has also been demonstrated that central arterial pressure falls during acute hypoglycaemia 
induced by the insulin infusion method (as used in chapter 4) (Sommerfield, 2007). This 
finding permits speculation that a resultant reduction in coronary blood flow may ensue, 
which may lead to precipitation of acute vascular events in a diseased circulation. The depth 
of hypoglycaemia achieved in this study ranged from 2.6 -2 9 mmol/1, but measurements 
were timed in relation to the autonomic reaction, which would suggest that counterregulatory 
hormone secretion had been activated even at fairly modest degrees of hypoglycaemia. 
Imaging studies have now been performed to assess the effects of hypoglycaemia on the 
cardiovascular system. One study examined, in non -diabetic subjects and subjects with type 
1 diabetes, whether hypoglycaemia would have an impact on myocardial blood flow using 
myocardial contrast echocardiography. They confirmed that myocardial blood flow 
decreases during hypoglycaemia as compared with a euglycaemic control period. This group 
also looked at endothelin -1 concentrations, which rose during hypoglycaemia. The depth of 
hypoglycaemia achieved in this study was 2.8mmo1/1 (Rana, 2011). This confirms the effect 
of hypoglycaemia on ET -1 production that was demonstrated in our initial vascular study, 
and has also determined that the effect is independent of insulin infusion itself. 
In the longer term, there are concerns that repeated exposure to hypoglycaemia, for example 
in those people with impaired hypoglycaemia awareness, will lead to chronic increased 
165 
vascular risk. A study reported in 2011 showed that this premise is of concern, with an 
increase in inflammatory markers, reduction in flow -mediated vasodilatation, and an 
increase in carotid intima -media thickness (CIMT) and femoral intima -media thickness 
(FIMT) in subjects with type 1 diabetes and impaired awareness with increased frequency of 
hypoglycaemia, when compared with subjects with type 1 diabetes and normal awareness 
(Gimenez, 2011). This team also conducted a short clamp study lasting 30 minutes to assess 
the effects of acute hypoglycaemia on the same individuals but did not see any significant 
increments in the parameters assessed. Furthermore, a longitudinal study of the effect of 
cardiovascular risk factors on evolution of CIMT in children with type 1 diabetes has shown 
that there is an inverse relationship between glycaemic control, as measured by HbA1 e and 
CIMT, i.e. the lower the HbAlc, the higher the CIMT measurement (Dalla Pozza, 2011). 
These study findings are of considerable concern as for a long time the drive to lower HbAl c 
has been the clinical priority, at the expense of an increased frequency of hypoglycaemia, 
and mounting evidence would now suggest that this is at odds with our desire to reduce 
vascular risk. 
6.2.3 Clinical relevance 
6.2.3.1 Clinical trial evidence 
A plethora of clinical trial evidence has now been reported to indicate that striving for tight 
glycaemic control may confer no benefit to the patient, and may in fact have the potential to 
cause harm. Two trials examining intensive glucose control in people with type 2 diabetes 
using insulin give us cause for concern. The Action to Control Cardiovascular Risk in 
Diabetes (ACCORD) trial and the Veterans Affairs Diabetes Trial (VADT) showed no 
cardiovascular risk benefit in the groups receiving intensive insulin therapy (Duckworth, 
2009, ACCORD Study Group, 2008). In fact, the ACCORD trial had to be terminated 
prematurely after 3.5 years due to increased all -cause (22% increase) and cardiovascular 
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(35% increase) mortality in the intensively treated arm, although rates of acute myocardial 
infarction were reduced (figure 6.1). 
The glycaemic target in ACCORD was an HbAlc of 6.0% in the intensively treated arm, and 
7.0 -7.9% in the conventional therapy arm. The achieved levels were 6.4% and 7.5% 
respectively. In the VADT trial, levels of 6.9% and 8.4% were achieved. The rate of severe 
hypoglycaemia was significantly increased in both trials in the tight control groups (10.5% 
vs 3.5% in ACCORD - severe hypoglycaemia requiring medical assistance; 12 episodes per 
100 patient -years vs. 4 episodes per 100 patient -years in VADT - episodes with some degree 
of impairment of conscious level). There was a threefold increase in sudden deaths in the 
intensively treated arm of the VADT trial. Subsequently, detailed post -hoc analysis of the 
ACCORD study data has suggested that the increased mortality seen was not attributable to 
symptomatic, severe hypoglycaemia. Both intensive and conventional study groups were 
shown to have increased mortality if they had experienced severe hypoglycaemia, but 
causality cannot be proven, and based on those results the mode of treatment (intensive vs 
conventional) cannot be held responsible. These findings do, however, remain concerning 
given the well -established fact that hypoglycaemia begets hypoglycaemia, and that much of 
it may be asymptomatic if impaired awareness becomes a factor. This means that the rates of 
hypoglycaemia reported may not be accurate. In addition, definitions of hypoglycaemia, and 
methods of reporting episodes vary greatly in these large scale clinical trials making 
comparisons and conclusions very challenging. 
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Figure 6.1 Kaplan -Meier Curves for the primary outcome (non -fatal MI, non- 
fatal stroke or death from cardiovascular causes) and death from any cause in 
the ACCORD trial. (Reproduced from ACCORD Study Group, 2008) 
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Moreover, if the mechanisms underlying the relationship between increased mortality and 
intensive control are considered in light of the findings reported in study 3, i.e. the prolonged 
and delayed effects following the hypoglycaemic insult, then this may suggest why absolute 
frequencies of severe hypoglycaemia did not explain the findings of ACCORD or VADT. If 
late and prolonged pro -atherogenic effects occur after each hypoglycaemic event, the overall 
burden of vascular disease may be gradually increasing, leading to increased mortality. In 
addition, it has been demonstrated that exposure to antecedent hypoglycaemia blunts cardiac 
autonomic function on repeated exposure to hypoglycaemia. This is another plausible 
mechanism for increasing cardiovascular mortality in people experiencing an increased 
frequency of hypoglycaemia, as cardiovascular autonomic impairment is associated with 
increased mortality (Adler, 2009). Interestingly, those abnormalities were still present at 16 
hours after the hypoglycaemic insult. 
6.2.3.2 Glycaemic control in critical illness 
Another area of glycaemic control to receive a lot of attention in the recent past is the control 
of glucose levels in hospital in- patients, and particularly in those in the coronary care, high 
dependency and intensive care setting. A large proportion of hospital in- patients have pre- 
existing diabetes before their hospital admission, and coupled with the added burden of 
stress hyperglycaemia in patients who are acutely unwell, the number of people with 
hyperglycaemia in the hospital setting is substantial. We know that high blood glucose levels 
can predispose to infection, poor wound healing and increased morbidity and mortality 
(Capes, 2000). This has provoked the conduct of several large scale trials designed to assess 
the impact of careful glucose control on hospital outcomes. 
Van den Berghe and colleagues examined intensive glucose control in surgical and medical 
intensive care patients and found it to impressively benefit mortality (Van den Berghe, 2001, 
Van den Berghe, 2006). The patients in these trials were highly selected, and the team 
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managing insulin infusion in this single intensive care unit was highly trained. DIGAMI 
assessed the impact of glucose control in acute myocardial infarction using an intensive 
intravenous insulin regimen followed by subcutaneous insulin for 3 months. This study was 
only conducted in people with pre- existing diabetes. This showed a survival benefit in those 
intensively controlled (Malmberg, 1997). Subsequently, DIGAMI 2 did not confirm the 
results of DIGAMI 1 from the point of view of intensive insulin therapy, but did reaffirm the 
importance of good glycaemic control around the time of the acute cardiac event (Malmberg, 
2005). A larger scale multicentre trial followed to assess intensive treatment further; NICE - 
SUGAR (Normoglycaemia in Intensive Care Evaluation - Survival Using Glucose 
Algorithm Regulation) showed that intensive glucose control in the ICU led to increased 
mortality (NICE -SUGAR Study Investigators, 2009). Furthermore, the Volume and Insulin 
Therapy in Severe Sepsis and Septic Shock study (VISEP) showed increased hypoglycaemia 
in the intensively treated group, who had higher mortality rates (Brunkhorst, 2008). In all of 
these trials there was an approximately sixfold increase in hypoglycaemia in the intensively 
treated arms. 
Therefore, the potential adverse impact of intensive glucose control must be recognised, 
whilst acknowledging that some improvement in glucose control in those who are 
hyperglycaemic will be beneficial. The anti -inflammatory effect of insulin infusion, per se, 
must also be recognised, and inducing hypoglycaemia and its potentially adverse 
consequences may reverse any possible benefit. This would suggest that a careful balance 
needs to be struck. Aiming for target ranges of 4.4- 6.lmmol/1, as in Van den Berghe's 
studies, should not be recommended, and a more sensible range of 6- 10rmnol/1 may be more 
practical, and safer, whilst still benefitting the patient. 
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6.2.3.3 Primary Care Quality and Outcomes Framework 
The Quality and Outcomes Framework (QOF) is an annual reward and incentive programme 
for all general practice surgeries in England. It was originally designed to recognise 
important clinical targets, as specified by The National Institute for Clinical Excellence 
(NICE). The targets identify many specific healthcare domains and reward good practice, i.e. 
the achievement of the predefined targets. The incentives are financial, and the financial 
health of GP surgeries depends on this revenue stream. Until 2011, the diabetes target 
according to the QOF programme was to achieve an HbAlc of less than 7% in 50% of their 
patients. This year, in 2012, the guideline has been raised to 7.5 %, in response to the recent 
influx of evidence relating to the lack of benefit gained from intensive glycaemic control. 
Thus, for several years, there was a financial incentive to tightly control HbAlc in primary 
care, with no scope for individualisation of targets. The move to adopt a higher HbAlc 
threshold in accordance with the current evidence is a sensible one, and should hopefully 
allow optimal glycaemic control to be encouraged without the adverse outcomes associated 
with strict control. Furthermore, with the exploding epidemic of type 2 diabetes necessitating 
that the majority of people with type 2 diabetes are cared for in the community and not by 
hospital specialists, there are a growing number of people who will be looked after in this 
treat to target manner. Even people with stable type 1 diabetes are being cared for by primary 
care in some areas of the United Kingdom, and if the target -based approach is adopted for 
all, there is considerable cause for concern even with these slightly higher HbAlc targets. 
6.2.4 Potential mechanisms of vascular damage and cardiovascular 
morbidity and mortality 
Although much of the clinical evidence behind the hypothesis of this body of research 
remains anecdotal, there is now mounting support from clinical trials in type 2 diabetes and 
in- patient glycaemic control, and from clinical research, in favour of this detrimental effect 
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of hypoglycaemia on vascular disease. Figure 6.2 summarises the plausible mechanisms 
behind this adverse effect. The profuse secretion of counterregulatory hormones in response 
to hypoglycaemia, particularly the catecholamines, is postulated as one way in which these 
changes may be stimulated. The epinephrine response has been shown to trigger many of the 
haematological changes observed in hypoglycaemia, and the magnitude of these responses 
can be attenuated by adrenoceptor- blockade. 
The increase in coagulation and viscosity may restrict blood flow to distal tissues, while the 
activation of leucocytes and platelets may encourage thrombosis or release local factors that 
may damage the endothelium. Advances in vascular research are focusing increasingly on 
the inflammatory processes underlying the development of many disease states. The stress 
response of acute hypoglycaemia is associated with a rise in inflammatory markers, which 
may potentially cause endothelial damage and contribute to the development of vascular 
disease and thrombosis. 
A further consequence of hypoglycaemia- induced epinephrine release is localised 
vasoconstriction, and promotion of the secretion of other factors such as endothelin -1, which 
can affect localised blood flow through vasoconstriction. This may precipitate capillary 
closure, leading to ischaemic damage in distal tissues. Vessel wall stiffness increases, more 
evident in those with longer duration of diabetes, and myocardial blood flow decreases. 
Whilst most of these alterations are likely to be transient in a normal circulation, in people 
with diabetes who have a diseased circulation, they may precipitate a catastrophic event. 
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The results of the ACCORD trial certainly suggested that there were a subgroup of patients 
who were more at risk of this link between severe hypoglycaemia and cardiovascular events, 
given that the association was not clear cut. Those individuals with longer duration of 
diabetes, older age, higher HbA1c at baseline and higher albumin:creatinine ratio were 
identified as at risk, and they were likely to have more pre- existing vascular dysfunction. 
The VADT showed that those with diabetes of longer duration, insulin treatment at baseline, 
pre- existing cardiovascular disease, lower BMI and higher albumin:creatinine ratio were the 
at -risk population; all factors suggestive of an increased cardiovascular risk, with the 
exception of low BMI which may be more related to lack of endogenous insulin secretion 
and increased reliance on exogenous insulin, perhaps a marker of their longer duration of 
diabetes. There is also now some evidence to suggest that those people exposed to frequent 
hypoglycaemia, with impaired hypoglycaemia awareness, are at increased long term, chronic 
risk of cardiovascular disease. The prolonged or delayed effects on some vascular 
biomarkers seen in chapter 5 following hypoglycaemia may explain the increase in 
likelihood of hypoglycaemia- induced macrovascular events in those exposed to recurrent 
hypoglycaemia, even though a direct association has not been identified thus far in the large 
scale trials. Moreover, the effects of recurrent hypoglycaemia on cardiac autonomic reflexes 
may explain the increased mortality seen without the direct association being made. 
6.3 The vascular effects of hypoglycaemia and their influence on the brain 
6.3.1 Acute cerebral alterations during hypoglycaemia 
Severe, protracted hypoglycaemia is recognised to occasionally cause permanent 
neurological dysfunction, but usually, even after hypoglycaemic coma, the patient will make 
a full neurological recovery once blood glucose is restored to normal. Large blood vessels 
could be subject to the pro -atherogenic, pro- coagulant changes seen during hypoglycaemia, 
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leading potentially to an increased risk of stroke. There is unfortunately no strong trial 
evidence to confirm this, as recent focus has been on cardiac events, although several 
anecdotal case reports would agree with this possibility (Cordonnier, 2005, Ben -Ami, 1999). 
Small vessel effects, e.g. vasoconstriction, may be responsible for the diversion of blood 
flow to important areas during hypoglycaemia in a protective sense, with resultant areas of 
relative ischaemia where blood flow is deemed less important during the acute episode. The 
regional cerebral blood flow changes seen during hypoglycaemia appear to be temporary and 
reversible, however (MacLeod, 1994). 
6.3.2 Chronic cerebral changes and association with hypoglycaemia 
The chronic effects of hypoglycaemia on the brain are not yet well understood, but it is 
possible that the vascular effects seen in this and other research programmes may contribute 
to the development of cerebrovascular disease, if the brain is considered to be an end -organ 
susceptible to conventional risk factors. It is plausible that repeated exposure to 
hypoglycaemia may result in gradual development of small vessel disease. Some evidence 
suggests that recurrent exposure to severe hypoglycaemia may lead to the development of 
dementia (Whitmer, 2009). This longitudinal study in a large cohort of patients with type 2 
diabetes examined associations of hypoglycaemia with dementia and found that there was an 
increased risk in those exposed to recurrent hypoglycaemia. Of course, the converse is also 
true, that people with developing cognitive impairment will manage their diabetes less well 
and may therefore be more prone to hypoglycaemia. This was demonstrated in the 
ADVANCE trial, with an increased risk of hypoglycaemia (HR 2.1) in those with known 
cognitive impairment (de Galan, 2009). Recently, the Edinburgh Type 2 Diabetes study has 
examined, in detail, the possible contributors to cognitive decline in type 2 diabetes. Severe 
hypoglycaemia occurrence has been shown to be associated with cognitive decline, even 
when adjusted for premorbid intelligence, duration of diabetes, vascular factors and other 
potential confounding variables (Aung, 2012). This study has also demonstrated an 
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association between raised inflammatory markers (IL -6, TNF -a and CRP) (Marioni, 2010') 
and plasma viscosity (Marioni, 20102) and poorer late life cognition in type 2 diabetes. The 
DCCT examined the effects of intensive control on cognitive decline and found no 
association (DCCT Group, 1996, DCCT /EDIC Study Group, 2007). The evidence for a 
causal link between hypoglycaemia and development of dementia therefore remains 
controversial, at least in type 1 diabetes. 
The brain is also susceptible to exposure to inflammation, for example during infection, as 
cytokines may cross the blood -brain barrier. These substances can activate microglia, which 
are the cerebral version of the macrophage, which can then activate a cascade of events 
leading to cell and neuronal damage (van Gool, 2010). Whether hypoglycaemia may exert 
these same effects is as yet unknown, and requires further consideration. 
Cerebral atrophy has been shown to be associated with increased exposure to severe 
hypoglycaemia using MRI ( Perros, 1997), which may support an association between 
hypoglycaemia and microangiopathy. As neuroimaging techniques become more sensitive, 
and the population of people with diabetes become more concerned over possible long term 
effects on their brains, more studies have been conducted in this area. Evidence has been 
conflicting, however, with several studies indicating no strong link between previous 
hypoglycaemia exposure and cognition or brain structure (Ferguson, 2003, Brands, 2006, 
Kodl, 2008). It does appear, though, that exposure to hypoglycaemia at a young age, in 
childhood, may predispose to structural brain changes and cognitive decline (Hershey, 2010, 
Northam, 2009, Ferguson, 2005). One of the main issues in interpreting these imaging 
studies with respect to previous hypoglycaemia is that there is no long term measure that can 
be assessed to tell how much hypoglycaemia a subject has been exposed to in the past. 
Retrospective recall of hypoglycaemia history by subjects themselves is not always accurate 
either, particularly if asked to recall events over a lifetime, but this remains the best method 
of determining previous exposure. As with any study examining previous hypoglycaemia 
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experience, there is a skewed distribution with few subjects experiencing a lot of episodes, 
and the majority experiencing few, if any, episodes. Definitions of previous exposure also 
vary between studies. 
In addition, cross- sectional studies have shown that intellectual decrements can occur in 
people diagnosed with type 1 diabetes in adulthood who are exposed to recurrent severe 
hypoglycaemia (Langan, 1991, Wredling, 1990, Lincoln, 1996). The patients in these studies 
were older than in the DCCT, so again we see that the individuals most susceptible to 
damage are the older ones, with longer diabetes duration, and higher likelihood of pre- 
existing abnormalities. 
6.4 Future research 
More evidence is needed from both clinical trials and experimental studies to determine the 
extent of the risk that hypoglycaemia poses for the vasculature in people with diabetes, both 
in the acute setting and in the longer term. It remains to be established how the depth of 
hypoglycaemia, duration of hypoglycaemia and speed of onset influence the changes in 
vascular biology that have been demonstrated, as these factors appear to influence the results 
in the studies performed to date. This would also allow us to better extrapolate these results 
into the real life setting, where these factors are significantly different from the experimental 
hyperinsulinaemic clamp setting. More information is required on the duration of alterations 
in blood constituents following a hypoglycaemic insult, as this may be a factor in increasing 
longer term risk. Further research utilising cardiac imaging modalities would also be useful 
to better inform us with regard to the longer term risks of recurrent hypoglycaemia on 
development of vascular disease. Investigation into cardiac autonomic dysfunction and its 
association with recurrent hypoglycaemia and possible increased mortality would be 
beneficial. Furthermore, there is a great need for more clinical trial evidence to establish 
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whether there is a causal role of hypoglycaemia in the increased mortality demonstrated by 
the ACCORD study. At the present time there is a clear association, but post -hoc analysis 
has been unable to shed more light on the subject. Large trials need to be designed with this 
specific question in mind. Additional research is also needed in the in- patient setting, as 
opinions remain divided on how best to target glycaemic control in the critically ill. It has 
also been demonstrated that spontaneous hypoglycaemia and iatrogenic hypoglycaemia are 
two distinct phenomena, with spontaneous hypoglycaemia more likely to cause harm in 
patients following acute myocardial infarction; this is not seen when the hypoglycaemia has 
been induced by treatment (Goyal, 2009, Kosiborod, 2009). This requires further 
consideration. In addition, the trial evidence suggesting an association between intensive 
glycaemic control and mortality has been gathered in people with type 2 diabetes. It remains 
to be established whether the same can occur in type 1 diabetes, particularly those patients 
with longer duration who may have pre- existing vascular abnormalities. More evidence of 
the mechanisms involved is needed in people with type 2 diabetes as well, as the majority of 
experimental studies to date have been in people with type 1 diabetes and in healthy 
volunteers. 
With respect to the brain, we need more information with regards to the impact of recurrent 
hypoglycaemia on long term brain function and cognition. Studies until now have yielded 
conflicting results, and there has been much heterogeneity particularly in the hypoglycaemia 
definitions utilised, and in the methods of reporting hypoglycaemia. Imaging modalities are 
becoming ever more sophisticated and are likely to provide further information on the 
processes affecting the brain. At the present time, it is unclear as to how hypoglycaemia 
affects brain volume. In order to interpret such imaging studies accurately, longitudinal, 
prospective studies are required to determine whether hypoglycaemia issues precede brain 
volume changes, or whether the brain volume changes can occur before the hypoglycaemia. 
In addition, neuroimaging has the capacity to help inform our understanding of the brain's 
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response to hypoglycaemia, to identify the most vulnerable regions, to explain why these 
areas are vulnerable, and to elucidate their role in the development of recurrent 
hypoglycaemia and hypoglycaemia- associated autonomic failure or cerebral adaptation to 
hypoglycaemia. 
6.5 Conclusions 
There is no doubt that achieving good glycaemic control prevents the development and 
progression of microangiopathy, as evidenced by the landmark DCCT /EDIC and UKPDS 
studies. Additionally the legacy effect that ensues from early optimal control will follow an 
individual throughout their diabetes journey, conferring a protective effect against the 
development of future complications. However, achieving strict glycaemic control inevitably 
introduces the side effect of hypoglycaemia, as exogenous insulin therapy cannot be adjusted 
real -time in the way that endogenous secretion is physiologically altered. It is therefore 
imperative that we fully understand the impact that hypoglycaemia can have - on both the 
brain, which has been well recognised for some time, but also on the vasculature, an area of 
evolving understanding. Spatial cognition is crucial for every day functioning so exposure to 
hypoglycaemia understandably poses a potentially dangerous hazard to people with insulin - 
treated diabetes, particularly relevant to driving. People with diabetes are at greater risk of 
developing vascular disease, and with recent clinical trial evidence showing an association 
between strict glycaemic control and increased mortality, hypoglycaemia is of course 
postulated as the culprit in susceptible individuals. Causality has not been established, 
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O R I G I N A L A R T I C L E 
Effects of Acute Insulin -Induced 
Hypoglycemia on Spatial Abilities 
in Adults With Type 1 Diabetes 
ROHANAJ. WRIGHT, MRCP'_ 
BRIAN M. FRIER, MD1'2 
IAN J. DEARY, PHD2'3 
OBJECTIVE - To examine the effects of acute insulin- induced hypoglycemia on spatial 
cognitive abilities in adult humans with type 1 diabetes. 
RESEARCH DESIGN AND METHODS - Sixteen adults with type 1 diabetes under- 
went two counterbalanced experimental sessions: euglycemia (blood glucose 4 :5 mmol/1 [81 
mg/dl]) and hypoglycemia (2.5 mmol/1 [45 mg/dl]). Arterialized blood glucose levels were 
maintained using a hyperinsulinemic glucose clamp technique. During each session, subjects 
underwent detailed assessment of spatial abilities from the Kit of Factor -Referenced Cognitive 
Tests and two tests of general cognitive function. 
RESULTS - Spatial ability performance deteriorated significantly during hypoglycemia. Re- 
sults for the Hidden Patterns, Card Rotations, Paper Folding, and Maze Tracing tests were all 
impaired significantly (P <_ 0.001) during hypoglycemia, as were results for the Cube Compar- 
isons Test (P = 0.03). The Map Memory Test was not significantly affected by hypoglycemia. 
CONCLUSIONS - Hypoglycemia is a common side effect of insulin therapy in individuals 
with type 1 diabetes, and spatial abilities are of critical importance in day -to -day functioning. The 
deterioration in spatial abilities observed during modest experimental hypoglycemia provides 
novel information on the cerebral hazards of hypoglycemia that has potential relevance to 
everyday activities. 
Hypoglycemia is a common side ef- 
fect of insulin treatment of diabetes. 
Strict glycemic control limits the 
development and severity of vascular 
complications of diabetes, but hypoglyce- 
mia is a frequent consequence. Strict gly- 
cemic control can increase the incidence 
of severe hypoglycemia by threefold (1). 
Hypoglycemia has an adverse effect on 
cognitive functions, as the human brain 
relies solely on glucose as its source of 
energy (2). It has a pronounced effect on 
complex cognitive tasks both in diabetic 
and nondiabetic individuals, whereas 
simple mental tasks are relatively unaf- 
fected (2). Cognitive function deteriorates 
when arterialized blood glucose concen- 
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trations decline to <3.0 minol/1 (3 -6). 
Simple and choice reaction times, speed 
of mathematical calculation, verbal flu- 
ency, attention, memory, and psychomo- 
tor function have all been demonstrated 
to be affected during hypoglycemia (7- 
10). The recovery of different aspects of 
cognitive function may vary from be- 
tween 40 and 90 min after restoration of 
blood glucose to normal (2,11). 
Whereas hypoglycemia impairs many 
domains of cognitive function, the effect 
of hypoglycemia on spatial cognitive abil- 
ities has not been investigated in detail, 
although spatial ability is undoubtedly a 
component of some of the tests used to 
assess other aspects of cognition (12). 
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Spatial abilities may be defined as the abil- 
ity to generate, retain, retrieve, and trans- 
form or manipulate structured visual 
images to orientate and interpret the sur- 
rounding environment. In real -life terms, 
spatial ability is concerned with how hu- 
man beings deal with issues concerning 
two- and three -dimensional objects, 
space, navigation, and pathfinding. Prac- 
tical daily cognition often involves infer- 
ring how shapes and objects will appear 
and function when they are rotated or 
otherwise oriented or viewed differently. 
In everyday interactions with the environ- 
ment, this process is very important, with 
particular relevance for complex tasks 
such as driving and map reading. A large 
variety of mental tests are available for the 
assessment of spatial abilities. Largely, 
these tests can be separated into tests of 
spatial perception, namely the ability to 
determine spatial relations despite dis- 
tracting information; spatial visualization, 
which is the ability to manipulate com- 
plex, multistep spatial information; and 
mental rotation, which is the ability to ro- 
tate two- or three -dimensional figures in 
one's mind (13). The present study was 
designed to investigate the effects of acute 
insulin- induced hypoglycemia on spatial 
abilities in adults with type 1 diabetes, 
using a well- characterized battery of spa- 
tial tests that incorporate all of these com- 
ponents of spatial cognition. 
RESEARCH DESIGN AND 
METHODS- Sixteen adults with 
type 1 diabetes (seven male and nine fe- 
male) participated in the study. Subjects 
were recruited from the diabetes clinic at 
the Royal Infirmary of Edinburgh. Base- 
line demographic characteristics were a 
median age of 28 years (interquartile 
range 25 -37.5 years), median duration of 
diabetes 10 years (4.2 -19 years), BMI 
(means ± SD) 26.4 ± 4.01 kg/m2, and 
A1C 7.91. ± 0.92%. A1C was measured 
by high -performance liquid chromatog- 
raphy (nondiabetic reference range 5.0- 
6.05%; Bio -Rad Laboratories, Munich, 
Germany) and was Diabetes Control and 
Complications Trial aligned. The sub- 
jects had no history of hypertension or 
macrovascular disease, and microvascu- 
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lar disease was excluded before recruit- 
ment. The presence of retinopathy was 
sought using digital retinal photography, 
neuropathy was assessed by clinical ex- 
amination, and nephropathy was identi- 
fied by the presence of microalbuminuria. 
Subjects were excluded if they had a his- 
tory of impaired awareness of hypoglyce- 
mia or a history of a previous severe 
reaction to hypoglycemia. None of the 
participants had a history of head injury, 
seizure, blackouts, alcohol or drug abuse, 
or psychiatric illness. Subjects were not 
taking any medications other than insulin 
or the oral contraceptive pill. All subjects 
gave written informed consent before par- 
ticipating in the study, which had been 
approved by the local research ethics 
committee. 
Each subject underwent two labora- 
tory sessions, separated by at least 2 
weeks. The study was conducted at the 
Clinical Research Facility at the Royal In- 
firmary of Edinburgh. A modified hyper - 
insulinemic glucose clamp (14) was used 
to maintain blood glucose at a predeter- 
mined level: euglycemia at 4.5 mmo1/1(81 
mg/dl) and hypoglycemia at 2.5 mmol/1 
(45 mg/di). Each subject underwent a eu- 
glycemia study and a hypoglycemia study 
in a randomized, counterbalanced fash- 
ion. The subjects were blinded to the ex- 
perimental condition. 
Study procedure 
The experimental session began at 
0830 h. All subjects monitored their 
blood glucose with care for the preceding 
48 h, including bedtime testing, and the 
study was postponed if they had any 
blood glucose value <3.5 mmol/1 or any 
symptoms suggestive of hypoglycemia. 
After an overnight fast the subjects omit- 
ted their morning insulin dose. A retro- 
grade intravenous cannula for regular 
blood glucose sampling was inserted into 
the nondominant hand and was placed in 
a heated blanket to arterialize the venous 
blood (15). A further cannula in the non- 
dominant antecubital fossa was used to 
infuse soluble insulin (Human Actrapid; 
Novo Nordisk Pharmaceuticals, Crawley, 
U.K.) and 20% dextrose. Insulin was in- 
fused at a constant rate of 1.5 mU kg -1 
min-1 using a Gemini PCI pump (Alaris 
Medical Systems, San Diego, CA). Dex- 
trose (20 %) was infused at a rate that var- 
ied according to the arterialized blood 
glucose concentration, which was mea- 
sured at 5 -min intervals using the glucose 
oxidase method (2300 Stat; YSI, Yellow 
Springs, OH). 
On each study day, the arterialized 
blood glucose was initially stabilized at 
4.5 mmol/1 for a period of 30 min. It was 
then either maintained at that level 
throughout the study (euglycemia condi- 
tion) or it was lowered over 20 min to 2.5 
mmol/1 and maintained at that level for 
the duration of the study (hypoglycemia 
condition). The experimental period 
lasted for 60 min, after which time the 
blood glucose concentration was restored 
to 4.5 mmol/l. Subjects were given a meal 
after completion of each study. 
Cognitive function tests 
Tests of spatial ability were drawn from 
the French and Ekstrom . Ki.t of Factor - 
Referenced Cognitive Tests (16,17). In 
addition, the Digit Symbol Substitution 
Test and Trail Making B Test were admin- 
istered to confirm the recognized effect of 
hypoglycemia on cognitive function, as 
described previously (7 -10). 
Spatial ability tests 
Hidden patterns test. The Hidden Pat- 
terns Test requires subjects to identify a 
figure that is hidden among other lines. 
The figure is the same throughout, with 
the same orientation, and subjects have 3 
min to correctly identify as many of the 
patterns in which the figure is concealed 
as possible. 
Card rotations test. The Card Rotations 
Test requires the subject to look closely at 
a shape on the left -hand side of a page and 
then assess whether the eight shapes on 
the right -hand side are the same shape 
rotated through a variable number of de- 
grees or whether the shapes are different 
and have in fact been reversed or are a 
mirror image of the initial shape. Three 
minutes are allowed to complete as many 
items as possible. 
Cube comparisons test. This test in- 
volves pairs of cubes, such as the wooden 
building blocks played with by children, 
with a letter or shape on each facet of the 
cube. Subjects have 3 min to analyze as 
many pairs of cubes as possible and must 
determine whether the two cubes could 
be the same cube viewed from different 
sides or whether they must be different 
cubes if the letters on the sides did not 
correspond with each other had the cube 
been turned over. 
Paper folding test. The Paper Folding 
Test involves showing participants a se- 
quence of folds in a piece of paper, 
through which a set of holes is then 
punched. The participants must choose 
which of a set of punched and unfolded 
papers corresponds to the one they have 
just seen. 
Map memory test. This is a test of the 
subject's ability to remember the position 
of buildings on a street map. Four min- 
utes are permitted to memorize the map 
and then a further 4 min to place the 
buildings correctly on a blank version of 
the map. 
Maze tracing test. This is a test of the 
subject's ability to find a path through a 
maze quickly. A pencil line must be 
drawn through the maze without crossing 
any of the "walls." The maze is broken 
down into blocks, and the score is the 
number of blocks that are successfully 
navigated in 3 min. 
Other cognitive function tests 
Digit symbol substitution test. This 
test is from the Wechsler Adult Intelli- 
gence Scale -III and assesses the ability of 
the subject to perform coding as quickly 
as possible. The subject is given a key of 
numbers 1 -9, which each have a corre- 
sponding symbol. They must then fill in 
as many symbols as possible for a list of 
numbers in 120 s. 
Trail making B test. The Trail Making B 
Test is a computerized version of the test 
and similar in principle to the classic test 
from the Halstead Reitan battery. It is 
used to assess complex visual processing 
and also assesses motor function with re- 
gard to visual motor tracking. It is per- 
formed on a handheld computer. The 
subject is presented with a grid contain- 
ing letters and numbers in a random order 
and must connect the numbers and letters 
in numerical and alphabetical order, al- 
ternating the number with the letter in the 
fashion "1- A- 2 -B -3 -C ..." etc. 
Hypoglycemia symptom score. The Ed- 
inburgh Hypoglycemia Scale was used to 
assess the symptoms experienced by sub- 
jects during each experimental session. It 
is a validated self- rating questionnaire 
comprising a list of common symptoms of 
hypoglycemia that can be classified into 
autonomic, neuroglycopenic, and non- 
specific symptoms. Each symptom is 
scored on a Likert scale from 1 (not 
present) to 7 (intensely present) (18). 
Statistical analysis 
Results were analyzed using SPSS (ver- 
sion 15.0 for Windows; SPSS, Chicago, 
IL). A general linear model (repeated - 
measures ANOVA) was used, with order 
of session (euglycemia- hypoglycemia or 
hypoglycemia -euglycemia) as a between - 
subjects factor and condition (euglycemia 
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score P Cohen's d T1n2 
Hidden Patterns 94.5 ± 21.8 73.7 ± 21.0 <0.001 0.97 0.627 
Card Rotations 51.9 ± 15.5 40.4 ± 18.7 0.001 0.67 0.580 
Cube Comparison 11.7 ± 4.1 9.4 ± 5.7 0.03 0.46 0.298 
Paper Folding 6.0 ± 1.9 4.7 ± 2.0 0.001 0.67 0.604 
Map Memory 8.6 ± 3.1 7.8 ± 2.1 0.3 0.30 0.081 
Maze Tracing 11.1 ± 3.0 9.4 ± 2.5 <0.001 0.62 0.621 
Data are means ± SD. Significance level was P < 0.05; effect sizes were computed as Cohen's d and ,1,2. 
or hypoglycemia) as a within- subjects fac- 
tor. P < 0.05 was considered to be signif- 
icant. Effect sizes were calculated using 
r)ß,2 to assess the degree to which hypo- 
glycemia accounts for the variance in re- 
sults, and Cohen's d was used to establish 
the extent of any effects of hypoglycemia 
on spatial abilities. Results are expressed 
as means ± SD unless stated otherwise. 
RESULTS 
Blood glucose 
The target blood glucose levels were 
achieved for each experimental condi- 
tion. The blood glucose concentration 
achieved during the hypoglycemia condi- 
tion was 2.46 ± 0.22 mmo]/1 and during 
the euglycemia condition was 4.53 ± 
0.24 mmol/1. 
Symptom scores 
Significant increments occurred in total 
autonomic (P < 0.001), total neuroglyco- 
penic (P < 0.001), and malaise symptom 
scores (<0.001) during hypoglycemia. 
General cognitive function 
In the present study, scores achieved for 
the Digit Symbol Substitution Test were 
significantly lower during the hypoglyce- 
mia study period (72.4 ± 20.2) compared 
with those during euglycemia (84.6 ± 
20.7) (P < 0.001), confirming that a stan- 
dard measure of speed of information 
processing was significantly impaired at 
blood glucose concentrations of 2.5 
mmo1/1. Performance on the Trail Making 
B Test was statistically not impaired by 
hypoglycemia, with a score of 50.4 ± 
20.9 s during hypoglycemia and a score of 
38.9 ± 11.5 s during euglycemia (P = 
0.07). 
Spatial ability 
Hypoglycemia resulted in a significantly 
lower score on all of the spatial ability 
tests except the Map Memory Test (Table 
1). Cohen's d results have shown that the 
impact of hypoglycemia on these spatial 
abilities was medium to large. Moreover, 
the 'q,2 values indicate that the hypogly- 
cemia condition accounted for a large 
proportion of the variance in the results 
(Table 1). No significant effects were ob- 
served of order of exposure to glycemic 
condition or test battery. 
CONCLUSIONS- Acute, insulin - 
induced hypoglycemia causes significant 
decrements in most spatial cognitive abil- 
ities examined here in a group of adults 
with uncomplicated type 1 diabetes. This 
impairment of function was accompanied 
by a deterioration in speed of mental pro- 
cessing as demonstrated by the decre- 
ment in score for the Digit Symbol 
Substitution Test. The effect sizes ob- 
tained indicate the development of me- 
dium to large decrements in spatial 
abilities during hypoglycemia in adults 
with type 1 diabetes. 
The present study examined a group 
of subjects with type 1 diabetes and did 
not include a control group of nondia- 
betic subjects. Although this is a limita- 
tion of the present study, in reality it is the 
everyday effect of hypoglycemia on this 
group of individuals that is of clinical 
importance. 
Other studies assessing the effects of 
hypoglycemia on aspects of cognitive 
function have used tests that require a 
spatial ability component (12), but to our 
knowledge no previous study has used a 
test battery specifically examining spatial 
abilities, although it has clear importance 
in the safe conduct of tasks such as driv- 
ing, which rely heavily upon the interpre- 
tation of the surrounding environment. 
The Map Memory Test was not af- 
fected significantly by the glycemic con- 
dition. This test assesses both spatial 
ability and visual memory. This finding is 
consistent with previous studies that ex- 
amined memory function using visual 
Wright, Frier, and Dewy 
memory tests from the Wechsler Adult 
Intelligence Scale, which also showed that 
visual memory is preserved during acute 
hypoglycemia (19). It is also notable that 
the Map Memory Test, unlike the other 
tests used here, does not have multiple 
items, and so its scores may be more 
idiosyncratic. 
Spatial ability relies on cerebral path- 
ways that predominantly involve the right 
cerebral hemisphere, particularly the pa- 
rietal lobe. The frontal cortex, thalamus, 
and, to some extent, the cerebellum are 
also involved in the coordination of spa- 
tial cognition (20,21). Neuroimaging 
studies during hypoglycemia have shown 
attenuation of functional response, e.g., 
blood oxygenation level- dependent acti- 
vation, in the premotor and supplemen- 
tary motor cortex, consistent with 
recognized areas of importance in spatial 
functioning (22). In addition, it has been 
shown previously that general fluid intel- 
ligence is impaired during hypoglycemia, 
and it is fluid intelligence rather than crys- 
tallized intelligence that is responsible for 
spatial cognition (10). 
In summary, the present study has 
shown that acute hypoglycemia has an 
adverse effect on spatial abilities. These 
novel data are important for two reasons. 
First, with regard to our understanding of 
the domains of cognitive function that ex- 
perience decrements during hypoglyce- 
mia, spatial abilities were a lacuna that has 
now been partly filled. Second, spatial 
abilities are relevant to the everyday activ- 
ities of individuals with type 1 diabetes, 
and there are now data to show that part 
of the inability to manage complex tasks 
during hypoglycemia is the inability to 
efficiently carry out spatial cognitive 
operations. 
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Abstract 
Aims To determine whether acute insulin- induced hypoglycaemia provokes a detectable alteration in peripheral plasma 
endothelin (ET) concentrations in humans with Type 1 diabetes. 
Methods Serial plasma concentrations of ET were measured in 20 patients with Type 1 diabetes during controlled 
hypoglycaemia induced by intravenous infusion of soluble insulin. 
Results A significant increase was observed in plasma ET concentrations, from 3.80 ± 0.31 pg/ml at baseline to 
6.72 ± 1.47 pg/ml at 60 min after the onset of the hypoglycaemic reaction (P < 0.05). 
Conclusions Acute insulin- induced hypoglycaemia induces a rise in plasma endothelin concentrations in people with Type 1 
diabetes. This finding is consistent with a putative role for ET in the mediation of hypoglycaemia- induced vasoconstriction, 
and the possible precipitation of macrovascular or microvascular events. 
Diabet. Med. 24, 1039 -1042 (2007) 
Keywords adrenaline, endothelin, hypoglycaemia, insulin, Type 1 diabetes mellitus 
Abbreviations ET, endothelin; R, autonomic reaction 
Introduction 
Acute hypoglycaemia induces haemodynamic, haemorrheo- 
logical and haemostatic responses, secondary to sympatho- adrenal 
activation and counter -regulatory hormonal secretion [1]. The 
cardiovascular effects are transient in healthy young adults 
with no pathophysiological consequences, but people with 
diabetes who have vascular disease may be at risk of tissue 
ischaemia [1]. Myocardial and cerebral ischaemia, and acute 
vascular events, can be precipitated by hypoglycaemia [2,3], 
and worsening of diabetic retinopathy may occur when strict 
glycaemic control is implemented [4,5]. The possible mechanisms 
by which hypoglycaemia might exacerbate vascular disease 
include haemorrheological changes, platelet and neutrophil 
activation, vasoconstriction [1,4], and release of inflammatory 
mediators and cytokines [6 -11]. 
The endothelins are potent vasoconstrictors that have a 
central role in cardiovascular regulation. The endothelium- derived 
Correspondence to: Professor B. M. Frier, Department of Diabetes, Royal 
Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh EH16 45A, UK. 
E -mail: brian.frier @luht.scot.nhs.uk 
peptide, endothelin -1 (ET -1), is the principal isoform in 
humans, causes prolonged vasoconstriction, and promotes 
smooth muscle proliferation [12]. Endothelins have been 
implicated in the pathogenesis of several disorders, including 
atherosclerosis, diabetes and hypertension [13 -15]. Plasma 
endothelin production is stimulated by hypoxia, ischaemia 
and adrenaline release, amongst other factors [12,15]. Plasma 
levels are elevated in people with uncomplicated Type 1 and 
Type 2 diabetes [16], increase with the presence of microalbu- 
minuria and retinopathy [17], and may have a pathogenetic 
role in microangiopathy [15]. Changes in plasma endothelin 
during acute insulin- induced hypoglycaemia were examined 
in adults with Type 1 diabetes, with the hypothesis that an 
increment in endothelin concentration would be observed. 
Patients and methods 
Twenty subjects with Type 1 diabetes were studied. Subject 
characteristics are presented in Table 1. All were receiving 
short- and intermediate -acting insulins in combination, or as 
multiple- injection therapy. They were taking no medications 
other than insulin, and had no other medical disorders. Subjects 
were screened for retinopathy using ophthalmoscopy, peripheral 
© 2007 The Authors. 
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Table 1 Characteristics of participants with Type 1 diabetes 
Age [median (range)] (years) 25.5 (19-42) 
Sex (male : female) 19 : 1 
Duration of diabetes [median (range)] (years) 2 (1-26) 
Body mass index (kg/m2) 24.6 ± 2.8 
Insulin dose (units/kg) 0.6 ± 0.3 
Systolic blood pressure (mmHg) 124 ± 8 
Diastolic blood pressure (mmHg) 74 ± 18 
HbAlC ( %) 7.8 ± 2.4 
Results are expressed as mean ± $EM unless stated otherwise. 
Non -diabetic range for glycated haemoglobin (HbAtc) is 
5.0 -6.5% (measured by ion exchange high -performance liquid 
chromatography). 
neuropathy by clinical examination, and autonomic neuropathy 
using a standard battery of cardiovascular reflexes [18]. None 
had any clinical evidence of microangiopathy. The local medical 
research ethics committee granted approval, and written informed 
consent was obtained from all subjects. 
After an overnight fast, hypoglycaemia was induced with a 
continuous intravenous infusion of soluble insulin at a rate of 
2.0 mU /kg/min in 0.15 mmol/1 saline, through an indwelling 
venous cannula in the antecubital fossa. The insulin infusion 
was continued until the onset of symptoms of hypoglycaemia, 
which was usually coincidental with objective evidence of an 
acute autonomic reaction (R). This was identified by a rapid 
increase in heart rate, a rise in systolic blood pressure, and the 
onset of sweating and finger tremor, as described previously 
[19]. This insulin infusion method produces a gradual, predictable 
and controlled decline in blood glucose to induce hypoglycaemia 
and simulates the development of hypoglycaemia in everyday 
life. It enables the glycaemic threshold for the acute autonomic 
activation to be identified objectively [20]. Blood sampling was 
timed subsequently in relation to R, the onset of which differs 
between individuals [19]. 
Arterialized venous blood was collected at 5 -min intervals 
for measurement of whole blood glucose concentration using 
a Yellow Springs Analyser (Yellow Springs, OH, USA). Blood 
samples were cold centrifuged, the plasma separated and 
flash -frozen, and stored at -70 °C for measurement of immuno- 
reactive ET by radioimmunoassay (ITS Production BV). The 
sensitivity of this assay is 2 pg/ml immunoreactive ET. Cross - 
reactivity of the assay with ET -1, ET -2, ET -3 and big ET -1 is 
100, 52, 96 and 7 %, respectively. Plasma ET concentrations 
were measured at baseline, at the onset of the hypoglycaemic 
reaction, and at 15 and 60 min following R. 
Mean endothelin concentrations were compared by paired 
t -test using SPSS version 12.0 for Windows (SAS Institute, 
Cary, NC, USA). 
Results 
Plasma glucose concentration declined steadily from a mean 
basal concentration of 5.2 ± 0.2 mmol/1 (mean ± sEM), until 
the symptomatic hypoglycaemic reaction (R) occurred at the 
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FIGURE 1 Plasma endothelin concentrations in response to acute 
insulin- induced hypoglycaemia in people with Type 1 diabetes. Results 
are shown as mean ± sua. Grey dotted lines indicate normal range 
(1.5 -4.5 pg/ml). R, autonomic reaction. °P < 0.05. 
rose from 3.80 ± 0.31 pg/ml at baseline to a peak of 
6.72 ± 1.47 pg/ml at R + 60 min (P < 0.05; Fig. 1). The differ- 
ent values at R and R + 15 min did not achieve significance. 
The observed increase was wide, ranging from 0.11 pg/ml to 
20.18 pg/ml. 
The temporal pattern of the rise in plasma endothelin 
response coincided with the rise in plasma adrenaline, cortisol 
and growth hormone (results not shown), but did not correlate 
significantly with any single variable measured. Haemodynamic 
changes (blood pressure and heart rate) returned to normal by 
R + 15 min (not shown). 
Discussion 
The present study has shown that a significant rise in plasma 
endothelin occurs in response to insulin- induced hypoglycaemia 
in adults with Type 1 diabetes. 
Although there is strong evidence to support a role for ET in 
the pathogenesis of diseases affecting the cardiovascular 
system, its influence in diabetes remains undefined, and its 
reliability as a marker of endothelial function in people with 
diabetes is debatable. The significance of the current findings 
is therefore uncertain. In vitro studies have shown that insulin 
[21], vasopressin and adrenaline [17] stimulate ET production 
from endothelial cells. In animal studies, the urinary excretion 
of ET rises following the development of diabetes and may 
represent endothelial damage induced by the diabetic state 
[22]. A regulatory role of insulin on ET -1 concentration has 
been suggested in patients with Type 2 diabetes in whom a rise 
in plasma ET concentrations occurs during a hyperinsulinaemic 
glucose clamp [23], and plasma ET and insulin concentrations 
are correlated closely in obese non -diabetic men [24]. The 
diabetic state in general [16], and diabetic complications in 
particular [16,25], are associated with an elevated concentration 
© 2007 The Authors. 
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of plasma endothelin. It is possible that the observed rise in 
plasma endothelin during hypoglycaemia could exacerbate 
ischaemia through its vasoconstrictive effects in a vasculature 
that is already compromised by micro- or macrovascular 
disease, and thereby enhance the risk of promoting an acute 
macrovascular event and possibly aggravate existing micro - 
vascular disease [1,4]. It is also plausible that endothelin- induced 
vasoconstriction may serve as a defence mechanism to protect 
vital organs such as the brain, and also to increase delivery of 
gluconeogenic precursors to the liver. Total cerebral blood 
flow increases at blood glucose concentrations below 2.0 mmol/1 
and the regional distribution of blood flow within the brain 
alters to provide glucose to the areas most vulnerable to 
neuroglycopenia, such as the cortex and the basal ganglia 
[26,27]. Total splanchnic blood flow is increased [28] (while 
splenic blood flow is reduced [29]), with a relative rise in 
hepatic blood flow, as mechanisms which should promote the 
production of glucose in the liver. 
These results permit speculation as to the possible role of 
endothelin in the pathogenesis of hypoglycaemia- induced 
vascular injury, or regional blood flow alterations, but do not 
provide definitive conclusions. One limitation of the current 
study is the absence of a control group of non -diabetic volunteers 
to allow the endothelin responses to be compared, and examine 
whether the response in healthy control subjects is similar to 
that observed in people with diabetes. The mechanism inducing 
the rise in plasma endothelin is not known. It may have been 
provoked by insulin per se, or it may have been secondary to 
the hormonal response to acute hypoglycaemia [1], in the form 
of elevated adrenaline or vasopressin concentrations [30]. 
The increased sympathetic nervous system activity, through 
haemodynamic effects, may increase shear stress on blood 
vessels and consequently trigger the release of endothelin. 
Alternatively, endothelin release may be a direct consequence 
of neuroglycopenia. 
Despite the limitations of this study, in response to hypogly- 
caemia a significant rise has been demonstrated of a peptide 
with potent vasoconstrictive properties, in a group of patients 
who are at high risk of developing vascular complications. The 
role of endothelin in this situation has yet to be explored. 
Competing interests 
None to declare. 
References 
1 Fisher BM, Frier BM. Effect on vascular disease. In: Frier, BM, 
Fisher, BM, eds. Hypoglycaemia and Diabetes: Clinical and 
Physiological Aspects. London: Edward Arnold, 1993: 355 -361. 
2 Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V. Association 
of hypoglycemia and cardiac ischemia. Diabetes Care 2003; 26: 
1485 -1489. 
3 Fisher BM, Heller S. Mortality, cardiovascular morbidity and 
possible effects of hypoglycaemia on diabetic complications. In: 
Frier, B M, Fisher, B M, eds. Hypoglycaemia in Clinical Diabetes, 1st 
edn. Chichester: John Wiley and Sons, 1999: 167-186. 
4 Frier BM, Hilsted J. Does hypoglycaemia aggravate the complications 
of diabetes? Lancet 1985; 326: 1175 -1177. 
5 Hanssen KF, Dahl- Jorgensen K, Lauritzen T, Feldt- Rasmussen B, 
Brinchmann- Hansen O, Deckert T. Diabetic control and microvascular 
complications. The near -normoglycaemic experience. Diabetologia 
1986; 29: 677 -684. 
6 Galloway PJ, Thomson GA, Fisher BM, Semple CG. Insulin- induced 
hypoglycemia induces a rise in C- reactive protein. Diabetes Care 
2000; 23: 861. 
7 Fisher BM, Quin JD, Rumley A, Lennie SE, Small M, MacCuish AC 
et al. Effects of acute insulin- induced hypoglycaemia on haemostasis, 
fibrinolysis and haemorrheology in insulin- dependent diabetic 
patients and control subjects. Clin Sci 1991; 80: 525 -531. 
8 Collier A, Patrick AW, Hepburn DA, Bell D, Jackson M, Dawes J, 
Frier BM. Leucocyte mobilization and release of neutrophil elastase 
following acute insulin- induced hypoglycaemia in normal humans. 
Diabet Med 1990; 7: 506 -509. 
9 Corrall RJM, Webber RG, Frier BM. Increase in coagulation 
factor VIII activity in man following acute hypoglycaemia: mediation 
via an adrenergic mechanism. Br J Haematol 1980; 44: 301 -305. 
10 Wieczorek I, Pell AC, McIver B, MacGregor IR, Ludlam CA, 
Frier BM. Coagulation and fibrinolytic systems in Type 1 diabetes: 
effects of venous occlusion and insulin -induced hypoglycaemia. Clin 
Sci 1993; 84: 79 -86. 
11 Frier BM, Corrall RJM, Davidson NM, Webber RG, Dewar A, 
French EB. Peripheral blood cell changes in response to acute 
hypoglycaemia in man. Eur J Clin Invest 1983; 13: 33 -39. 
12 Gossl M, Lerman A. Endothelia: beyond a vasoconstrictor. Circulation 
2006; 113: 1156 -1158. 
13 Hopfner RL, Gopalakrishnan V. Endothelin: emerging role in diabetic 
vascular complications. Diabetologia 1999; 42: 1383 -1394. 
14 Luscher TF, Barton M. Endothelins and endothelin receptor antagonists. 
Circulation 2000; 102: 2434 -2440. 
15 Dhaun N, Goddard J, Webb DJ. The endothelin system and its 
antagonism in chronic kidney disease. J Am Soc Nepbrol 2006; 17: 
943 -955. 
16 Takahashi K, Ghatei MA, Lam HC, O'Halloran J, Bloom SR. 
Elevated plasma endothelin in patients with diabetes mellitus. 
Diabetologia 1990; 33: 306 -310. 
17 Collier A, Leach JP, McLellan A, Jardine A, Morton JJ, Small M. 
Plasma endothelin -like immunoreactivity levels in IDDM patients 
with microalbuminuria. Diabetes Care 1992; 15: 1038 -1040. 
18 Ewing DJ, Martyn CN, Young RJ, Clarke BF. The value of cardio- 
vascular autonomic function tests: 10 years experience in diabetes. 
Diabetes Care 1985; 8: 491 -498. 
19 Hepburn DA, Patrick AW, Brash HM, Thomson I, Frier BM. 
Hypoglycaemia unawareness in Type 1 diabetes: a lower plasma 
glucose is required to stimulate sympathoadrenal activation. Diabet 
Med 1991; 8: 934 -945. 
20 Hepburn DA, MacLeod KM, Frier BM. Physiological, symptomatic 
and hormonal responses to acute hypoglycaemia in Type 1 diabetic 
patients with autonomic neuropathy. Diabet Med 1993; 10: 940- 
949. 
21 Hu R, Levin ER, Pedram A, Frank HJL. Insulin stimulates production 
and secretion of endothelin from bovine endothelial cells. Diabetes 
1993; 42: 351-358. 
22 Morabito E, Corsico N, Martelli EA. Endothelins urinary excretion 
is increased in spontaneously diabetic rats BB/BB. Life Sci 1994; 56: 
13 -18. 
23 Ferri C, Carlomagno A, Coassin S, Baldoncini R, Cassone Faldetta 
MR, Laurenti O et al. Circulating endothelin -1 levels increase during 
euglycemic hyperinsulinemic clamp in lean NIDDM men. Diabetes 
Care 1995; 18: 226 -233. 
24 Ferri C, Bellini C, Desideri G, Di Francesco L, Baldoncini R, Santucci A 
et al. Plasma endothelin -1 levels in obese hypertensive and normotensive 
men. Diabetes 1995; 44: 431 -436. 
© 2007 The Authors. 
Journal compilation © 2007 Diabetes UK. Diabetic Medicine, 24, 1039 -1042 1041 
DIABETICMedicine 
25 Morise T, Takeuchi Y, Kawano M, Koni I, Takeda R. Increased 
plasma levels of immunoreactive endothelin and von Willebrand 
factor in NIDDM patients. Diabetes Care 1995; 18: 87 -89. 
26 Bryan RM. Cerebral blood flow and energy metabolism during 
stress. Am J Physiol 1990; 259: H269 -H280. 
27 MacLeod KM, Hepburn DA, Deary IJ, Goodwin GM, Dougall N, 
Ebmeier KP et al. Regional cerebral blood flow in IDDM patients: 
effects of diabetes and of recurrent severe hypoglycaemia. Diabetologia 
1994; 37: 257 -263. 
Endothelin response to hypoglycaemia R. J. Wright et al. 
28 Beam AG, Billing BH, Sherlock S. The response of the liver to insulin 
in normal subjects and in diabetes mellitus: hepatic vein catheterisa- 
tion studies. Clin Sci 1952; 11: 151 -164. 
29 Braatvedt GD, Flynn MD, Stanners A, Halliwell M, Corrall RJM. 
Splanchnic blood flow in man: evidence for mediation via a beta - 
adrenergic mechanism. Clin Sci 1993; 84: 201 -207. 
30 Attinà T, Camidge R, Newby DE, Webb DJ. Endothelin antagonism 
in pulmonary hypertension, heart failure, and beyond. Heart 2005; 
91: 825 -831. 
© 2007 The Authors. 
1042 Journal compilation ® 2007 Diabetes UK. Diabetic Medicine, 24, 1039 -1042 
Pathophysiology/Complications 
O R I G I N A L A R T I C L E 
Effects of Acute Insulin - Induced 
Hypoglycemia on Indices of Inflammation 
Putative mechanism for aggravating vascular disease in diabetes 
ROHANA J. WRIGHT, MRCP' 
DAVID E. NEWBY, PHD2 
DAVID STIRLING, PHD3 
CHRISTOPHER A. LUDLAM, PHD3 
IAN A. MACDONALD, PHD4 
BRIAN M. FRIER, MD' 
OBJECTIVE - To examine the effects of acute insulin -induced hypoglycemia on inflamma- 
tion, endothelial dysfunction, and platelet activation in adults with and without type 1 diabetes. 
RESEARCH DESIGN AND METHODS- We studied 16 nondiabetic adults and 16 
subjects with type 1 diabetes during euglycemia (blood glucose 4.5 mmol/1) and hypoglycemia 
(blood glucose 2.5 mmol/1). Markers of inflammation, thrombosis, and endothelial dysfunction 
(soluble P- selectin, interleukin -6, von Willebrand factor [vWF] , tissue plasminogen activator 
[tPA], high -sensitivity C- reactive protein [hsCRP] , and soluble CD40 ligand [sCD4OL]) were 
measured; platelet -monocyte aggregation and CD40 expression on monocytes were determined 
using flow cytometry. 
RESULTS - In nondiabetic participants, platelet activation occurred after hypoglycemia, 
with increments in platelet -monocyte aggregation and P- selectin (P s 0.02). Inflammation was 
triggered with CD40 expression increasing maximally at 24 h (3.13 ± 2.3% vs. 2.06 ± 1.0 %) 
after hypoglycemia (P = 0.009). Both sCD4OL and hsCRP (P = 0.02) increased with a nonsig- 
nificant rise in vWF and tPA, indicating a possible endothelial effect. A reduction in sCD4OL, 
tPA, and P- selectin occurred during euglycemia (P = 0.03, P < 0.006, and P = 0.006, respec- 
tively). In type 1 diabetes, both CD40 expression (5.54 ± 4.4% vs. 3.65 ± 1.8 %; P = 0.006) and 
plasma sCD4OL concentrations increased during hypoglycemia (peak 3.41 ± 3.2 vs. 2.85 ± 2.8 
ng/ml; P = 0.03). Platelet -monocyte aggregation also increased significantly at 24 h after hypo- 
glycemia (P = 0.03). A decline in vWF and P- selectin occurred during euglycemia (P s 0.04). 
CONCLUSIONS - Acute hypoglycemia may provoke upregulation and release of vasoac- 
tive substances in adults with and without type 1 diabetes. This may be a putative mechanism for 
hypoglycemia- induced vascular injury. 
In people with type 1 diabetes the rapid 
institution of strict glycemic control 
aggravates microvascular complica- 
tions, particularly retinopathy (1). Al- 
though attributed to reduced capillary 
blood flow causing localized ischemia (1), 
greater exposure to hypoglycemia may 
have worsened microangiopathy through 
its putative effects on local vasculature 
(2). In addition, cardiovascular stress as- 
sociated with hypoglycemia may precipi- 
Diabetes Care 33:1591 -1597, 2010 
tate acute macrovascular events in a 
diseased circulation. While supported by 
anecdotal reports (3), the increase in car- 
diovascular mortality in people with type 
2 diabetes in the Action to Control Car- 
diovascular Risk in Diabetes (ACCORD) 
trial (4) (and possibly in the Veterans Af- 
fairs Diabetes Trial [5]), in which inten- 
sive treatment had tripled the frequency 
of severe hypoglycemia, has caused 
concern. 
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Possible mechanisms by which hypo- 
glycemia may damage blood vessels in- 
clude changes in regional blood flow, 
mobilization and activation of neutro- 
phils, platelet activation, and enhanced 
coagulation and viscosity of the blood 
(3,6 -8). Plasma concentrations of C- 
reactive protein, interleukin -6 (IL -6), 
and endothelin -1 increase during hypo- 
glycemia (9 -11) and may promote vas- 
cular disease (12). 
Investigation of processes operating 
at a cellular level to cause atherosclerosis 
has focused on the potential influences 
of vascular inflammation, endothelial 
dysfunction, coagulation, and platelet ac- 
tivation. The present study sought to de- 
termine the effects of acute insulin - 
induced hypoglycemia on inflammation, 
coagulation, and platelet and monocyte 
function in adults with and without type 1 
diabetes. 
RESEARCH DESIGN AND 
METHODS- Participants in the 
study included 16 nondiabetic adult vol- 
unteers with no medical history and 16 
healthy adults with type 1 diabetes (Table 
1). Those with diabetes had no history of 
hypertension or macrovascular disease, 
and microvascular disease was excluded. 
Screening for retinopathy used digital ret- 
inal photography, absence of neuropathy 
was confirmed by clinical examination, 
and nephropathy was excluded by the ab- 
sence of microalbuminuria. Subjects with 
a history of impaired awareness of hypo- 
glycemia or a previous serious reaction to 
hypoglycemia were excluded. None had a 
history of head injury, seizure, blackouts, 
alcohol or drug abuse and psychiatric ill- 
ness, and their only other medication was 
the contraceptive pill. Diabetes Control 
and Complications Trial aligned A 1 
was measured using high performance 
liquid chromatography (nondiabetic ref- 
erence range 5.0- 6.05 %; Bio -Rad Labo- 
ratories, Munich, Germany); the mean ± 
SD of the participants with diabetes was 
7.91 ± 0.92%. All gave written informed 
consent before participation, and the 
study was approved by the Local Medical 
Research Ethics Committee. 
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Table 1- Baseline demographic characteristics 
Nondiabetic subjects Subjects with diabetes 
11 16 16 
Age (years) 28 (26.7 -35) 28 (25 -37.5) 
BMI (kg/m2) 22.86 ± 2.4 26.40 ± 4.0 
Male /female 6/10 7/9 
Duration of diabetes (years) N/A 10 (4.2 -19) 
AIC ( %) N/A 7.91 ± 0.9 
Data are median (interquartile range) and means ± SD unless otherwise indicated. 
A modified hyperinsulinemic glucose 
clamp (13) was used to maintain blood 
glucose at a predetermined level: euglyce- 
mia at 4.5 mmo1/1 and hypoglycemia at 
2.5 mmol/1. Each subject underwent two 
laboratory sessions, separated by at least 2 
weeks (mean 7.2 weeks), of a euglycemic 
study and a hypoglycemic study in a ran- 
domized, counterbalanced fashion. 
The participants with type 1 diabetes 
monitored blood glucose intensively dur- 
ing the 48 h preceding each study, which 
was postponed if any blood glucose value 
was <3.5 mmol/1 or if symptoms sugges- 
tive of hypoglycemia were experienced. 
After fasting overnight, morning insulin 
was withheld. A retrograde- intravenous 
cannula for blood -glucose sampling was 
inserted into the nondominant hand, 
which was heated to arterialize the venous 
blood (14). A cannula in the nondomi- 
nant antecubital fossa was used to infuse 
20% dextrose and soluble insulin (Hu- 
man Actrapid; Novo Nordisk, Crawley, 
U.K.) at a constant rate of 1.5 mU/kg/min 
using a Gemini PCI pump (Alaris Medical 
Systems, San Diego, CA). The dextrose 
was infused at a variable rate depending 
on arterialized blood glucose concentra- 
tions, which were measured at 5 min in- 
tervals using the glucose oxidase method 
(2300 Stat; Yellow Springs Instruments, 
Yellow Springs, OH). A third cannula in 
the other antecubital fossa was dedicated 
to blood sampling for inflammatory 
markers. 
On each study day, the arterialized 
blood glucose was stabilized initially at 
4.5 mmol/1 for 30 min and either main- 
tained at that level (euglycemia) or low- 
ered over 20 min to 2.5 mmol/1 for 60 min 
(hypoglycemia), after which blood glu- 
cose was restored to 4.5 mmo1/1. Subjects 
consumed a standardized meal after each 
study. Blood sample time points were: 
baseline, during the experimental session 
( +45 min), during recovery ( +105 min), 
at +6 h, and at +24 h. 
Flow cytometry 
Whole blood samples were collected 
at the predetermined time points using 
D- Phenylalanyl -L- prolyl- L- arginnne chlo- 
romethyl ketone, a selective thrombin in- 
hibitor, as an anticoagulant. Samples (100 
µl) of whole blood were immediately in- 
cubated with 10 µl of each monoclonal 
antibody (AbD Serotec, Kidlington, U.K.) 
for 30 min at room temperature, with 
subsequent red cell lysis by the addition 
of 1 ml of fluorescent- activated cell sorter 
(FACS) Lyse solution (Becton Dickinson, 
Oxford, U.K.). Flow cytometry using the 
FACS Calibur system (Becton Dickinson, 
Oxford, U.K.) was performed immedi- 
ately after the experimental session to as- 
sess platelet -monocyte aggregation 
(CD14 /CD42a) and CD40 expression on 
monocytes (CD 14/CD40). Isotype con- 
trols were performed in addition to both 
mono- and dual -stain for each parameter 
assessed at each time point. 
Soluble marker assays 
Citrated plasma and serum samples 
were collected at the predetermined 
time points. These were separated imme- 
diately and frozen at - 80 °C until analysis 
for the soluble markers: 
Von Willebrand factor (vWF) (enzyme- 
linked immunosorbent assay [ELISA]; co- 
efficient of variation [CV] 7.3 %), tissue 
plasminogen activator (tPA) antigen (Hy- 
phen Biomed Zymutest; intra -assay CV 
3.5 %, inter -assay CV 4.4 %), soluble 
CD40 ligand (sCD4OL) (high sensitivity 
ELISA, Bender Medsystems; intra -assay 
CV 5.5 %, inter -assay CV 7.2 %), soluble 
P- selectin (ELISA, R&D Systems; intra- 
assay CV 5.1 %, inter -assay CV 8.8 %), 
IL -6 (High sensitivity ELISA, R&D Sys- 
tems; intra -assay CV 5.9 %, inter -assay CV 
9.9 %), and high sensitivity CRP (DRG.Di- 
agnostics; DRG Instruments, Marburg, 
Germany; intra -assay CV 4.2 %, inter - 
assay CV 4.1 %). 
Catecholamine assays 
Samples for epinephrine quantification 
were collected in EDTA tubes and imme- 
diately separated and frozen at -80 °C 
until analysis by high -performance liquid 
chromatography and electrochemical de- 
tection (intra -assay CV 1.2 %, inter -assay 
CV 3.9 %). 
Hypoglycemia symptom score 
The Edinburgh Hypoglycemia Scale (15) 
was used to assess the symptoms experi- 
enced during each experimental session. 
Statistical analyses 
Results were analyzed using SPSS version 
15.0 for Windows (SPSS, Chicago, IL). A 
general linear model (repeated- measures 
ANOVA) was used, with order of session 
(euglycemia -hypoglycemia or hypoglyce- 
mia-euglycemia) as a between- subjects 
factor, and condition (euglycemia or hy- 
poglycemia) as awithin- subjects factor, to 
compare hypoglycemia with euglycemia. 
Additional analysis using paired t tests 
was performed to assess the change in any 
given parameter from baseline. A P value 
<0.05 was considered to be significant. 
Results are reported as mean ± SD unless 
otherwise stated. 
RESULTS - Hypoglycemia provoked 
a symptomatic response in all subjects 
with increased scores of autonomic (P 
0.002), neuroglycopenic (P < 0.001), 
and malaise (P < 0.008) symptoms com- 
pared with baseline. Comparison of base- 
line levels of inflammatory, endothelial 
and platelet markers in nondiabetic sub- 
jects and subjects with type 1 diabetes 
showed a significantly higher concentra- 
tion of soluble P- selectin (P = 0.01) and 
of CD40 expression on monocytes (P = 
0.006) in those with diabetes, demon- 
strating the chronic inflammatory re- 
sponse associated with diabetes. 
Blood glucose 
Target blood glucose concentrations were 
achieved (Fig. 1). In nondiabetic subjects, 
blood glucose concentrations were 
2.58 ± 0.2 and 4.42 ± 0.5 mmol/1 during 
hypoglycemia and euglycemia, respec- 
tively. In those with type 1 diabetes, blood 
glucose concentrations were 2.46 ± 0.22 
and 4.53 ± 0.24 mmol/1, respectively. 
The blood glucose nadir was similar in 
both groups. 
Counterregulatory response 
Plasma epinephrine increased during hy- 
poglycemia in participants with and with- 
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Figure 1 -A: Blood glucose concentrations during hyperinsulinemic hypoglycemic and euglycemic clamp studies. B: Epinephrine responses to 
experimental procedures. i. nondiabetic subjects; ii. subjects with type 1 diabetes. 
out type 1 diabetes (P < 0.001; Fig. 1). 
The epinephrine response occurred only 
during hypoglycemia and returned rap- 
idly to baseline as anticipated (16). 
Platelet activation 
Platelet -monocyte aggregation. In non- 
diabetic subjects, platelet -monocyte ag- 
gregation appeared to rise, from a baseline 
level of 0.72 -!- 0.8% to 3.09 ± 81% 
during hypoglycemia, with a peak of 
3.49 ± 10.4% at 24 h (Fig. 2). Platelet - 
monocyte aggregation remained un- 
changed throughout euglycemia. The 
difference between conditions, and 
from baseline, did not achieve statistical 
significance. 
In participants with diabetes, there 
was a late rise in platelet -monocyte aggre- 
gation after hypoglycemia at 24 h com- 
pared with baseline (P = 0.03). 
Soluble P- selectin. Soluble plasma P- 
selectin concentrations increased after 
hypoglycemia in nondiabetic subjects, 
exhibiting a late response at 6 h (P = 
0.01) and 24 h (P = 0.02; Fig. 2) but 
decreasing during euglycemia (P = 
0.006). 
P- selectin also decreased during eu- 
glycemia in the diabetic group (P = 0.04), 
but did not change during hypoglycemia. 
Endothelial markers 
tPA. In nondiabetic subjects, plasma tPA 
concentrations increased during hypogly- 
cemia, with a higher peak tPA concentra- 
tion (12.55 ± 16.7 compared with 
6.80 ± 7.9 ng/ml) (NS between condi- 
tions). Plasma tPA decreased significantly 
between baseline and test phase (P = 
0.004) and recovery phase (P = 0.006), 
with a paradoxical rise between baseline 
and 24 h (P = 0.06) after euglycemia (Ta- 
ble 2). However, a diurnal variation in tPA 
concentration is recognized to occur, 
which may account for the decline ob- 
served during euglycemia (17). No signif- 
icant differences occurred in the diabetic 
group (Table 2). 
vWF. A trend toward a difference in 
plasma vWF concentrations was observed 
between hypoglycemia and euglycemia at 
6 h in the nondiabetic subjects (P = 0.07) 
(Table 2). 
Plasma vWF concentrations de- 
creased between baseline and test phase 
(P = 0.02) and recovery phase (P = 0.03) 
after euglycemia in the participants with 
diabetes. No such decrement was ob- 
served during hypoglycemia (Table 2). 
Inflammation 
CD40 expression. CD40 expression on 
monocytes increased after hypoglycemia 
in nondiabetic subjects, from a baseline of 
1.92 ± 2.2% to a maximum of 3.13 ± 
2.3% at 24 h (P = 0.009). A significant 
difference between hypoglycemia and eu- 
glycemia conditions was present at 6 h 
(P = 0.05) and at 24 h (P = 0.04) 
(Table 2). 
In participants with type 1 diabetes, 
monocyte CD40 expression increased 
from 3.69 -!- 3.4% to 5.54 -!- 4.4% during 
hypoglycemia (P = 0.006), compared 
with no change during euglycemia 
(3.64 ± 2.0% to 3.65 ± 1.8 %, respec- 
tively; P = NS). The increment during 
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Figure 2- Platelet activation in response to experimental hypoglycemia and euglycemia. A: Platelet -monocyte aggregation. B: Soluble P- selectin, 
i. Nondiabetic subjects, ii. Subjects with type 1 diabetes. 
hypoglycemia had dissipated by the time 
of the recovery phase and remained un- 
changed thereafter (Table 2). 
sCD4OL. In nondiabetic subjects, 
plasma sCD4OL concentrations were 
higher during hypoglycemia than during 
euglycemia (2.80 ± 3.2 vs. 2.41 ± 2.8 
ng/ml), with a trend toward significance 
(P = 0.09). A significant reduction in 
sCD4OL concentration occurred during 
euglycemia between baseline and recov- 
ery phase (P = 0.03) (Table 2). 
In those with diabetes, a significant 
difference was observed between the 
baseline levels on each study day: 3.36 ± 
2.9 ng/ml on the hypoglycemia day com- 
pared with 2.86 ± 2.8 ng/ml on euglyce- 
mia day (P = 0.03), rendering subsequent 
measurements difficult to compare. A sig- 
nificant difference was again observed be- 
tween the experimental condition levels, 
with a level of 3.41 ± 3.2 ng/ml during 
hypoglycemia and 2.85 ± 2.8 ng/ml dur- 
ing euglycemia (P = 0.03) (Table 2). 
Changes from baseline did not achieve 
significance. 
IL -6. IL -6 levels rose in all experi- 
ments, maximally at 6 h, irrespective of 
condition, with no clear differences iden- 
tifiable in either group between the study 
conditions (Table 2). 
hsCRP. Test phase hsCRP was higher 
in all subjects during hypoglycemia 
(1.81 ± 1.9 vs. 1.22 ± 1.9 ng/ml in non- 
diabetic participants [P = 0.02]; 2.72 ± 
3.1 vs. 2.20 ± 2.9 ng/ml in subjects with 
diabetes [P = ns]) (Table 2). A significant 
difference was observed in the baseline 
concentrations in the nondiabetic partic- 
ipants (P = 0.01), frustrating interpreta- 
tion of subsequent responses. 
CONCLUSIONS - Previous studies 
have demonstrated that hypercoagulabil - 
ity, platelet and neutrophil activation, C- 
reactive protein, IL -6, and Endothelin -1 
are upregulated after acute hypoglycemia 
(3,6 -11), while a euglycemic insulin in- 
fusion (for at least 2 h) was shown to re- 
duce inflammatory markers, consistent 
with an anti -inflammatory effect of insu- 
lin (18). The present study sought to 
replicate these effects, while investigat- 
ing other underlying mechanisms of 
vascular disease, and tests were selected 
to investigate the effect of acute hypo- 
glycemia on important cellular pro- 
cesses (platelet activation, endothelial 
dysfunction and inflammation) under- 
lying the development of acute and 
chronic vascular complications in type 
1 diabetes. 
The present study showed that hypo- 
glycemia generated a response in some of 
these markers, suggesting that hypoglyce- 
mia- induced metabolic stress may have 
adverse pathophysiological consequences 
while the euglycemic insulin infusion 
caused a potentially beneficial decrement 
in some parameters. However, the magni- 
tude of most observed changes was small, 
and not all markers changed significantly. 
The present study confirmed that 
platelet activation is promoted by hypo- 
glycemia (8), with increments both in 
platelet -monocyte aggregation and solu- 
ble P- selectin. Conversely, P- selectin de- 
creased during euglycemia. Endothelial 
function, using vWF and tPA Ag as surro- 
gate markers, may have been disrupted, 
as shown by the increase in vWF after 
hypoglycemia in nondiabetic volunteers, 
but this change was not replicated in 
those with diabetes. However, a reduc- 
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Lion in vWF occurred after euglycemia in 
diabetic participants, which should con- 
fer vascular benefit. tPA Ag also appeared 
to increase in nondiabetic subjects during 
hypoglycemia, while declining during eu- 
glycemia, whereas no significant changes 
occurred in the diabetic group. Soluble 
markers of inflammation, sCD4OL and 
hsCRP, were higher during hypoglyce- 
mia, with an elevation of hsCRP being ob- 
served in all subjects. Unfortunately, 
baseline differences in hsCRP in nondia- 
betic subjects, and in sCD4OL in the dia- 
betic subjects, frustrated interpretation of 
subsequent responses. sCD4OL was ap- 
parently reduced during euglycemia in 
nondiabetic participants. Surprisingly, 
IL -6 increased in all experiments regard- 
less of glycemic status, with a maximal 
response at 6 h. This response is inexpli- 
cable, and contrasts with a previous re- 
port (10). Monocyte CD40 expression 
also increased, suggesting promotion of 
the interaction of the CD40 -CD40 ligand 
dyad (from the tumor necrosis factor re- 
ceptor family), thus affecting another 
process in the pathway leading to athero- 
sclerotic plaque rupture (19,20). This 
change occurred much earlier in the dia- 
betic than the nondiabetic subjects, in 
whom the response was delayed, pro- 
longed, and still present at 24 h. The per- 
sistence of these vascular changes for 24 h 
after the hypoglycemic stimulus, or their 
later emergence, suggests that the period 
of risk after hypoglycemia may be present 
long after blood glucose recovery. 
For some markers, a positive trend 
after hypoglycemia was evident, without 
achieving statistical significance, or the 
only measurable difference between con- 
ditions was a beneficial effect associated 
with euglycemia. The sample size may 
have been insufficient to achieve signifi- 
cance, particularly as the magnitude of re- 
sponses was small. It was not feasible to 
study a larger number of subjects using a 
procedure that is labor -intensive and 
costly. In a previous study, larger incre- 
ments in inflammatory markers were ob- 
served during an insulin tolerance test, 
where hypoglycemia of <39 mg/dl (<2.2 
mmol/1) was induced (21). The more 
rapid reduction to a lower blood glucose 
causing a greater hypoglycemic stimulus 
may have heightened the magnitude of 
the responses, compared with the more 
modest changes that occurred during a 
controlled glucose clamp (blood glucose 
2.5 mmol/1 [45 mg/dl]), as observed in 
the present study. A further limitation 
of the present study was the need to ex- 
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amine the experimental conditions on two 
separate days in a counterbalanced fash- 
ion. Because the baseline levels of many 
inflammatory markers can differ on sepa- 
rate days, as was observed with sCD4OL 
and hsCRP, this biological variability hin- 
ders the interpretation and comparison of 
subsequent results. However, the present 
study design was necessary to allow com- 
parison of the euglycemia and hypoglyce- 
mia conditions in individual subjects, as 
both time and insulin infusion per se may 
exert effects on biomarker levels. This 
study design cannot control for other day - 
to -day factors that could influence base- 
line levels of inflammatory markers. 
However, the effects of hypoglycemia 
could be evaluated, as each participant 
acted as their own control. This produces 
less variability than a comparison of re- 
sults among individuals, as more inter - 
individual variation in inflammatory 
marker levels is present than intra- 
individual variation. In addition, it was 
possible to analyze each study separately, 
by examining changes in parameters from 
baseline on that particular day, enabling 
the detection of significant effects exerted 
by hypoglycemia compared with euglyce- 
mia. Baseline levels of all markers (except 
IL -6) were higher in the diabetic group 
(significant for P- selectin and CD40 ex- 
pression). This could affect the magni- 
tude of response induced by the 
experimental procedures. However, an 
analysis of the percentage change from 
baseline was consistent with the trends 
identified in the absolute results (shown 
as in the online appendix available at 
http:/ /care.diabetesjournals.org /cgi/ 
c ontent/full/dc 10- 0013/D C1). 
As anticipated, epinephrine secre- 
tion was stimulated by hypoglycemia. It 
is likely that hormonal changes underlie 
the activation and upregulation of the 
vascular biomarkers. Catecholamines 
promote platelet activation (22), while 
adrenoceptor blockade attenuates these 
effects (23,24). The participants with 
type 1 diabetes exhibited attenuated 
plasma epinephrine responses to hypo- 
glycemia compared with the nondia- 
betic subjects, who were naive to such a 
hypoglycemic stimulus, this being con- 
sistent with the recognized decline in 
the magnitude of counterregulatory 
hormonal responses with increasing 
duration of type 1 diabetes (25). This 
attenuated epinephrine response may 
explain the lower responses of vascular 
biomarkers to hypoglycemia. 
In summary, the effects of hypogly- 
cemia on several vascular biomarkers 
that are implicated in the pathogenesis 
of vascular disease, would support the 
premise that acute hypoglycemia may 
be detrimental to an already diseased 
vasculature (2). Euglycemia may have a 
protective, anti- inflammatory effect. In 
the present study, the participants had 
no overt vascular disease and were un- 
likely to develop any demonstrable ef- 
fects from a short period of exposure to 8. 
hypoglycemia. However, in people with 
diabetes of long duration, who are likely 
to have underlying vascular disease, 
these responses may not be benign. The 
release of potent vasoactive substances 
could potentially aggravate chronic vas - 
culopathy, and contribute to the precip- 
itation of acute macrovascular events. 
This may aggravate established diabetic 10. 
micro- and macrovascular disease in 




Acknowledgments - The cost of assays was 
supported by research grants from the Scottish 
Society of Physicians and the Edinburgh 
branch of Diabetes UK. 
No potential conflicts of interest relevant to 
this article were reported. 
References 
1. Hanssen KF, Dahl Jorgensen K, Lauritzen 
T, Feldt- Rasmussen B, Brinchmann -Han- 
sen O, Deckers T. Diabetic control and 
microvascular complications: the near- 
normoglycaemic experience. Diabetolo- 
gia 1986;29:677 -684 
2. Frier BM, Hilsted J. Does hypoglycaemia 
aggravate the complications of diabetes? 
Lancet 1985;2:1175 -1177 
3. Wright RJ, Frier BM. Vascular disease and 
diabetes: is hypoglycaemia an aggravating 
factor? Diabetes Metab Res Rev 2008;24: 
353 -363 
4. Action to Control Cardiovascular Risk in 
Diabetes Study Group, Gerstein HC, 
Miller ME, Byington RP, Goff DC Jr, Big- 
ger JT, Buse JB, Cushman WC, Genuth S, 
Ismail -Beigi F, Grimm RH Jr, Probstfield 
JL, Simons- Morton DG, Friedewald WT 
Effects of intensive glucose lowering in 
type 2 diabetes. N Engl J Med. 2008;358: 
2545 -2559 
5. Duckworth W, Abraira C, Moritz T, Reda 
D, Emanuele N, Reaven PD, Zieve FJ, 
Marks J, Davis SN, Hayward R, Warren 
SR, Goldman S, McCarren M, Vitek ME, 
Henderson WG, Huang GD, for the 
VADT Investigators. Glucose control and 
vascular complications in veterans with 
type 2 diabetes. N Engl J Med 2009;360: 
129 -139 










ber RG, Dewar A, French EB. Peripheral 
blood cell changes in response to acute 
hypoglycaemia in man. Eur J Clin Inv 
1983;13:33 -39 
Fisher BM, Quin JD, Rumley A, Lennie 
SE, Small M, MacCuish AC, Lowe GD. 
Effects of acute insulin- induced hypogly- 
caemia on haemostasis, fibrinolysis and 
haemorheology in insulin- dependent di- 
abetic patients and control subjects. Clin 
Sci 1991;80:525 -531 
Trovati M, Anfossi G, Cavalot F, Vitali S, 
Massucco P, Mularoni E, Schinco P, Tam - 
poni G, Emanuelli G. Studies on mecha- 
nisms involved in hypoglycemia- induced 
platelet activation. Diabetes 1986;35: 
818 -825 
Galloway PJ, Thomson GA, Fisher BM, 
Semple CG. Insulin- induced hypoglyce- 
mia induces a rise in C- reactive protein 
(Letter). Diabetes Care 2000;23:861 
Dotson S, Freeman R, Failing HJ, Adler GK. 
Hypoglycemia increases serum interleu- 
kin -6 levels in healthy men and women. Di- 
abetes Care 2008;31:1222 -1223 
Wright RJ, Macleod KM, Perros P, 
Johnston N, Webb DJ, Frier BM. Plasma 
endothelin response to acute hypoglycae- 
mia in adults with type 1 diabetes. Diabet 
Med 2007;24:1039-1042 
Libby P, Ridker PM, Maseri A. Inflamma- 
tion and atherosclerosis. Circulation 
2002;105:1135 -1143 
De Fronzo R, Tobin JD, Andres R. Glu- 
cose clamp technique: a method for quan- 
tifying insulin secretion and resistance. 
Am J Physiol 1979;273:E214 E223 
Abumrad NN, Rabin D, Diamond MP, 
Lacy WW. Use of a heated superficial 
hand vein as an alternative site for the 
measurement of amino acid concentra- 
tions and for the study of glucose and ala- 
nine kinetics in man. Metabolism 1981; 
30:936 -940 
Gold AE, MacLeod KM, Frier BM. Fre- 
quency of severe hypoglycemia in pa- 
tients with type 1 diabetes with impaired 
awareness of hypoglycemia. Diabetes 
Care 1994;17:697 -703 
Thompson CJ, Baylis PH. Endocrine 
changes during insulin- induced hypogly- 
caemia. In Hypoglycaemia and Diabetes: 
Clinical and Physiological Aspects. Frier BM, 
Fisher BM, Eds. Edward Arnold, London, 
U.K., 1993, p.116 -131 
Rydzewski A, Urano T, Nagai N, Takada 
Y, Katoh -Oishi Y, Taminato T, Yoshimi T, 
Takada A. Diurnal variation in serum 
remnant -like lipoproteins, platelet aggre- 
gation and fibrinolysis in healthy volun- 
teers. Haemostasis 1997;27:305 -314 
Dandona P, Chauduri A, Ghanim H, Mo- 
hanty P. Insulin as an anti- inflammatory 
and antiatherogenic modulator. J Am Coll 
Cardiol 2009;53 (Suppl. 5):S14S20 
Schönbeck U, Libby P. CD40 signaling 
and plaque instability. Circ Res 2001;89: 
1092 -1103 
1596 DIABETES CARE, VOLUME 33, NUMBER 7, JULY 2010 care.diabetesjournals.org 
20. Mach F, Schönbeck U, Libby P. CD40 sig- 
naling in vascular cells: a key role in 
atherosclerosis? Atherosclerosis 1998; 
137(Suppl.):S89 -S95 
21. Razavi Nematollahi L, Kitabchi AE, Kitab- 
chi AE, Stentz FB, Wan JY, Larijani BA, 
Tehrani MM, Gozashti MH, Omidfar K, 
Taheri E. Proinflammatory cytokines in 
response to insulin -induced hypoglyce- 
mic stress in healthy subjects. Metabolism 
2009;58:443 -448 
22. Steel CM, French EB, Aitchison WR. 
Studies on adrenaline -induced leucocyto- 
sis in normal man. 1. The role of the spleen 
and of the thoracic duct. Br J Haematol 
1971;21:413 -421 
23. Fisher BM, Hepburn DA, Smith JG, Frier 
BM. The effect of alpha -adrenergic block- 
ade on responses of peripheral blood cells 
to acute insulin- induced hypoglycaemia 
in humans. Eur J Clin Invest 1990; 
20:51 -55 
24. Takeda H, Kishikawa H, Shinohara 
M, Miyata T, Suzaki K, Fukushima H, 
Wright and Associates 
Ichinose K, Shichiri M. Effect of alpha 
2- adrenoceptor antagonist on platelet 
activation during insulin- induced hypo- 
glycaemia in type 2 (noninsulin- depen- 
dent) diabetes mellitus. Diabetologia 
1988;31:657 -663 
25. Kerr D, Richardson T. Counterregula- 
tory deficiencies in diabetes. In Hypogly- 
caemia in Clinical Diabetes. 2nd edition. 
Frier BM, Fisher M, Eds. John Wiley and 
Sons, Chichester, U.K., 2007, p. 121- 
140 
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 7, JULY 2010 1597 
